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Chapter 1
Glomerular filtration
 One of the major functions of the kidney is to filter the blood and thereby removing 
waste products like urea, mineral salts and toxic substances via the urine. This process 
is regulated by a large number of small functional units within the kidney, known as 
nephrons. Nephrons are composed of a glomerulus, in which ultrafiltration takes place 
under high pressure and a tubule, which is specialized in reabsorption of necessary fluid 
and molecules into the blood and in secretion of other waste products into the urine. 
Glomeruli consist of a large network of capillaries enclosed in Bowman’s capsule. 
Due to high hydrostatic pressure in the glomeruli, water and small solutes in the blood 
can pass the filtration barrier freely, whereas blood cells and proteins are retained. The 
glomerular filtration barrier is composed of fenestrated glomerular endothelial cells, 
the glomerular basement membrane (GBM), and podocytes with interdigitating foot 
processes (Figure 1). 
Figure 1. The glomerular filtration 
barrier. A) The glomerulus is a network 
of capillaries in which filtration occurs. 
The glomerular filtration barrier consists 
of the fenestrated glomerular endothelial 
cells covering the inner sites of the 
capillaries, the GBM and podocytes with 
interdigitating foot processes, covering the 
outer site (urinary space). Blood is filtered 
from the capillary lumen to urinary space. 
Reproduced with permission from Prof. 
Dr. W. Kriz (Institute of Anatomy and 
Cell Biology, University of Heidelberg, 
Germany). B) Transmission electron 
microscopic picture of the glomerular 
filtration barrier.  
 Physiological studies have revealed that glomerular ultrafiltration is dependent 
on hemodynamic factors such as blood pressure, oncotic forces determined by the 
concentration of protein in the blood and size- and charge-selective properties of the 
GBM, determined by the mesh-like structure of the GBM [1]. The major structural 
components of the GBM include type IV collagens, nidogens, laminin, fibronectin 
and heparan sulfate proteoglycans (HSPG), which include agrin, and to a lesser extent 
perlecan and collagen XVIII [2].
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Heparan sulfate proteoglycans
 HSPG consist of a core protein to which one or more heparan sulfate (HS) 
polysaccharide side chains are covalently attached. HSPG are present in extracellular 
matrices, especially basement membranes and at the cell surface where they are 
anchored in or attached to the cell membrane. HSPG are involved in cell-cell and cell-
matrix adhesion, and act as receptors mediating outside-in signaling [3, 4]. Because 
of its specific and complex structural features, HS can bind a wide range of bioactive 
molecules, including extracellular matrix molecules, enzymes, enzyme inhibitors, 
chemokines, growth factors and cytokines. HS is involved in several physiological 
and pathological processes such as development, tissue repair, embryogenesis, 
inflammation, auto-immunity, angiogenesis and tumor metastasis [3-5]. The 
interaction between HS and its ligands is very specific and depends on the relative 
spatial presentation of sulfate and carboxyl groups within a given HS chain as will be 
detailed below [4].
Heparan sulfate biosynthesis and degradation
Biosynthesis
 The biosynthesis of HS occurs in the Golgi apparatus and is a multistep process 
carried out by a large number of enzymes. The initial HS chain is generated by HS 
polymerases (EXT1/2) and consists of repeating N-acetyl-glucosamine (GlcNAc) and 
glucuronic acid (GlcA) residues [6]. Concomitant with HS polymerization several 
different modification steps take place such as N-deacetylation/N-sulfation, C5-
epimerization and O-sulfation at various positions (C2, C6 and C3). The large number 
of possible combinations of modifications within a HS chain leads to an enormous 
structural and functional diversity of HS (Figure 2). 
N-deacetylase/N-sulfotransferases. NDSTs appear to be the key regulators of HS 
modification, since their activity will lead to different domains in HS composed of 
N-acetylated (NA) regions, N-sulfated (NS) regions and the NA/NS mixed regions, 
which are believed to be required for further modifications to take place. The N-
deacetylase activity of NDST removes acetyl groups of N-acetylated glucosamine 
residues, generating free amino groups, which then can eventually be sulfated by 
the N-sulfotranferase activity of NDST. At present four NDST isoforms have been 
identified in mammalian organisms [7-12], of which NDST-1 and NDST-2 are most 
widely expressed in tissues [13]. Overexpression of NDST-1 or NDST-2 in transfected 
cells results in HS production with different N-sulfation patterns and chain lenghts 
[14]. The four NDST isoforms show differences in the ratio between N-deacetylase 
and N-sulfotransferase activity [8]. It appears that NDST-3 has an extremely high ratio 
of N-deacetylase to N-sulfotransferase activity, whereas NDST-4 displays a very low 
ratio, while the values for NDST-1 and NDST-2 are comparable. Mice with a targeted 
disruption of the NDST enzymes have been generated and were used to study the role 
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of NDST in HS synthesis. It appeared that homozygous NDST-1 deficient mice are 
neonatally lethal due to pulmonary failure [15, 16], whereas mice lacking NDST-2 
have a normal life span, but show profound defects in mast cell number and heparin 
secretion. However, N-sulfation of HS in NDST-2 knock-out mice appears to be 
normal [17, 18]. 
C5-epimerase. The next enzyme involved in the HS modification is C5-epimerase, 
which catalyzes the epimerization of GlcA into iduronic acid (IdoA) [19]. Due to the 
substrate specificity of epimerase, this reaction requires the position of a glucosamine 
residue towards the non-reducing end to be N-sulfated [20]. Mice with a targeted 
disruption of C5-epimerase are lethal with defective development of kidneys, lungs 
and skeletal muscles [21]. 
Figure 2. Heparan sulfate biosynthesis.  Schematic overview of the modification steps 
involved in HS biosynthesis: A) N-deacetylation/N-sulfation of GlcN residues by NDSTs, B) 
Conversion of GlcA to IdoA by C5-epimerase, C) 2-O-sulfation of GlcA and IdoA by 2-O-
sulfotransferase, D) 6-O-sulfation of GlcN by 6-O-sulfotransferases, and E) 3-O-sulfation of 
GlcN by 3-O-sulfotransferases. Abbreviations: HS, heparan sulfate; NDSTs, N-deacetylase/N-
sulfotransferase enzymes; GlcN, glucosamine; GlcA, glucuronic acid; IdoA, iduronic acid. 
Chapter 1
10 11
O-sulfotransferases. Further modification of HS includes the incorporation of 
sulfate groups within HS, in which O-sulfotransferases (OSTs) with three different 
specificities are involved, i.e. 2-OST, 6-OSTs and the 3-OSTs. Only one isoform of 2-
OST is described, whereas three and seven isoforms are known of 6-OST and 3-OST, 
respectively [22]. 2-OST catalyzes the incorporation of a sulfate group to C2 of both 
IdoA and GlcA of which 2-O-sulfation of IdoA is more common [23]. The three 6-O-
sulfotransferases add a sulfate group to C6 of GlcN(S) units, however, each isoform 
shows a different specificity toward GlcA and IdoA residues [24]. All seven known 
HS 3-OST isoforms catalyze the addition of a sulfate group to C3 of GlcN(S) residues, 
but substrate specificity differs. For example, 3OST-1 and 3OST-5 have the capacity 
to form the anti-thrombin binding sequence within HS (i.e. domains containing GlcA-
GlcNS3S) [25, 26]. Several isoforms, i.e. 3OST-2, -3A, -3B, -4, -5 and -6 can transfer 
a sulfate group to N-unsubstituted glucosamine residues (GlcNH
3
+) [22].
Degradation and editing
 Modification of HS chains may also occur by HS-degrading enzymes, such as 6-O-
endosulfatases, sulfamidase, and heparanase (Figure 3).
 
Endosulfatases. In addition to sulfation of HS, desulfation can also occur. Removal 
of 6-O-sulfate groups from the HS chain is catalyzed by 6-O-endosulfatases. This 
enzyme was recently discovered in the quail embryo (Qsulf1) and appeared to target 
trisulfated HS IdoA2S-GlcNS6S disaccharide units in the HS chains at neutral pH 
[27]. This enzyme influences the function of many factors, including Wnt, fibroblast 
growth factor, hepatocyte growth factor, and heparin-binding epidermal growth factor 
[28-32]. In human and mice, 2 isoforms of these endosulfatases have recently been 
cloned. Expression of sulf-1 was restricted to testis, stomach, skeletal muscle, lung 
and kidney, whereas sulf-2 was mainly expressed in ovary, skeletal muscle, stomach, 
brain, uterus, heart, kidney, and placenta. Mice homozygous deficient for the sulf-2 
gene are viable and fertile and have no major developmental defects on several genetic 
backgrounds [33].
 
Sulfamidase. The heparan N-sulfatase (sulfamidase) is a lysosomal enzyme involved 
in the degradation of HS in mammalian cells. Sulfamidase catalyzes the hydrolysis of 
an N-linked sulfate group from the non-reducing terminal glucosamine residues of HS. 
A deficiency in sulfamidase leads to Sanfillopo syndrome with the lysosomal storage 
of HS-derived oligosaccharide terminating in GlcNS residues [34] and an excessive 
urinary excretion of HS [35].
Heparanase. Cleavage of HS is mediated by heparanase (HPSE), an endo-β(1-4)-D-
glucuronidase that hydrolyzes the β(1,4)-glycosidic bond within the HS polysaccharide 
chain at specific sites [36]. Studies for heparanase substrate specificity revealed that 
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heparanase requires specific modifications for binding and cleavage (Figure 3). The 
presence of a N-sulfated residue at the reducing end and a 6-O-sulfated residue at 
the non-reducing end of the cleavage site are essential for cleavage by heparanase. 
No essential requirements were found for 2-O-sulfation of GlcA or IdoA, which is 
located two residues away from the cleavage site toward the reducing end or for the 
presence of an IdoA residue. The presence of 3-O-sulfate groups at the reducing side 
caused inhibition of heparanase enzyme activity [37]. Two isoforms of the heparanase 
enzyme have been reported, HPSE-1 and HPSE-2, of which HPSE-2 showed no 
enzymatic activity [38]. Furthermore, several splice variants of heparanase have been 
reported [39]. The HPSE cDNA encodes for an inactive 68 kDa pre-proheparanase. 
After removal of a 3 kDa N-terminal signalling protein, yielding a 65 kDa inactive 
proheparanase, heparanase can be activated after proteolytic processing by cathepsin 
L. This yields a heterodimer consisting of an 8 kDa subunit and a 50 kDa subunit 
[40, 41]. Formation of this heterodimer is necessary for heparanase activity [42]. 
Heparanase is stored in endosomes and processed in lysosomes and secreted in 
response to a proper stimulus [43, 44]. The optimal pH for heparanase enzyme activity 
is between pH 5.0 and 6.0, whereas at physiological pH heparanase is not active and 
can function as an adhesion molecule or signal inducer by binding to cells [45].
Figure 3: Enzymes involved in degradation and editing of HS. 6-O-sulfate endosulfatases 
are involved in the removal of a 6-O-sulfate group from GlcN residues (grey arrow). The large 
arrow indicates the HS cleavage site for heparanase, which degrades HS in short fragments. 
Sulfamidase catalyzes the removal of a sulfate group from GlcNS (black arrow). Abbreviations: 
HS, heparan sulfate; GlcN, glucosamine; GlcNS, N-sulfated glucosamine.
Development and application of anti-HS(PG)  antibodies
 Through the development of monoclonal antibodies against both the HS side 
chain and the major HSPG core protein agrin in the GBM [46, 47], we were able to 
analyze HS and agrin expression in various glomerular diseases [48]. In general, in 
many experimental and human glomerular diseases, a decreased expression of HS 
was found in the GBM, which inversely correlated with the degree of albuminuria. 
Importantly, expression of the agrin core protein in the GBM was not affected in 
glomerular diseases. Because the focus of this thesis on diabetic nephropathy (DNP), 
we will briefly review the findings with regard to DNP.
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Heparan sulfate in diabetic nephropathy
 A decade ago, about 30-40% of the patients with type 1 diabetes eventually 
developed DNP, in most cases on average 15 years after the onset of diabetes. However, 
in recent years the cumulative incidence of DNP in type 1 diabetes has dropped, due 
to more intensive glycemic control [49]. In contrast, the cumulative incidence of DNP 
in type 2 diabetes is dramatically increased, in general due to the massive increase in 
average body weight in the Western world, and due to the prolonged survival of type 2 
diabetic patients [50]. One of the earliest detectable changes in the occurrence of DNP 
is the presence of elevated levels of protein (albumin) in the urine. At the onset of DNP, 
a small amount of albumin (30-300 mg/24h) is excreted, defined as microalbuminuria. 
Microalbuminuria may progress to macroalbuminuria (>300 mg/24h), which can 
eventually lead to end stage renal disease. 
 For the last 2 decades, loss of HS in the GBM has been suggested to play a key role 
in the pathophysiology of DNP, with a primary role of GBM-HS in charge-selective 
filtration. In both experimental and human DNP, a decrease of HS and HS-associated 
anionic sites has been demonstrated in the basement membranes of vessel walls and 
skin [51-53]. Furthermore, we have previously reported a loss of HS expression in 
the GBM of patients with advanced stages of DNP, which was inversely correlated 
with the degree of proteinuria [54, 55]. The loss of HS from the GBM was mainly 
documented in advanced stages of DNP, while in patients with microalbuminuria this 
decrease was not found [56, 57]. Therapeutic intervention studies with heparin or 
heparinoids in experimental and human type 1 diabetes prevented loss of GBM anionic 
sites and reduced albuminuria [58]. In rats with diabetes, undersulfated HS has been 
described in liver, intestine and glomeruli [59, 60]. The Steno hypothesis postulated 
that the decrease of HS in the extracellular matrix is caused by a genetic defect in the 
regulation of HS production and in particular N-sulfation mediated by NDSTs, which 
determined the susceptibility for the development of proteinuria in patients with DNP 
[61]. Therefore, a possible explanation for the decreased expression of HS may be a 
decrease in the biosynthesis of HS by one or more NDST isoforms. Alternatively, we 
propose an increase in the HS degradation by heparanase as a possible mechanism of 
reduced HS expression in basement membranes in DNP (see below).
Involvement of NDSTs in diabetic nephropathy
 Undersulfation and loss of HS in DNP could be due to an altered and/or decreased 
biosynthesis and modification of HS, regulated by the key NDST enzymes. A number 
of studies have reported a diabetes-induced inhibition of NDST expression and 
activity in liver and glomeruli of rats with streptozotocin-induced diabetes [62-64]. 
Importantly, the degree of NDST inhibition correlated with the blood glucose level in 
diabetic rats [65]. Very recently, HS disaccharide analysis revealed that less N-sulfated 
HS was present in glomeruli of rats with prolonged diabetes [66]. In contrast with 
these findings, no changes in N-sulfation or glomerular HS structure were observed in 
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rats with streptozotocin-induced diabetes in another recent study [57]. We also found 
no changes in mRNA expression of the different NDST isoforms expression in isolated 
glomeruli of diabetic rats and in glomerular cell lines, cultured in the presence of high 
glucose, advanced glycation end products (AGEs) or TGF-β (unpublished results). In 
conclusion, there is no evidence for changes in HS structure, in particular sulfation or 
an altered expression of NDSTs during early stages of DNP. 
Involvement of heparanase in diabetic nephropathy
 As mentioned, we hypothesize that an increased degradation of HS may also 
contribute to the loss of HS in DNP. This hypothesis was fueled by the fact that in 
several glomerular diseases an increased glomerular expression of heparanase was 
found, which was consistently associated with a decreased expression of HS in the 
GBM [67-71]. Importantly, in passive Heymann nephritis, inhibition of heparanase 
with specific heparanase neutralizing antibodies reduced proteinuria [69]. Finally, in 
the urine of patients with diabetes, an increased heparanase activity was detected [72-
74]. Taking these results together, a role for heparanase in the pathogenesis of DNP is 
likely.
Scope of this thesis
The studies presented in this thesis were aimed at: 
1) Evaluation of the expression of heparanase in diabetic nephropathy.
2) Identification of possible mechanisms involved in the regulation of glomerular  
 heparanase expression in vivo and in vitro.
Heparanase expression in diabetic nephropathy
 In the first part of the thesis we examined the role of heparanase in DNP. A decrease 
of HS expression in the GBM in DNP was proposed to be caused by an increased 
degradation of HS by heparanase. We determined the expression of heparanase and 
the possible association with HS expression in the GBM in advanced stages of both 
experimental and human DNP (Chapter 2). 
Heparanase cleaves HS at specific sites and specific structures within HS are required 
for the binding to heparanase and the cleavage of HS by heparanase. In Chapter 3, 
we studied whether heparanase induced a differential loss of HS domains in patients 
with overt DNP.
 Since patients with diabetes showed increased levels of active heparanase in the 
urine, we investigated whether this increased activity was associated with the degree 
of albuminuria in the urine of patients with type 1 and type 2 diabetes, and in the urine 
of patients with membranous glomerulopathy, as non-diabetic proteinuric controls 
(Chapter 4).
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Regulation of heparanase expression
 In the second part of this thesis, we addressed the mechanisms that could play a 
role in the regulation of heparanase expression. Treatment with angiotensin converting 
enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB) have a beneficial 
effect on proteinuria in several renal diseases, which is not only mediated by regulation 
of the intraglomerular pressure, but possibly also by preservation of HS integrity in the 
GBM [75]. Additionally, scavenging hydroxyl radicals also prevented the loss of HS 
in the GBM [76]. We evaluated whether interfering with the renin-angiotensin-system 
or reactive oxygen species (ROS) influenced heparanase expression in adriamycin 
nephropathy, a model for chronic proteinuria-induced renal damage (Chapter 5). 
 Aldosterone has been implicated as an additional mediator for the development 
and progression of renal disease, independent of renin or angiotensin II. Addition of 
an aldosterone receptor blocker (aldoRB) to an ACEi has additional beneficial effects 
in the prevention of renal injury [77, 78]. To our knowledge, no data are available 
about the effects of aldosterone on heparanase expression. Therefore, we studied the 
effect of treatment with ACEi, aldoRB or their combination on glomerular HS and 
heparanase expression in adriamycin nephropathy. Furthermore, we studied in vitro 
the effect of aldosterone, angiotensin II and ROS on heparanase mRNA expression by 
cultured mouse podocytes (Chapter 6). 
 Mice with transgenic heparanase overexpression (HPSE-tg) were recently 
generated and showed impaired renal function. In Chapter 7, we further analyzed 
the effect of transgenic heparanase overexpression on the expression of different HS 
domains in kidney and other tissues, and on the renal phenotype of HPSE-tg mice 
and control wild-type littermates. Furthermore, we mimicked the in vivo action of 
heparanase by treating renal sections of normal mice with recombinant heparanase.  
Considerations
 The impact of heparanase on glomerular HS expression and proteinuria are 
reviewed and discussed in Chapter 8. Furthermore, recent findings are addressed, 
which question the primary role of HS for glomerular permselectivity for proteins. 
Finally, the findings of the studies presented in this thesis are summarized and the 
future perspectives are discussed in Chapter 9.
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Abstract
 In overt diabetic nephropathy (DNP), an increase in the permeability of the 
glomerular basement membrane (GBM) has been associated with a loss of negatively 
charged heparan sulfates (HS) in the GBM. Heparanase (HPSE), an endo-β(1-4)-D-
glucuronidase, can cleave HS and could be a potential candidate for the degradation 
of glomerular HS, leading to the development of proteinuria. We analyzed whether 
changes in HS expression are associated with HPSE expression in overt DNP. 
 Immunofluorescence staining was performed to analyze HS, HPSE, and agrin core 
protein expression in kidney biopsies from patients with overt DNP and from rats and 
mice with streptozotocin (STZ)-induced diabetes. We also investigated the effect of 
transgenic HPSE overexpression in mice on glomerular HS and agrin expression. 
 We demonstrate that the loss of GBM HS (-50%) and tubular HS (-60%) is 
associated with a four-fold increased HPSE expression in overt DNP. In addition, 
glomerular HPSE expression is upregulated in rats mRNA 2.5-fold, protein three-
fold) and mice (mRNA seven-fold, protein 1.5-fold) with STZ-induced diabetes. 
Furthermore, transgenic HPSE overexpression results in disappearance of HS, whereas 
expression of the core protein agrin remains unaltered. 
 Our observations suggest that HPSE is involved in the pathogenesis of proteinuria 
in overt DNP by degradation of HS.
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Introduction
 DNP develops in patients with type 1 (insulin-dependent) or type 2 (non-insulin-
dependent) diabetes mellitus and is the most common cause of end-stage renal disease 
in the western world [1, 2]. In the early phase of human DNP, there is a preferential 
urinary loss of albumin, consistent with a loss of negatively charged HS in the GBM. 
Several human and experimental studies have shown that a reduction of glomerular 
HS was associated with an increased permeability of proteins through the GBM. 
Heparitinase digestion of glomerular HS resulted in an increased permeability for 
native albumin and ferritin in rats [3, 4]. Administration of a monoclonal antibody 
against HS caused massive albuminuria in rats [5]. Importantly, a decrease of HS side 
chains in the GBM has been described in human DNP, which was inversely correlated 
with the degree of albuminuria [6, 7]. Finally, treatment with heparin or heparinoids 
in experimental and human DNP prevented loss of GBM anionic sites and reduced 
albuminuria [8, 9]. 
 Several mechanisms could lead to the reduction of HS in proteinuric diseases [10]: 
(1) masking of HS by immune complexes [11]; (2) HS depolymerization by radicals 
[12]; (3) hyperglycemia-induced reduction of both HS expression and HS sulfation 
[13]; (4) complement-mediated cleavage of HS [14]; and (5) proteolytic cleavage of 
the HS attachment site on heparan sulfate proteoglycans by enzymes [15]. 
 We hypothesize that the HS-specific endo-β-D-glucuronidase HPSE can be 
involved in the degradation of HS in overt DNP. HPSE catalyzes the hydrolytic 
cleavage of the β(1,4)-glycosidic bond between glucuronic acid and glucosamine 
residues within HS [16]. HS degradation by HPSE results in the release of many HS-
bound molecules including growth factors, extracellular matrix molecules, enzymes, 
enzyme inhibitors, chemokines, and cytokines, which are involved in processes such 
as extravasation, growth, and chemotaxis of cells. In addition, cleavage of HS chains 
leads to disassembly of the basement membranes and facilitates cell migration and 
invasion of tumor cells into tissues [16, 17]. Besides its role in extracellular matrix 
degradation, HPSE is also involved in many other biological and pathological 
processes, such as liver development, embryonic development, cell differentiation, 
cell growth, morphogenesis, tissue repair, tumor metastasis, angiogenesis, and 
inflammation [18-20]. 
 Recent studies revealed that HPSE could be involved in the degradation of HS 
within the GBM, leading to proteinuria in several (experimental) proteinuric diseases. 
It has been demonstrated that HPSE activity is increased in the urine of patients with 
type 1 diabetes [21, 22]. Several experimental studies showed that glomerular HPSE 
expression was upregulated in rats with puromycin aminonucleoside nephrosis [23], in 
passive Heymann nephritis (PHN) [24] and in a model of accelerated anti-GBM disease 
[25]. Administration of the HPSE inhibitor PI-88 to rats with PHN reduced proteinuria 
almost two-fold, which was associated with preservation of the amount of HS in 
the GBM [26]. Transgenic overexpression of HPSE in mice resulted in proteinuria, 
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which was accompanied by effacement of podocyte foot processes [27]. Involvement 
of glomerular HPSE has also been demonstrated in patients with minimal change 
disease (Rutjes et al., submitted) and HPSE activity was increased in the urine of 
children with steroid-sensitive nephrotic syndrome [28]. A recent study demonstrated 
an upregulation of HPSE in the glomeruli of patients with DNP. Additionally, in vitro 
data in this study demonstrated that high glucose was able to induce HPSE expression 
in podocytes, which was associated with a slight reduction of cell surface HS [29].
 In this study, we evaluated whether changes in glomerular HS are associated 
with an increased HPSE expression in overt DNP. We demonstrated a correlation 
between glomerular HPSE and HS expression in patients with DNP. In streptozotocin 
(STZ)-induced diabetes in rats and mice, both glomerular HPSE mRNA and protein 
expression were upregulated. Finally, we found that transgenic overexpression of 
HPSE, leads to loss of glomerular HS expression, whereas the expression of the agrin 
core protein did not change.
Materials and methods
Human renal tissue
 We evaluated renal biopsies from 11 patients with overt DNP from patients 
with type 2 diabetes mellitus. Control renal tissue was obtained from five non-
diabetic individuals, from donor kidneys for anatomical reasons not suitable for 
transplantation, and from a normal part of kidneys removed for renal adenocarcinoma. 
Clinical characteristics of the diabetic patients are presented in Table 1. The Human 
Ethics Review Committee of the Academic Medical Center Amsterdam approved the 
analysis of the human kidney biopsies.
Patient
Age
(years)
Gender
Duration
of diabetes 
(years)
HbA1c
(%)
Systolic 
BP
(mmHg)
Diastolic 
BP
(mmHg)
Proteinuria
(g/24 h)
1 66 M > 4 6.8 180 80 2.4
2 59 F 28 7.8 190 110 5.0
3 71 M > 3 6.2 150 90 4.6
4 76 M 5 7.3 150 70 18.0
5 51 F 4 8.8 160 80 2.4
6 65 M 20 7.2 120 65 4.1
7 49 M > 12 6.4 160 85 15.9
8 59 F 19 7.4 130 70 6.1
9 57 M 20 NA 186 75 3.0
10 64 F 14 NA 150 70 3.0
11 64 F 7 6.0 160 90 3.5
Table 1. Clinical characterization of patients with type 2 diabetes and overt DNP 
included in this study.
BP, blood pressure; DNP, diabetic nephropathy; F, female; M, male; NA, not available.
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Animal models
 Rats. Diabetes was induced in male Wistar–Münich rats (n=4; Jackson Laboratory, 
Bar Harbor, USA) by intravenous injection of STZ (55 mg/kg body weight). Sex- 
and age-matched control rats (n=4) received saline. Blood glucose levels were 
maintained around ~25 mmol/l by treatment with 1.2 IU of bovine insulin (Ultralente; 
Novo, Copenhagen, Denmark) three times a week. Body weight, blood glucose, 
urine production, and albuminuria were measured as described previously [13]. 
Characteristics are listed in Table 2. Five months after the induction of diabetes, rats 
were killed and kidneys were processed for analysis.
 Mice. C57Bl6/J female mice (n=6; Harlan, Horst, The Netherlands) were injected 
intraperitoneally with 200 mg/kg body weight STZ in 10mM citrate buffer (pH 4.6). 
Controls (n=4) received citrate buffer only. Blood glucose levels were measured every 
3 days and urine samples were collected at 2, 4, 6, 9, 11, and 13 weeks after induction 
of diabetes to determine albuminuria as described previously [30]. Slow release insulin 
pellets (Linshin Canada Inc., Ontario, Canada) were implanted subcutaneously when 
blood glucose rose above 20 mmol/l. Mice were not ketotic and were killed after 17 
weeks of diabetes and tissue samples were processed for analysis. Characteristics are 
listed in Table 2. In addition, kidney tissue was analyzed from transgenic mice, which 
overexpress HPSE in all tissues [27]. Radial immunodiffusion, as described previously 
[31, 32], was used to determine albuminuria in HPSEtg mice (n=11) and controls 
(n=9). Urinary creatinine was measured enzymatically (Roche Diagnostics, Penzberg, 
Germany) and urinary albumin excretion was expressed as the ratio: mg albumin/mg 
creatinine. The local Animal Ethical Committees approved the animal experiments.
Parameters
Rats (5 months) Mice (17 weeks)
Controls (n=4) Diabetic (n=4) Controls (n=4) Diabetic (n=6)
Body weight at 
day 0 (g) 211 ± 13.0 211 ± 11.0 22.7 ± 2.0 22.4 ± 1.0
Body weight at 
sacrifice (g) 365 ± 36.0 268 ± 30.0
* 27.9 ± 3.4 24.4 ± 1.6
Blood glucose 
(mmol/l) 3.9 ± 0.2 21.1 ± 1.3
* 7.4 ± 1.5 24.8 ± 1.8*
Albuminuria 0.3 (0.1-0.6)† 39.3 (33.1-64.4)†* 43 (29.5-59)‡ 135.5 (83.5-169)‡*
RNA isolation and real-time reverse transcription-polymerase chain reaction
 Total RNA was isolated from rat and mouse kidney tissue using the RNeasy mini-kit 
(Qiagen Benelux, Venlo, The Netherlands). In rats, mRNA was isolated from purified 
glomeruli [33] and in mice from renal cortex. One microgram of RNA was reverse 
Heparanase expression in diabetic nephropathy
Table 2. Characteristics of rats and mice with STZ-induced diabetes and controls.
Data are given as means ± SD or as medians (range). * P< 0.05 compared to rat or mice controls. 
†Albuminuria (mg/24 hours). ‡Albuminuria (mg/g creatinine). STZ, streptozotocin. 
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transcribed into cDNA using Oligo-dT priming and Superscript reverse transcriptase 
(Invitrogen Life Technologies, Breda, The Netherlands). HPSE expression was 
quantified by real-time polymerase chain reaction using iQTM SYBR Green Supermix 
and the MyiQTM real-time polymerase chain reaction system (Bio-Rad Laboratories, 
Veenendaal, The Netherlands). Polymerase chain reaction conditions: denaturation 
at 95ºC for 3 min, followed by 40 cycles of 95ºC for 15 s, 57ºC for 30 s, and 72ºC 
for 30 s and finally elongation at 72ºC for 10 min. Rat primers: HPSE: forward (F) 
5’-gaagcaaactccgagtgtac-3’, reverse (R) 5’-ggtttgaccgttcagttgg-3’; RNA polymerase 
II: (F) 5’-gactttgatgacgtggagg-3’, (R) 5’-ggtcgttcaccagatgggag-3’. Mouse primers: 
HPSE: (F) 5’-ggagcaaactccgagtgtatc-3’, (R) 5’-cagaatttgaccgttcagttgg-3’; β-actin: 
(F) 5’-tgggccgctctaggcaccaa-3’, (R) 5’-ctctttgatgtcacgcacgatttc-3’; RNA polymerase 
II: (F) 5’-caccacgtccaatgatattgtgg-3’, (R) 5’-gtgctgctgcttccataagg-3’ (Biolegio BV, 
Malden, The Netherlands). Expression of the housekeeping genes β-actin and/or RNA 
polymerase II was used to quantify HPSE expression by the delta-delta cycle time (C
t
) 
method.
Immunofluorescence staining and HPSE treatment of mouse kidney sections
 Human DNP. Kidney biopsy sections (5 µm) were fixed in 100% acetone for 10 min 
at 4ºC. Sections were incubated with primary antibodies (all listed in Table 3) diluted 
in phosphate-buffered saline (PBS) for 1 h at room temperature, washed twice in PBS, 
and incubated with the appropriate secondary antibodies diluted in PBS containing 
4% normal human serum and 4% normal goat serum for 1 h at room temperature. 
Subsequently, sections were washed in PBS, embedded in Vectashield mounting 
medium H-1000 (Vector Laboratories Inc., Burlingame, CA, USA) and examined 
with confocal laser scanning microscopy (CLSM; Leica, Heidelberg, Germany). At 
least three glomeruli per section were evaluated by three independent observers. For 
agrin and HS expression, linearity of the GBM was scored at an arbitrary scale of 
0–10 (arbitrary units (A.U.); 0= no staining, 1= 10% linear GBM staining, etc., with 
a maximum score of 10 for 100% linearity) and for HPSE expression, a scale of 0–5 
was used for staining intensity. Scoring between the three different observers was 
consistent, because regression analysis yielded a good correlation for the scores of HS 
(r2 = 0.84, r2 = 0.83, r2 = 0.84; all P< 0.001) and HPSE (r2 = 0.80, r2 = 0.74, r2 = 0.79; 
all P< 0.001). To investigate which cell type could be responsible for the expression 
of HPSE in the glomeruli of patients with DNP, immunofluorescence double stainings 
with HPSE were performed as described above, except that antibodies were diluted in 
PBS with 1% bovine serum albumin. Synaptopodin was used as a podocyte marker, 
agrin was used to distinguish between the inside and the outside of the glomerular 
capillaries, and perlecan was used as a marker for the mesangium. To test in which 
tubuli from both controls and patients with DNP expression of HPSE was observed, 
we performed immunofluorescence double stainings with HPSE and a marker for 
proximal tubuli (P-glycoprotein), a marker for distal convoluted tubuli (calbindin D-
28k) or aquaporin 2, which recognizes the collecting duct (Table 3).
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 Experimental DNP and HPSE treatment. HS, agrin, and HPSE expression was 
determined in kidneys of rats and mice with STZ-induced diabetes, in kidneys of mice 
with HPSE overexpression, and in normal mouse kidney tissue after treatment with 
HPSE. Sections (2 µm) were fixed in 100% acetone for 10 min at 4ºC. For treatment 
of normal mouse kidney tissue with active HPSE, unfixed kidney sections were 
incubated with 0.22 µg/ml active recombinant mouse HPSE [34] for 2 h at 37ºC in 
50mM sodium acetate buffer (pH 5) after which sections were washed in PBS and 
fixed for 10 min in 100% acetone at 4ºC. Staining of HS, HPSE, and the agrin core 
protein was performed as described above. Normal goat serum (4%) and normal rat 
serum (4%) were added to the secondary antibodies on rat sections. To detect HS on 
mouse kidney tissue, we labeled our monoclonal antibody JM403 with digoxigenin 
(DIG; Roche Diagnostics, Penzberg, Germany). Sections were coded randomly and 
evaluated by two independent observers as described above.
Western blot analysis
 Renal cortex from rats with STZ-induced diabetes and controls was lysed in 50mM 
Tris-HCl (pH 8.0), 150mM NaCl, 0.5% Triton X-100 (Sigma, Zwijndrecht, The 
Netherlands), and ethylenediaminetetraacetic acid-free protease inhibitors (Roche). 
Equal amounts of total protein (3 mg; determined with bicinchoninic acid (Sigma)) were 
incubated overnight at 4ºC with 100 µl of washed heparin-agarose beads (Sigma) [35]. 
Beads were washed in PBS and then boiled in 100 µl Laemli sample buffer. Sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis was performed and proteins were 
transferred to a polyvinylidene difluoride membrane (Bio-Rad). After blocking with 
1% Boehringer blocking reagent (Roche) in PBS, HPSE protein was detected by 
incubation with HPA1 for 1 h (ProsPecTany, 1:700), followed by a 1-h incubation with 
a peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology, Heidelberg, 
Germany, 1:8000). HPSE protein was visualized using a chemiluminescence substrate 
(Perbio Science, Etten-Leur, The Netherlands) and enhanced chemiluminescence 
hyperfilm (Amersham Biosciences, Buckinghamshire, UK).
Statistical analysis
 Values are expressed as means ± SD or as medians with ranges when appropriate. 
Comparison of expression levels between the different groups was evaluated using the 
non-parametric Mann-Whitney U test. The non-parametric Spearman’s rank test was 
used to calculate correlation between the different variables. A value of P< 0.05 was 
considered significant. We used GraphPad Prism 4.0 (GraphPad Software Inc., San 
Diego, CA, USA) for the analysis of our data.
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Results
Expression of HPSE in human diabetic nephropathy 
 Clinical characteristics of the diabetic patients are presented in Table 1. We 
evaluated the expression of HS, HPSE, and agrin, by indirect immunofluorescence in 
kidney biopsies from macroalbuminuric diabetic patients and normal controls (Figure 
1). In control kidney sections, a linear staining of the core protein of agrin and HS 
was observed along the GBM, which fully co-localized (Figure 1A). However, in 
the glomeruli of patients with DNP, a decreased staining of HS along the GBM was 
observed, whereas the expression of the core protein of agrin in the GBM did not 
change (Figure 1C). Glomerular HPSE expression was increased in patients with DNP 
(Figure 1D), whereas in the normal human kidney, only a weak staining of HPSE could 
be observed (Figure 1B).
Figure 1. Expression of HS, HPSE, and agrin in human DNP. Immunofluorescence double 
stainings of (A and C) agrin (red) with HS (green) and (B and D) HS (green) with HPSE (red) 
in kidney sections from (C and D) patient with overt DNP and (A and B) a control. (A) Co-
staining of agrin with HS revealed a linear colocalization (yellow) along the GBM in controls, 
(C) whereas reduction of glomerular HS was observed in patients with DNP. Decrease of 
glomerular HS expression in diabetic patients was associated with an upregulation of HPSE in 
the glomeruli of (D) diabetic patients compared to (B) controls. Original magnification x63. For 
full-colour representation see; Colour Figures.
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 In Figure 2, we present the quantitative analysis of the expression of HS and HPSE. 
In the glomeruli, HS was significantly decreased in patients with DNP (P< 0.001, 
Figure 2A), which was associated with an increased HPSE expression (P< 0.001, 
Figure 2B). A similar change was found in the tubular expression of HS and HPSE (P< 
0.001, Figure 2C and D). In this study, we found an inverse correlation between GBM 
HS expression and the degree of proteinuria (Figure 2E; r = -0.56, P< 0.001), which 
is in line with our previous results [6]. In addition, we observed a correlation between 
glomerular HS and HPSE expression (Figure 2F; r = -0.29, P< 0.05).
Figure 2. Quantitative analysis 
of HS and HPSE expression 
in human DNP. Staining of HS 
and HPSE was scored by three 
independent observers on a scale 
between 0 and 10 for HS linearity 
or on a scale between 0 and 5 for 
HPSE intensity in arbitrary units 
(A.U.). Points represent mean 
scores from each individual 
glomerulus or tubular photograph 
and horizontal lines represent 
median values of these scores. 
HS expression was significantly 
reduced both in (A) glomeruli and 
(C) tubuli, whereas expression 
of HPSE was increased in both 
(B) glomeruli and (D) tubuli 
of patients with overt DNP 
compared to the controls. There 
was an inverse correlation 
between (E) glomerular HS and 
proteinuria and between (F) 
glomerular HS and glomerular 
HPSE expression. ***P< 0.001. 
 To evaluate the localization of the increased glomerular HPSE expression in 
diabetic patients, we performed double stainings with HPSE and antibodies against 
epitopes localized in the GBM (agrin), podocytes (synaptopodin), and mesangial cells 
(perlecan). Staining of HPSE co-localizes partly with agrin (Figure 3A), as well as 
with synaptopodin (Figure 3B), but not with perlecan (Figure 3C). The staining along 
the GBM with agrin reveals the extracellular presence of HPSE, whereas the staining 
with synaptopodin supports the intracellular localization of HPSE in podocytes. 
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Furthermore, the positive staining of HPSE within some capillary loops suggests that 
also endothelial cells express HPSE. We do have unpublished data that conditionally 
immortalized mouse glomerular endothelial cells [36] and podocytes express HPSE 
both at the mRNA and protein level.
 To define more precisely in which tubular segment HPSE was mainly localized, 
we performed co-stainings of HPSE with markers for specific segments of the 
tubular system, that is proximal tubules (P-glycoprotein), distal convoluted tubules 
(calbindin D-28k), and the collecting ducts (aquaporin-2). As shown in Figure 3D, 
HPSE expression was mainly localized in the proximal tubules identified with anti-
P-glycoprotein in both controls and diabetic patients. HPSE expression did not co-
localize with calbindin D-28 k and aquaporin-2 (data not shown).
Figure 3. Localization of 
HPSE in human DNP. 
Immunofluorescence double 
staining of HPSE with 
glomerular markers for the 
GBM (agrin), podocytes 
(synaptopodin), or mesangial 
cells (perlecan) in a patient with 
overt DNP. HPSE expression co-
localizes with both (A) agrin and 
(B) synaptopodin, representing 
the extracellular and intracellular 
HPSE expression, respectively. 
(C) However, HPSE is not 
expressed by mesangial cells. 
(D) Tubular HPSE is mainly 
expressed in proximal tubuli, 
determined by co-staining with 
anti-P-glycoprotein. Original 
magnification x63. For full-
colour representation see; 
Colour Figures.
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Figure 4. HS and HPSE expression in rats with STZ-induced diabetes. (A) 
Immunofluorescence staining of the increased HPSE expression and decreased HS expression 
in kidneys of diabetic rats. (B) Western blot analysis was used to confirm an increased HPSE 
protein expression in renal cortex of rats with STZ-induced diabetes compared to controls. 
(C) HS expression was decreased, however, no statistical significance could be observed. (D) 
Quantification revealed that both HPSE protein and HPSE mRNA expression were upregulated 
in glomeruli of diabetic rats compared to controls. Horizontal lines represent median values. 
*P< 0.05. A.U. arbitrary units; rHPSE, recombinant heparanase.
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HPSE expression in rats and mice with STZ-induced diabetes 
 Five months after the induction of diabetes in rats, we observed an increased 
staining of glomerular HPSE compared to controls, which was accompanied by 
a reduction of GBM HS (Figure 4A). Increased HPSE protein expression in rats 
with STZ-induced diabetes was confirmed by Western blot analysis. In renal 
cortex of diabetic rats, the 50 kDa subunit, which is the active form of HPSE, was 
present, whereas it was undetectable in controls (Figure 4B). Quantification of 
immunofluorescence stainings showed that HS expression was reduced in diabetic 
rats. However, loss of HS expression in the GBM did not reach statistical significance 
(Figure 4C). Furthermore, both HPSE protein (immunofluorescence) as well as mRNA 
expression were significantly increased in diabetic rats compared to controls (P< 0.05, 
Figure 4D). In diabetic mice, we also observed elevated levels of HPSE mRNA (seven-
fold; P< 0.01) compared to controls (Figure 5A). In addition, glomerular HPSE protein 
expression was also significantly increased (P< 0.05, Figure 5B), although glomerular 
HS expression was not significantly reduced (P< 0.05, Figure 5C). Interestingly, the 
decrease of HS expression correlated with both the elevated HPSE protein expression 
(Figure 5D; r = -0.82, P< 0.05) and HPSE mRNA expression (data not shown; 
r = -0.72, P< 0.05).
Figure 5. HS and HPSE 
expression in mice with STZ-
induced diabetes. (A) Renal 
cortex of mice with STZ-
induced diabetes contained a 
significantly higher amount 
of HPSE mRNA compared 
to controls. (B) HPSE protein 
expression was significantly 
increased and (C) HS 
expression was decreased, 
although not significant. 
Sections were coded randomly 
and staining was evaluated by 
two independent observers on 
a scale of 0–10 for HS linearity 
and on a scale of 0–5 for HPSE 
staining intensity. Horizontal 
lines represent median values. 
(D) HS expression inversely 
correlated with HPSE mRNA 
expression. **P< 0.01, 
*P< 0.05. A.U., arbitrary 
units.
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Transgenic overexpression of HPSE in mice
 To investigate whether overexpression of HPSE is associated with a decrease of 
glomerular HS expression, we stained kidney sections from mice with transgenic 
overexpression of HPSE (HPSE-tg) with specific antibodies. Overexpression of HPSE 
was observed in both tubuli and glomeruli of transgenic mice compared to controls, 
which resulted in an almost complete absence of the expression of HS (Figure 6A). 
This underlines the importance of HPSE for HS degradation. Next, we evaluated 
whether HPSE overexpression affects the expression of the core protein of agrin, to 
which HS is attached. No differences in expression of the core protein of agrin were 
observed between HPSEtg mice and controls (Figure 6A). Expression of perlecan and 
collagen IV in HPSEtg mice also remained unchanged (data not shown). In addition, 
we observed a significant increase in urinary albumin excretion in HPSEtg mice 
compared to controls (Figure 6B). To mimic the effect of HPSE overexpression, we 
applied recombinant active HPSE to normal mouse kidney sections. Similar to the 
in vivo situation with transgenic overexpression of HPSE, we observed an almost 
complete disappearance of HS, whereas the expression of the core protein of agrin 
was unaffected (Figure 6C).
Figure 6. Glomerular expression of HPSE, HS, and agrin in mice with transgenic HPSE 
overexpression and after treatment with active HPSE. (A) HPSE expression is increased 
in the HPSE-tg mouse kidney compared to the control. HS expression was markedly reduced 
in the kidney of mice with transgenic overexpression of HPSE, whereas agrin core protein 
expression did not differ. (B) A significant increase in the urinary albumin excretion was 
observed in HPSE-tg mice compared to controls. (C) After exposure of kidney sections to 
recombinant active HPSE, HS staining almost completely disappeared, whereas it did not 
affect agrin expression. Original magnification x100. *P< 0.05.
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Discussion
 We demonstrate that the reduction of HS moieties in the glomeruli of patients 
with type 2 diabetes and overt DNP is correlated with an upregulation of HPSE. 
This association has been suggested previously in studies that describe an increased 
HPSE expression in experimental models of proteinuria, such as PHN, puromycin 
aminonucleoside nephropathy, and anti-GBM nephritis [23-25] Inhibition of HPSE 
in PHN by PI-88 reduced proteinuria and partly preserved HS staining, which 
suggests that HPSE is at least partly responsible for the development of proteinuria 
[26]. Recently, it has been reported that glomerular HPSE expression was increased 
in patients with DNP. However, needle biopsies from autopsy specimens were used 
and renal HS expression was not evaluated [29]. We found a correlation between the 
loss of HS and the expression of HPSE in the glomeruli, which suggest that HPSE is 
responsible for the glomerular degradation of HS and, possibly, for the development of 
proteinuria in overt human DNP.
 These data are further supported by our observations in the STZ-induced diabetes 
model (model for type 1 diabetes) in rats and mice. Both HPSE mRNA and protein 
expression were increased in diabetic rats and mice, which was associated with a 
decrease in HS expression. In mice with STZ-induced diabetes, this HS expression 
was correlated with both HPSE mRNA and protein expression. However, this decrease 
in HS expression did not reach statistical significance. This is in line with our previous 
observation in this model using JM403 for HS staining, in which only a relative 
decrease of HS compared to increased collagen IV content of the GBM was observed 
[13, 37]. JM403 reacts with free amine groups in glucosamine [38] and a decrease in 
N-sulfation (leading to an increased staining) may compensate a decrease in staining 
owing to a decrease in the amount of HS. This possibility is underlined by our 
observation that in basement membranes of capillary muscles, an increased staining of 
JM403 was found in diabetic patients with normo- and microalbuminuria, whereas in 
patients with macroalbuminuria staining was decreased [39]
 Recently, we obtained evidence that in the very early phase of DNP (i.e. 
microalbuminuria) glomerular HS was not decreased [40, 41]. This was also suggested 
by a study of Vernier et al. [42], which demonstrated that cuprolinic blue staining 
in the GBM was not decreased in microalbuminuria, suggesting that decrease of 
glomerular HS starts in more advanced phases of DNP, as we have found in this study. 
Previously, we demonstrated that HS expression was decreased in the dermal basement 
membrane in skin biopsies from patients with DNP [43]. Preliminary data show that 
HS expression in skin biopsies from diabetic patients normalized after succesful 
pancreas transplantation, suggesting that changes in HS are reversible if euglycemia is 
restored.
 Glomerular HPSE expression in patients with overt DNP is mainly localized in 
podocytes and endothelial cells. This is supported by observations that podocytes and 
endothelial cells are the main cell types that express and release HPSE [23, 26]. It 
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is not clear yet what drives the increased HPSE expression in these cells, but there 
are some clues which mechanisms may be operative. Recently, it was demonstrated 
that high glucose was able to increase HPSE expression in podocytes, which was 
associated with a reduction of cell surface HS [29]. Another possible factor able to 
induce HPSE expression and activity may be angiotensin II. We have preliminary 
unpublished data that angiotensin II induces HPSE mRNA expression in cultured 
mouse podocytes. This is further corroborated by our observation that angiotensin-
converting enzyme inhibition in adriamycin nephropathy prevents loss of HS from 
the GBM [44] and that angiotensin II receptor 1 blockade reduces increased HPSE 
expression, restores HS loss from the GBM, and reduces proteinuria in the same model 
[45]. Finally, reactive oxygen species, especially hydroxyl radicals, are involved in the 
development of proteinuria in adriamycin nephropathy [12]. Recently, we found that 
besides depolymerization of HS [12], HPSE was also upregulated in this model, which 
could be prevented by the hydroxyl scavenger dimethylthiourea [45]. Currently, we 
are trying to elucidate the mechanisms that could be involved in a disturbed expression 
of HPSE in overt DNP and other nondiabetic glomerulopathies.
 HPSE expression was also observed in the cytoplasm of proximal tubules in both 
controls and diabetic patients. The presence of HPSE in tubuli of normal subjects 
suggests that HPSE is also involved in the normal physiology of these cells. In diabetic 
patients, increased urinary HS has been reported [46, 47]. As tubular HPSE expression 
is increased in diabetic patients, it is possible that the increased urinary excretion of HS 
originates from tubuli rather than from the glomerulus.
 Additionally, we demonstrate that transgenic HPSE overexpression results in a 
markedly reduced glomerular HS expression, whereas agrin core protein expression 
remains unchanged. As described previously and confirmed in this study, transgenic 
overexpression of HPSE resulted in an increased urinary protein excretion [27] which, 
along with our findings provides further evidence for a possible involvement of HPSE 
in the development of proteinuria. The reduction of HS expression in HPSE-tg mice 
was mimicked by treating kidney sections with HPSE, supporting that the decrease 
of HS was secondary to HPSE overexpression. Very recently, HPSE knockout mice 
have been generated and induction of diabetes into this model would be interesting to 
further elucidate the role of HPSE in the pathophysiology of DNP (Dr JP Li, Uppsala, 
Sweden, personal communication).
 We (yet unpublished) and others observed that heparin and several low molecular 
weight heparins can inhibit the enzymatic activity of HPSE [48-53]. Both experimental 
and clinical studies have shown that these heparin(oid)s can reduce proteinuria in both 
microalbuminuric and macroalbuminuric DNP (reviewed by Gambaro and van der 
Woude [54]). In experimental DNP, Gambaro et al. [9] showed that treatment with 
sulodexide reduced albuminuria, prevented GBM thickening and loss of HS from the 
GBM. At that time, it was not clear how this beneficial effect was exerted. Sulodexide 
can inhibit HPSE, so it is conceivable that this explains the renoprotective effect of 
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sulodexide. In addition, the HPSE inhibitor PI-88 was able to reduce proteinuria 
in PHN nephritis [26]. Unfortunately, these compounds do not only inhibit HPSE 
activity, but also exert other effects such as anti-coagulant activities. Recently, some 
well-defined specific HS-based HPSE inhibitors have been developed, but these 
compounds have a very short half-life of about 4 h, which makes it very difficult 
to study long-term HPSE inhibition in vivo in experimental DNP (I. Vlodavsky; yet 
unpublished results). Nevertheless, inhibition of HPSE has already been successfully 
applied in cancer treatment for its anti-metastatic potential [55]. Therefore, it remains 
to be determined whether inhibition of biological actions of HPSE in vivo with non-
coagulant heparinoids is a feasible goal for therapy in DNP.
 In conclusion, our data demonstrate that increased glomerular HPSE expression in 
human and experimental DNP and in mice with transgenic overexpression of HPSE 
is associated with a decrease of HS in the GBM and albuminuria. These data suggest 
that increased HPSE expression could be responsible for the decrease of HS in the 
GBM and the development of proteinuria. The observed anti-proteinuric effects of low 
molecular weight heparins in DNP underscore this idea [54]. Elucidation of the signals 
and underlying mechanisms that lead to HPSE overexpression by specific glomerular 
cell types may provide new clues for the generation of drugs against the development 
of DNP.
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Abstract
 Recent studies suggest that loss of heparan sulfate (HS) in the glomerular basement 
membrane (GBM) of the kidney with diabetic nephropathy (DNP) is due to the 
increased production of heparanase (HPSE), a HS-degrading endoglycosidase. Our 
present study addresses whether HS with different modifications is differentially 
reduced in the GBM and whether HPSE selectively cleaves HS with different domain 
specificities. 
 The HS content of renal biopsies (14 DNP and 5 normal) were analyzed by 
immunofluorescence staining with 4 anti-HS antibodies, including: JM403, a mAb 
recognizing N-unsubstituted glucosamine residues; two phage display-derived single 
chain antibodies HS4C3 and EW3D10, defining sulfated HS domains; and anti-K5 
antibody, a mAb recognizing unmodified HS domains. 
 We found that modified HS domains (JM403, HS4C3, and EW3D10) but not 
unmodified domains (anti-K5) and agrin core protein were reduced in the GBM of 
kidneys from patients with DNP, compared with controls. Glomerular HPSE levels 
were increased in DNP kidneys and inversely correlated with the amounts of modified 
HS domains. Increased HPSE production and loss of JM403 staining in the GBM 
correlated with the severity of proteinuria. Loss of modified HS in the GBM, as a 
result of degradation by HPSE was confirmed by HS staining of HPSE-treated normal 
kidney biopsy specimens.  
 Our data suggest that loss of modified HS in the GBM is mediated by an increased 
HPSE presence and may play a role in the pathogenesis of diabetes-induced 
proteinuria. 
44 45
Introduction
 HS is a negatively charged glycosaminoglycan linked to a core protein to form a 
HS proteoglycan, which is a major component of extracellular matrices [1]. Due to its 
negative charge, HS in the GBM has been implicated as having an important role in 
the maintenance of the charge-selective permeability of the glomerular capillary wall 
by electrostatic repulsion of negatively charged serum proteins, especially albumin. 
Elimination of GBM-HS after perfusion of isolated rat kidneys or glomeruli with the 
bacterial HS-degrading enzyme heparinase III resulted in increased permeability of 
the GBM to native ferritin and albumin [2-4]. Neutralization of GBM anionic charges 
after perfusion of isolated rat kidneys or infusion of the renal artery with the cationic 
probe protamine also resulted in an increased permeability of the GBM to albumin 
[4, 5]. In addition, binding to GBM-HS after intravenous injection of rats with the 
monoclonal anti-HS antibody JM403 induced an acute selective proteinuria [6]. 
 Patients with diabetes mellitus may develop nephropathy, which is a major cause 
of end-stage renal disease. DNP is initially characterized by a minor increase in 
urinary excretion of albumin, called microalbuminuria, which generally progresses 
to macroalbuminuria or overt proteinuria with subsequent decline of glomerular 
function. Ultrastructural changes in DNP include mesangial matrix expansion and 
thickening of the glomerular and tubular basement membranes [7-9]. In addition, 
changes in GBM-HS expression have been associated with the pathogenesis of DNP. 
Studies in patients with overt DNP revealed a decreased HS content within the GBM 
[10-14], which inversely correlated with the degree of albuminuria [11]. Expression of 
the core protein of agrin, the major HS proteoglycan in the GBM, was not aberrant [11, 
13]. However, these HS changes occur at the macroalbuminuric stage of DNP, since 
no glomerular HS alterations were found at the microalbuminuric stage [15]. Recently, 
we showed that glomerular expression of HPSE, an endo-β(1-4)-D-glucuronidase 
involved in the hydrolytic cleavage of the β(1-4)-glycosidic bond between glucuronic 
acid and glucosamine residues within N-sulfated and/or N-acetylated/N-sulfated 
domains of HS [16, 17], was increased in patients with overt DNP [11, 18]. In addition, 
HPSE activity could be detected in the urine of diabetic patients [19].
 Not only quantitative alterations, but also qualitative differences in GBM-HS 
expression may play a role in the pathogenesis of DNP. HS biosynthesis starts by the 
addition of a xylose-galactose-galactose-glucuronic acid tetrasaccharide to specific 
serine residues in the core protein. After addition of the first N-acetylglucosamine, 
polymerization takes place by the alternating addition of glucuronic acid and N-
acetylglucosamine residues. The growing HS polysaccharide precursor may undergo 
extensive but localized modifications, including N-deacetylation and N-sulfation, C5-
epimerization, and O-sulfation at the C2, C6, and C3 positions. These modification 
reactions are generally incomplete, resulting in a high degree of structural diversity 
in and between HS chains. Regions that do not undergo modification remain N-
acetylated, regions with intermediate modifications contain alternating N-acetylated 
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and N-sulfated disaccharide units, whereas regions which are highly modified and 
sulfated consist predominantly of contiguous N- and O-sulfated disaccharide units. 
 Though previous studies using JM403, a monoclonal antibody that is specific for 
N-unsubstituted glucosamine residues of HS domains, suggest that HS contents were 
reduced in the GBM of the kidney of patients with overt DNP [10-14], it remains to be 
determined if loss of HS, as detected by JM403, is due to the change of HS structures 
that favor the binding by this antibody. Alternatively, loss of HS in the GBM could be 
due to the reduced biosynthesis of the nascent HS backbone structure. In the present 
study, we analyzed renal HS domains using 4 different anti-HS antibodies, directed 
against sulfated HS domains, HS domains with N-unsubstituted glucosamine residues 
or unmodified HS domains consisting of N-acetylglucosamine - glucuronic acid 
residues.
Materials and methods
Subjects 
 Kidney biopsies of 14 diabetic patients were obtained at the Rush University Medical 
Centre. The biopsies were taken after informed consent from all subjects. At the time 
of the biopsy, all patients had proteinuria. Characteristics of the patients at the time 
of the biopsy are summarized in Table 1. Routine histology of the biopsy specimens 
was conducted to monitor the hyalinization, Kimmelstiel Wilson nodules, mesangial 
hypercellularity, interstitial fibrosis, and tubular atrophy. Electron microscopy was 
conducted to monitor the thickness of the GBM and foot process effacement. Control 
renal tissue was obtained from either non-diabetic donor kidneys, which were not 
suitable for transplantation for anatomical reasons (n=4), or from normal parts of a 
kidney removed for renal adenocarcinoma (n=1). The institutional review board of 
Rush University and the human ethics committee of Radboud University Nijmegen 
Medical Centre approved all experiments. 
Immunofluorescence staining
 Two different staining procedures, described below, were used to visualize different 
HS domains, the agrin core protein and HPSE, respectively.
HS4C3 and EW3D10. Frozen kidney sections were air-dried and blocked with PBS 
containing 2% (w/v) bovine serum albumin and 0.05% (v/v) Tween-20 (blocking 
buffer) for 20 minutes. Cryosections were then incubated for 1 hour in blocking 
buffer with the phage display-derived VSV-tagged anti-HS antibodies HS4C3 and 
EW3D10 [20, 21], both of which recognize sulfated HS domains. Bound antibodies 
were detected by incubation with mouse IgG anti-VSV tag antibody P5D4 and rabbit 
IgG anti-VSV tag antibody 9E10 (both 1:10; Boehringer Mannheim, Mannheim, 
Germany), followed by Alexa 488-conjugated goat anti-mouse IgG and Alexa 
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594-conjugated goat anti-rabbit IgG (both 1:200; Molecular Probes, Eugene, OR), 
respectively, both for 45 minutes. After each antibody incubation, cryosections were 
washed with PBS containing 0.1% (v/v) Tween-20. Finally, cryosections were fixed in 
100% (v/v) ethanol for ∼10 seconds, air-dried, and embedded in 10% (w/v) Mowiol 
(Calbiochem, La Jolla, CA).
JM403, JM72, anti-K5 antibody and anti-HPSE antibody. Frozen kidney sections 
were air-dried and fixed in 100% (v/v) acetone for 10 minutes at 4°C. After air-
drying, (double)staining was performed by a 1 hour incubation of cryosections with 
(1) monoclonal anti-HS antibody JM403 (1:300), that recognizes HS domains with 
N-unsubstituted glucosamine residues [6, 12, 22], and monoclonal anti-agrin core 
protein antibody JM72 (1:600) [12, 23]; (2) monoclonal anti-K5 antibody (1:100; 
Seikagaku, Tokyo, Japan), recognizing unmodified HS domains consisting of N-
acetylglucosamine - glucuronic acid residues, and (3) monoclonal anti-HPSE antibody 
HP3/17 (1:100; ProsPec-Tany Technogene, Rehovot, Israel) and monoclonal anti-HS 
antibody JM403 (1:300). Bound antibodies were detected by incubation with Alexa 
488-or 594-conjugated goat anti-mouse IgM (for JM403 and anti-K5 antibody), Alexa 
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Patient Sex Age 
(years)
GBM 
Width 
(nm)
Diabetes 
duration 
(years)
Proteinuria 
(g/24 hr)
Serum 
creatinine 
(mg/dl)
Systolic 
BP
(mmHg)
Diastolic 
BP
(mmHg)
1 F 52 N/A 15 3.00 1.0 133 75
2 M 76 >1000 16 3.60 1.6 163 93
3 M 72 400 8 0.13 1.2 134 59
4 M 74 750 29 1.40 2.0 134 74
5 M 50 1200 N/A 7.30 5.6 174 110
6 M 70 500 >10 6.30 2.1 140 60
7 F 70 1000 >30 1.27 0.9 128 74
8 M 55 500 15 3.50 2.8 136 78
9 F 59 500-700 N/A 3.10 3.1 144 63
10 M 79 450-625 N/A >5 4.6 118 58
11 F 68 500-800 >20 6.81 2.7-5.7 213 76
12 F 44 <350 10 4.00 1.0 140 86
13 M 55 900-1000 15 4.50 5.0 N/A N/A
14 F 36 N/A N/A 2.00 4.1 N/A N/A
Table 1. Characteristics of patients in this study.
a All patients have type 2 diabetes, except for one patient (9), which had type 1 diabetes. Macroalbuminuria: 
urinary albumin excretion of >0.3 g/24hr; serum creatinine normal value: 0.7-1.2 mg/dl for men, 0.5-1.0 
mg/ml for women; systolic BP normal value: 120 mm Hg; diastolic BP normal value: 80 mm Hg; GBM 
width normal value: 300-350 nm.  F: female; M: male; N/A: not applicable; BP: blood pressure; GBM: 
glomerular basement membrane; EM: electron microscopy.
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568-conjugated goat anti-mouse IgG1 (for JM72), and Alexa 488-conjugated goat 
anti-mouse IgG2b (for HP3/17) (all 1:200; Molecular Probes) in PBS containing 4% 
(v/v) normal human serum and 4% (v/v) normal goat serum for 1 hour. After each 
antibody incubation, cryosections were washed with PBS. Finally, cryosections were 
fixed with 1% paraformaldehyde in PBS for 15 minutes and embedded in Vectashield 
mounting medium H-1000 (Vector Laboratories, Burlingame, CA). 
 Immunofluorescence staining was evaluated on coded sections by two independent 
observers using a Leica CTR6000 microscope. For JM403, JM72 and anti-K5 
antibody, linearity of the GBM was scored on a scale of 0 to 10 (0= no staining, 
5= 50% linear GBM staining, 10= 100% (maximum) GBM staining). For HS4C3, 
EW3D10 and anti-HPSE antibody, glomerular staining intensity was scored on a scale 
of 0 to 5 (0= no staining, 2.5= 50% staining, 5= 100% (maximum) staining). Scoring 
between the different observers was consistent, because regression analysis yielded a 
good correlation for the scores obtained (r = 0.95, P<0.001). Figures show the mean 
score of all glomeruli per biopsy/kidney. 
Immunohistochemical staining 
 HPSE expression was also visualized by immunohistochemical staining. Paraffin-
embedded tissue sections were de-waxed with xylene and rehydrated. Endogenous 
peroxidases were inactivated in 3% (v/v) hydrogen peroxide for 10 minutes. Sections 
were processed for immunohistochemical staining with a rabbit anti-HPSE antiserum 
(anti-HPR1) as previously described [18]. The same concentration of a normal rabbit 
serum was used as a negative control. No non-specific signals were observed (data not 
shown).
Treatment of renal sections with active HPSE
 Cryosections of normal human kidneys were treated with 0.5 µg/ml active human 
recombinant HPSE in 50 mM sodium acetate buffer (pH 5.0) for 2 hours at 37°C. 
After washing the sections in PBS, staining for different HS domains (using JM403, 
HS4C3, EW3D10 and anti-K5 antibody) and the agrin core protein (using JM72) was 
performed as described above. 
Statistical analysis
 Differences between groups were determined by the non-parametric Mann-
Whitney U test using GraphPad Prism 4.0 (GraphPad Software, Inc., San Diego, CA). 
The non-parametric Spearman’s rank test was used to calculate correlation between 
different variables. Statistical significance was regarded if P<0.05. 
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Figure 1. Expression of HS domains with N-unsubstituted glucosamine residues (JM403) 
and of the agrin core protein in the GBM of patients with overt DNP and controls. 
A) Immunofluorescence double staining of renal cryosections from a control and a patient 
with DNP with anti-HS antibody JM403 (green) and anti-agrin antibody JM72 (red). In control 
kidneys, a normal linear expression of HS domains recognized by JM403 was detected in 
the GBM. HS expression in the GBM nicely co-localized with agrin core protein expression 
in controls (merge). However, in patients with DNP a decreased expression of HS domains 
recognized by JM403 was observed in the GBM, whereas agrin expression was unaltered. B) 
Quantification of the stainings revealed that the expression of HS domains with N-unsubstituted 
glucosamine residues, detected with JM403, was significantly reduced in the GBM of patients 
with DNP compared to controls. C) No differences in agrin core protein expression were 
observed between controls and diabetic patients. D) An inverse correlation between the 
expression of HS domains recognized by JM403 and the level of proteinuria was observed. Due 
to the lack of glomeruli in one biopsy, only 13 biopsies were evaluated. AU, arbitrary units. 
**P<0.01. For full-colour representation see; Colour Figures.
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Results
Differential loss of HS domains in the GBM of patients with overt DNP 
Our previous study showed a reverse correlation between the content of the GBM 
HS and proteinuria [11].  Here we first attempted to see if these observations could 
be confirmed. The expression of HS in the GBM and mesangium was evaluated by 
immunofluorescence (double) staining of kidney biopsies from proteinuric diabetic 
patients and normal kidneys. Control kidney sections showed a linear expression of the 
agrin core protein along the GBM (Figure 1A) and HS staining, using antibody JM403, 
co-localized with the agrin staining (Figure 1A). However, glomeruli of patients with 
DNP showed a decreased expression of HS domains with N-unsubstituted glucosamine 
residues along the GBM, whereas expression of agrin was unaltered. Quantitative 
50 51
Chapter 3
analysis revealed that the expression of HS domains in the GBM recognized by 
JM403 was significantly decreased in DNP patients (Figure 1B), whereas expression 
of the agrin core protein was not different (Figure 1C). These results indicate that 
the decreased staining of the GBM by anti-HS antibody JM403 is not due to reduced 
synthesis of the core protein of agrin, which is the major HS proteoglycan in the GBM 
[24, 25]. An inverse correlation between the expression of HS domains in the GBM 
and the level of proteinuria was observed also in this analysis (Figure 1D). However, 
we did not find any correlation between the GBM width (Table 1) and HS signal 
intensity, suggesting that reduced HS in the GBM of the DNP kidneys is not due to 
the diffused presence of HS due to the expansion of the GBM. There was also no 
correlation between loss of the GBM HS and foot process effacement or the severity 
of arteriole sclerosis and hyalinization (data not shown). 
Figure 2. Expression of sulfated HS domains (HS4C3 and EW3D10) in the GBM and 
mesangium of patients with overt DNP and controls. A) Immunofluorescence staining of 
renal cryosections from a control and a patient with DNP with anti-HS antibody HS4C3 and 
anti-HS antibody EW3D10, both of which predominantly recognize sulfated HS domains in the 
mesangium, but also sulfated HS domains in the GBM. A reduced expression of HS domains 
recognized by HS4C3 and EW3D10 was observed in the GBM of diabetic patients compared 
to controls. The staining intensity of these antibodies in the mesangium was comparable for 
patients and controls, whereas in the patients with DNP mesangial matrix expansion was 
observed. B) Quantification analysis of the stainings revealed that expression of sulfated 
HS domains recognized by HS4C3 and EW3D10 in the GBM of patients with DNP was 
significantly reduced. C) Staining with HS4C3 and EW3D10 revealed a significantly increased 
mesangial matrix expansion in patients with DNP. AU, arbitrary units. *P< 0.05, **P< 0.01.
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 In addition to HS domains containing N-unsubstituted glucosamine residues, 
the expression of sulfated HS domains was studied using the phage display-derived 
anti-HS antibodies HS4C3 and EW3D10. These antibodies predominantly stain the 
mesangial matrix, but also the GBM in control kidneys (Figure 2A). Analysis revealed 
that the expression of sulfated HS domains in the GBM, as detected with HS4C3 and 
EW3D10, was significantly decreased in patients with DNP (Figure 2B), whereas the 
staining intensity of the mesangial matrix was not altered (data not shown). However, 
using both antibodies, obvious mesangial matrix expansion was observed in the 
diabetic patients (Figure 2C). Interestingly, staining for the unmodified HS domains 
with N-acetylglucosamine - glucuronic acid residues, i.e. HS precursor domain, using 
anti-K5 antibody, was similar in control subjects and DNP patients (Figure 3A,B). This 
latter result suggests that either remnants of HS or non-modified HS side chains are 
still present in the GBM. 
Figure 3. Glomerular expression of unmodified HS domains (anti-K5 antibody) in the 
GBM of patients with overt DNP and controls. A) Immunofluorescence staining of renal 
cryosections from a control and a patient with DNP with anti-K5 antibody, which recognizes 
unmodified HS domains consisting of N-acetylglucosamine– glucuronic acid residues. No 
differences in expression of unmodified HS domains in the GBM were observed between the 
controls and the diabetic patients. B) Quantification of the stainings revealed no significant 
differences in expression of unmodified HS domains between the diabetic patients and the 
controls. AU, arbitrary units. 
Increased expression of HPSE in the glomeruli of patients with overt DNP 
Emerging evidence suggests that HPSE expression is increased in glomerular epithelial 
cells (podocytes) and glomerular endothelial cells of patients with DNP [11, 18] and in 
glomerular cells cultured under high glucose conditions [18]. Here we tested whether 
loss of GBM HS may be due to an increased HPSE expression. HPSE signals were 
very weak in normal human glomeruli, but increased in glomeruli of DNP patients 
(Figure 4A). The increased glomerular HPSE expression in patients with DNP 
compared to control subjects was statistically significant (Figure 4B). Analysis of 
the immunofluorescence double staining with JM403 and HPSE revealed that the 
52 53
decreased expression of HS domains with N-unsubstituted glucosamine residues in 
the GBM correlated with an increased glomerular HPSE expression (Figure 4C). 
These data suggest that HPSE expression in the glomeruli of patients with overt DNP 
plays an important role in the degradation of HS in the GBM. However, there was no 
correlation between HPSE expression or HS loss and mesangial matrix expansion or 
GBM thickness (data not shown).
Figure 4. Expression of glomerular 
HPSE in patients with overt DNP 
and controls. A) Immunofluorescence 
staining of renal cryosections from a 
control and a patient with DNP with 
anti-HPSE antibody HP3/17 revealed 
an increased glomerular expression 
of HPSE in patients with DNP. B) 
Quantification of the stainings revealed 
that patients with DNP showed a 
significantly increased glomerular 
HPSE expression compared to 
controls. C) A reduced expression of 
HS domains in the GBM, as detected 
with anti-HS antibody JM403, 
correlated with increased levels of 
HPSE expression. AU, arbitrary units. 
**P< 0.01.  
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 Since the immunofluorescence staining does not allow a proper localization of 
HPSE, we also performed in situ immunohistochemistry with a different antibody, 
which can be used on paraffin-embedded sections [18]. As showing in Figure 5A 
and B, strong HPSE signals were present in the podocytes (grey arrows) and in the 
proximal tubular cells (black arrows) in a specimen with overt DNP. Again, HPSE was 
not present in the glomerulus and only weakly stained in the tubules of a normal kidney 
(C). 
Loss of HS domains in the GBM is mediated by HPSE
 We reasoned that, if the loss of HS domains in the GBM of diabetic patients was due 
to the degradation of HS by HPSE, incubation of normal renal cryosections with active 
HPSE should lead to similar data as obtained for patients with DNP, i.e. differential loss 
of HS domains. Indeed, treatment of normal human kidney cryosections with active 
HPSE, resulted in a complete loss of the HS domains recognized by antibodies JM403 
and EW3D10, whereas presence of the HS domain recognized by antibody HS4C3 
was strongly decreased. The expression of the unmodified HS domains consisting of 
N-acetylglucosamine - glucuronic acid and of the agrin core protein was not affected 
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by HPSE treatment (Figure 6). These data mirror the stainings observed in the DNP 
patients, which strongly suggests that the increased glomerular expression of HPSE is 
responsible for the differential loss of HS domains in the GBM of patients with overt 
DNP. 
Discussion
 Our present study showed that, though the expression of the agrin core protein in 
the GBM in overt DNP was similar to controls, whereas modified HS domains with N-
unsubstituted glucosamine residues (detected with JM403 antibody) and sulfated HS 
domains (detected with two phage display derived scFv antibodies) were undetectable 
or greatly reduced in overt DNP. In contrast, unmodified HS domains (detected with 
anti-K5 mAb), consisting of N-acetylglucosamine - glucuronic acid residues, remained 
unchanged. Since HPSE preferentially cleaves sulfated HS, and HPSE expression was 
increased in the glomeruli of patients with overt DNP and inversely correlated with 
the levels of modified HS in the GBM, it is conceivable that the reduction of modified 
HS in the GBM is due to degradation by HPSE, whereas the unmodified HS domains, 
which are resistant to HPSE degradation [26], may represent the nascent chains of HS 
or the large fragments of sparsely sulfated HS after HPSE degradation. In support of 
this notion, pretreatment of normal human kidney sections with the active recombinant 
Figure 5. Renal localization of HPSE in patients with overt DNP. 
A) Immunohistochemical staining of paraffin-embedded renal sections from a patient with 
DNP with a rabbit anti-HPSE antiserum (anti-HPR1) revealed strong HPSE signals in the 
podocytes (grey arrows) and in the proximal tubular cells (black arrows). B) Enlargement from 
part A.  A normal kidney specimen was included and showed no HPSE signal in the glomerulus 
and weak signals in the tubule (C).  A normal rabbit serum for a biopsy specimen was included 
as a negative control (D). For full-colour representation see; Colour Figures.
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Figure 6. Expression of different HS domains and of the agrin core protein after 
treatment of normal human kidney sections with active HPSE. After treatment of normal 
human kidney cryosections with active recombinant HPSE, the expression of HS domains 
recognized by JM403 and EW3D10 completely disappeared, whereas expression of the HS 
domains recognized by HS4C3 was strongly reduced. In contrast, the expression of unmodified 
HS domains, detected with anti-K5, was not affected by HPSE treatment as well as expression 
of the agrin core protein. 
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human HPSE, did not reduce the presence of unmodified HS (detected by anti-K5 
mAb), whereas a complete loss or significant reduction of modified HS domains 
(detected with antibodies JM403 and EW3D10, or HS4C3 respectively) was found. 
Consistent with these studies, we found that only the unmodified HS domain can be 
detected by the anti-K5 antibody in the GBM of transgenic mice overexpressing HPSE 
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(van den Hoven et. al., in press). Taken together, our observations strongly suggest that 
agrin expression and biosynthesis of the HS precursor are not reduced in human DNP, 
and that the reduction of modified HS domains with N-unsubstituted glucosamine 
residues and sulfated HS domains is due to accelerated degradation by increased HPSE 
expression. 
 While our study suggests that HPSE plays an important role in eliminating 
modified HS in the GBM of patients with overt DNP, we surprisingly found that the 
presence of sulfated HS, as detected by the two scFv antibodies, was not decreased in 
the mesangium of kidneys with overt DNP. There are several putative explanations for 
this paradox. First, our recent study demonstrated that HPSE was largely located in 
the GBM and podocytes, but not in the mesangial cells [11]. Therefore, increased HS 
expression in the mesangium of the kidneys with overt DNP could be due to mesangial 
matrix expansion and the lack of HPSE degradation. Second, HS-binding growth 
factors such as FGF and VEGF, which are abundantly present in the mesangium 
[27, 28], may bind and protect HS from HPSE access and cleavage. Third, increased 
HS in the mesangium may be due to special modifications of HS domains that are 
preferentially recognized by the two scFv antibodies. Nevertheless, it appears that 
lack of HS reduction in the mesangium is pathologically relevant since HS in the 
mesangium serves as the co-receptor for many growth factors such as FGF and 
VEGF [27, 28] and can enhance their mitogenic effect on mesangial cells, leading 
to increased cell proliferation, extracellular matrix protein production, and mesangial 
matrix expansion. 
 In the past 5 years, up-regulation of glomerular HPSE expression was shown in 
several experimental models including puromycin aminonucleoside nephrosis [29], 
passive Heymann nephritis [30], anti-GBM nephritis [31], adriamycin nephropathy 
[32], streptozotocin-induced DNP [11], as well as in human kidney diseases such as 
overt DNP [11,18], minimal change nephrotic syndrome, membranous glomerulopathy 
[33] and IgA nephropathy (Rutjes et al., unpublished observations). The molecular 
mechanisms that regulate HPSE expression and activity still have to be elucidated. 
Preliminary evidence from our laboratories suggests that hyperglycemia, angiotensin 
II, aldosterone, reactive oxygen species, and activation of B-Raf kinase, depending 
on the cell type, are involved in regulating HPSE expression. HPSE expression was 
increased under high glucose conditions in cultured podocytes, the main cell type that 
expresses HPSE, [18]. Very recently, we demonstrated increased HPSE expression in 
adriamycin nephropathy, which could be reduced or prevented after treatment with 
an angiotensin II receptor antagonist or a scavenger of hydroxyl radicals [32]. We 
also have preliminary data that aldosterone may regulate HPSE expression, since 
we observed an increased expression of HPSE after stimulation of podocytes with 
aldosterone. This effect could be abrogated by pretreatment with an aldosterone 
receptor blocker (van den Hoven et al., conditionally accepted). 
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 It has long been postulated that HS plays an important role in the charge-selective 
permeability properties of the GBM and the development of proteinuria. For example, 
rats developed massive albuminuria after injection of the monoclonal antibody JM403 
[6]. Degradation of HS by the bacterial HS-cleaving enzyme heparinase III resulted 
in an increased permeability of the GBM for ferritin and albumin [2-4]. In addition, 
a loss of HS in the GBM was observed in many glomerular diseases, including DNP, 
and correlated with the degree of proteinuria [10-14]. However, several recent studies 
suggest that HS in the GBM may not play a primary decisive role for the charge-
selective permeability properties and development of proteinuria. For example, van 
den Born recently reported that there was no change in glomerular HS expression in 
early human and experimental DNP, though in both cases albuminuria was present 
[15]. Additional studies showed that rats did not develop acute albuminuria after in 
vivo degradation of HS by heparinase III [34]. HPSE transgenic mice with complete 
loss of glomerular HS expression only developed very mild albuminuria [11]. 
Furthermore, podocyte-specific agrin knockout mice [35] and podocyte-specific EXT1 
knockout mice [36] were generated, which both lack HS in the GBM. Despite the 
absence of HS, these mice do not develop proteinuria under normal conditions. While 
these recent data suggest that loss of HS in the GBM alone does not lead to proteinuria, 
it is not clear if loss of heparan sulfate under pathologic conditions such as diabetic 
nephropathy will accelerate or worsen proteinuria. An earlier study showed that loss 
of another HSPG, perlecan, leads to proteinuria in albumin-overloaded perlecan-
deficient mice [37]. We speculate that loss of HS may contribute to the pathogenesis 
of proteinuria under prolonged hyperglycemic conditions. Our present study, along 
with a recent related study by our group [11], demonstrating that the reduction of 
glomerular HS correlated with the degree of proteinuria, supports this notion. Loss of 
HS in the GBM may exacerbate proteinuria not by directly increasing the permeability 
of the GBM but rather by other indirect mechanisms, such as affecting the mitogenic 
effect of HS-binding growth factors (FGF-2, VEGF, TGF-β, CTGF) and disrupting 
the cell-GBM interactions, leading to dedifferentiation of glomerular cells and loss of 
podocytes. Loss of HS may also result in structural GBM alterations and compromise 
the integrity of the glomerular capillary wall. Finally, loss of HS in the GBM may 
increase the deposition of lipoproteins. Use of HPSE knockout mice or conditioned 
HPSE knockout mice and HPSE-specific inhibitors will provide direct and definitive 
evidence to clarify if HPSE is a critical molecule for the development of proteinuria.
 The supposition that loss of HS in the GBM contributes to proteinuria in overt 
DNP is indirectly supported by the observation of an antiproteinuric effect in diabetic 
patients treated with several glycosaminoglycan-based drugs, including heparin 
(highly sulfated HS) [38], sulodexide (80% fast-moving heparin and 20% dermatan 
sulfate) [39-42], enoxaparin (low molecular weight heparin) [43], and danaparoid 
(mixture of glycosaminoglycans consisting of predominantly HS) [44]. Since these 
drugs can also inhibit HPSE activity [45, 46], it is possible that their ameliorating 
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effect on proteinuria is due to inhibition of HPSE. A study by Levidiotis et al. showed 
that inhibition of HPSE with the specific HPSE inhibitor PI-88 reduced proteinuria in 
passive Heymann nephritis [47].
 In summary, our present study showed that the expression of modified HS domains 
was reduced in the GBM of patients with overt DNP, whereas expression of the 
unmodified precursor of HS was unaltered. The loss of HS in the GBM correlated 
with an increased expression of glomerular HPSE in these patients. In addition, HS 
expression also correlated with the degree of proteinuria. Our data suggest that the 
increased glomerular HPSE expression in patients with DNP may be responsible 
for the differential loss of HS domains in the GBM, which may participate in the 
pathogenesis of diabetes-induced proteinuria. 
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Abstract
 A loss of heparan sulfate (HS) expression in the glomerular basement membrane 
(GBM) of patients with overt diabetic nephropathy (DNP) is associated with an 
increased glomerular heparanase expression. In this study, we investigated the possible 
association of urinary heparanase activity with the development of proteinuria in 
patients with type 1 diabetes, type 2 diabetes and with membranous glomerulopathy 
(MGP).
 Heparanase activity, albumin, HS and creatinine were measured in the urine of 
patients with type 1 (n=58) and type 2 (n=31) diabetes, which were either normo-, 
micro- , or macroalbuminuric, in macroalbuminuric patients with MGP (n=52) as 
non-diabetic proteinuric controls and in healthy non-proteinuric controls (n=10). 
Heparanase mRNA expression in leukocytes was determined in a subgroup of patients 
with type 1 diabetes (n=19).
 Urinary heparanase activity was increased in patients with type 1 and type 2 
diabetes, which was more prominent in patients with macroalbuminuria, whereas no 
activity could be detected in the urine of healthy controls. Levels of albuminuria were 
associated with the increased heparanase activity in the urine of patients with type 1 
diabetes or type 2 diabetes (r= 0.20; P< 0.05), but not in patients with MGP (r = 0.11; 
P= 0.43). A reduced heparanase activity was observed in the urine of diabetic patients 
treated with inhibitors of the renin-angiotensin-aldosterone system (RAAS) when 
compared to diabetic patients treated with other anti-hypertensives. Additionally, 
urinary heparanase activity was associated with age in type 1 diabetes (r = 0.55; 
P< 0.001) and MGP (r = 0.33; P< 0.05). In MGP, excretion of heparanase and β2-
microglobulin excretion (a marker for tubular damage) correlated (r = 0.34; P< 0.05).  
In patients with type 1 diabetes with either normo-, micro or macroalbuminuria, no 
differences in heparanase mRNA expression in leukocytes could be observed. 
 In conclusion, heparanase activity is increased in the urine of diabetic patients with 
proteinuria, especially in patients with macroalbuminuria. However, it is not possible 
to conclude yet whether increased heparanase activity is a cause or a consequence of 
proteinuria. 
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Introduction
 DNP is a frequent cause of chronic renal failure and end-stage renal disease. One 
of the first symptoms of DNP is an increased urinary excretion of albumin (30-300 
mg/24h) defined as microalbuminuria. Alterations in both size- and charge selective 
properties of the glomerular filter have been implicated in the development of this 
albuminuria [1]. The charge-dependent permeability of the glomerular capillary wall 
has been attributed to the presence of negatively charged molecules in the GBM, 
mainly HS. HS side chains are covalently attached to core proteins of heparan sulfate 
proteoglycans (HSPG), which is predominantly agrin in the GBM [2]. In advanced 
stages of DNP and also in several other glomerular proteinuric diseases, a loss of HS 
expression in the GBM has been reported, which consistently correlated negatively 
with the degree of proteinuria [3-6]. We and others have shown that this decrease 
of HS in the GBM was associated with an upregulation of glomerular heparanase 
in DNP, adriamycin nephropathy, minimal change nephrotic syndrome, puromycin 
aminonucleoside nephrosis and passive Heymann nephritis [7-13]. 
 Heparanase is an endo-β(1,4)-glucuronidase, which is able to cleave HS side chains 
at specific sites and hence is involved in the degradation of HS in the extracellular 
matrix [14, 15]. Heparanase is synthesized as a 65 kDa inactive precursor, which 
becomes activated after proteolytic processing by cathepsin L, yielding a heterodimer 
consisting of an 8 kDa and 50 kDa subunit [16]. Upregulation of heparanase has been 
implicated in tumor progression and metastasis and correlated negatively with the 
survival rate of cancer patients [17]. Activity of heparanase has also been detected 
in plasma and/or urine of cancer patients already in early stages, which suggest that 
heparanase activity in body fluids can serve as a diagnostic marker for the detection 
and/or progression of disease [17, 18]. Urinary heparanase activity was also measured 
in patients with proteinuric diseases, including type 1 diabetes and minimal change 
disease, suggesting a role for heparanase in the pathogenesis of proteinuria [18-20]. 
Both normo-, and microalbuminuric patients showed increased heparanase levels in 
the urine, whereas it was undetectable in the urine of controls. Whether this increased 
activity was associated with the degree of proteinuria was not investigated in these 
studies [19, 20].
 Heparanase is expressed by several cells including platelets, leukocytes, and 
endothelial cells, but also by glomerular and tubular cells. In overt DNP, the increased 
glomerular heparanase expression in patients with type 2 diabetes was mainly confined 
to podocytes and glomerular endothelial cells [7, 13]. Recently, it has been demonstrated 
that hyperglycemia could induce heparanase expression and activity in podocytes [13], 
providing further evidence that increased urinary heparanase could originate from the 
glomerulus. However, heparanase was also expressed by the proximal tubuli of healthy 
persons, which was increased in diabetic patients [7]. Therefore, since proteinuria can 
also result from tubular damage or can cause tubular damage, it could also be possible 
that urinary heparanase originates from tubular cells. 
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 Since heparanase expression is upregulated in several proteinuric diseases and its 
activity is detected in the urine of these patients, it is plausible that this upregulation of 
heparanase could lead to degradation of HS side chains, resulting in several different 
processes that could initiate or enhance proteinuria. First, heparanase could cleave HS 
in the GBM and/or at cell surfaces (podocytes or endothelial cells), thereby changing 
charge-selective properties of the glomerular capillary wall. Second, heparanase 
may result in the release of HS-bound growth factors such as TGF-β, inducing a 
profibrotic response such as mesangial matrix expansion and GBM thickening. Third, 
HS degradation by heparanase may lead to a disturbance in cell-matrix interactions, 
leading to loss of podocytes in the urine. Finally, the binding of the heparanase protein 
to glomerular cells may lead to cellular activation [21]. 
 In this study, we investigated whether increased urinary heparanase activity in 
patients with type 1 or type 2 diabetes and in patients with MGP, who served as non-
diabetic proteinuric control patients, was associated with the degree of albuminuria. 
We also determined whether urinary heparanase was associated with age, the use of 
certain anti-hypertensive drugs or the presence of urinary heparanase inhibitors, such 
as HS. Finally, we evaluated whether urinary heparanase activity could originate from 
circulating blood cells, such as leukocytes, and whether there was an association with 
tubular damage by measuring urinary β2-microglobulin. 
Material and Methods
Patients
 This study was approved by the Ethics Committee of the Radboud University 
Nijmegen Medical Centre and all participating patients gave informed consent. 
Mid-stream urine was collected from type 1 diabetic patients (n=58), type 2 diabetic 
patients (n=31), patients with MGP (n=52), and from healthy, age-matched controls 
(n=10). Patients with type 1 or type 2 diabetes were subdivided in groups with 
either normo-, micro-, or macroalbuminuria, defined if patients had an albumin 
excretion of < 2.5, 2.5-30  or >30 mg/mmol creatinine in the last two consecutive 
measurements, respectively. The collected urine samples were snap-frozen in liquid 
nitrogen immediately and stored at -80°C until analysis. Urinary creatinine was 
measured with standard techniques and the concentration of albumin was measured by 
immunonephelometry, using specific antibodies [22]. Urinary β2-microglobulin was 
determined using a specific enzyme-linked immunosorbent assay (ELISA) [23]. 
Heparanase activity assay
 Heparanase activity in urine was measured using a commercially available assay 
(Takara Bio Inc., Shiga, Japan). Briefly, urinary samples were mixed 1:1 (v/v) with 
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reaction buffer, added to 100 μl of biotinylated HS and incubated for 45 minutes at 
37°C. Reactants were transferred to a well coated with a HS-binding protein followed 
by an incubation of 15 minutes at 37°C, during which non-degraded HS substrates 
could bind. The plate was washed three times with phosphate buffered saline (PBS) 
containing 0.05% (v/v) Tween 20. Avidin phenacetin O-deethylase (POD) conjugate 
was added and incubated for 45 minutes at 37°C. POD substrate was added to start the 
peroxidase reaction and stopped by adding 1M H
2
SO
4
. The absorbance at 450 nm was 
measured with a microplate reader. Heparanase activity was determined according to a 
HS standard and corrected for urinary creatinine concentration.
Urinary HS excretion
 The amount of urinary HS was determined by an inhibition ELISA method, as 
described previously [24]. Microtitre plates were coated overnight at room temperature 
with 2 μg/ml HS from bovine kidney (Sigma, Zwijndrecht, The Netherlands). After 
washing with PBS, plates were blocked with 1% (w/v) gelatin (Difco Laboratories 
Inc., Detroit, Mich, USA) in PBS for 2 hours at room temperature. In a separate plate, 
60 µl of each urine sample was incubated with 60 µl monoclonal anti-HS antibody 
JM403 (diluted 1:1600 in 1% (w/v) gelatin in PBS for 2 hours at room temperature. 
Subsequently, after washing the HS-coated plate with PBS containing 0.05% Tween 
20 (PBST), 100 μl of urine sample/JM403 mixture was transferred to the HS-coated 
wells and incubated for 2 hours at room temperature. Then, plates were washed in 
PBST and JM403 binding was detected by incubation for 1 hour with a peroxidase-
labeled goat-anti mouse IgM conjugate (Nordic Immunological Laboratories, Tilburg, 
Netherlands; 1:8000 diluted in 1% (w/v) gelatin). Tetramethylbenzidine substrate 
solution (SFRI Laboratories, Berganton, France) was used to visualize the reaction, 
which was stopped after 20 minutes by adding 1M H
2
SO
4
 and absorbance at 450 nm 
was measured. 
Leukocyte isolation
 Blood samples from 19 type 1 diabetic patients with normo-, micro-, or 
macroalbuminuria were collected for leukocyte isolation, using a Percoll gradient 
with a density of 1085 g/l. After centrifugation, the buffy coat with leukocytes was 
aspirated and washed briefly with Hanks’ balanced salt solution (HBSS). The pellet 
was dissolved in 70% ethanol and stored at -20°C until analysis. 
RNA isolation and real-time PCR
Total RNA was isolated using the RNeasy mini kit, according to the instructions of 
the manufacturer (Qiagen Benelux, Venlo, The Netherlands). 1 µg RNA was reversed 
transcribed (RT) into cDNA with oligo(dT) primers using the SuperScript first-strand 
synthesis system for RT-PCR in a final volume of 20 μl (Invitrogen Life Technologies, 
Breda, The Netherlands). Subsequently, cDNA was amplified by real-time PCR 
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using a MyiQTM single color real-time PCR detection system (Bio-Rad Laboratories, 
Veenendaal, The Netherlands) with gene-specific primers. Human heparanase 
(hHPSE): forward 5’-GAGCCAAGGAATCAACCTTTGAAG-3’, reverse 5’-
GATCGTAGTCCAGGAGCAACTGAG-3’, and human glyceraldehyde-3-phosphate 
dehydrogenase (hGAPDH): forward 5’-GAAGGTGAAGGTCGGAGT-3’, reverse 
5’-AGATGGTGATGGGATTTC-3’. PCR was performed under following conditions: 
denaturation at 95°C for 10 minutes followed by 40 cycli of 95°C for 1 minute, 55°C 
for 30 seconds, and 72°C for 15 seconds, and finally elongation at 72°C for 10 minutes. 
The cycle time (Ct) values for heparanase were subtracted from the Ct values of the 
housekeeping gene GAPDH, yielding the ΔCt values. The relative expression of 
heparanase was finally expressed as 2-ΔCt. 
Statistical analysis
 Data are presented as mean ± standard deviation (SD) and, if not normally 
distributed, as median with interquartile range. For comparisons of the different 
groups the non-parametric Kruskal-Wallis H test and Mann-Whitney U test were used. 
Spearman’s rank analysis was used to calculate correlations between the different 
parameters. Statistical analysis was performed using GraphPad Prism 4.0 (GraphPad 
Software Inc., San Diego, CA, USA) and SPSS statistical software version 12.0 (SPSS 
Inc., Chicago, IL, USA). Statistical significance was assumed if P< 0.05.
Results
Clinical parameters
 Urinary heparanase activity was measured in patients with type 1 diabetes (n=58), 
type 2 diabetes (n=31), patients with MGP (n=52) and in healthy controls (n=10). 
Clinical characteristics of the patients are summarized in Table 1. The mean age (± 
s.d.) of the healthy controls (4 males, 6 females) was 45.6 ± 13.2 years and did not 
differ from the patients. The mean albumin excretion ratio (AER; with interquartile 
range) in diabetic patients with normoalbuminuria (0.66 (0.1-1.1) mg/mmol) was 
not different from the AER of healthy controls (0.25 (0.2-0.7) mg/mmol), whereas 
AER according to allocation was significantly increased in diabetic patients with 
micro- or macroalbuminuria. Additionally, both type 1 and type 2 diabetic patients 
with macroalbuminuria showed significantly higher serum creatinine levels (P< 0.05) 
and a significantly lower glomerular filtration rate (calculated by the Modification 
of Dier in Renal Disease formula (MDRD-GFR) [37]) (P< 0.05) than normo- and 
microalbuminuric diabetic patients.
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Urinary heparanase activity is increased in patients with diabetes and MGP
 Heparanase activity (expressed per mmol creatinine) could be detected in the urine 
of 55% (22/58) of the patients with type 1 diabetes. More specific, urinary heparanase 
activity was found in 50% (13/26), 40% (6/15), and 76% (13/17) of the normo-, 
micro-, and macroalbuminuric diabetic patients, respectively. Significant higher levels 
of urinary heparanase activity could be detected in patients with macroalbuminuria 
compared to controls (Figure 1A). In patients with type 2 diabetes, urinary heparanase 
activity could be measured in 77% of all cases, corresponding to 70% (7/10), 82% 
(9/11), and 80% (8/10) of the normo-, micro-, and macroalbuminuric patients, 
respectively. Urinary heparanase activity was significantly increased in normo-, micro, 
and macroalbuminuric patients with type 2 diabetes compared to controls (Figure 1B). 
Furthermore, an increased urinary heparanase activity could be measured in the urine 
of 35% (18/52) of patients with MGP, although for the whole group of patients with 
MGP this activity was not significantly higher compared to controls (Figure 1C). 
Figure 1. Heparanase activity in the urine 
of patients with proteinuric diseases and 
controls. A) Urinary heparanase activity was 
increased in patients with type 1 diabetes 
compared to controls, in which no heparanase 
activity could be detected. A significant 
increase was observed in the urine of patients 
with macroalbuminuria compared to controls. 
B) Patients with type 2 diabetes with 
normo-, micro-, and macroalbuminuria showed 
a significantly increased urinary heparanase 
activity in all groups. C) Urinary heparanase 
activity was also higher in proteinuric patients 
with MGP, but this was not significantly 
different from controls. * = P< 0.05; 
** = P< 0.01
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Association between urinary heparanase activity, albuminuria, age, anti-
hypertensive treatment and urinary HS excretion
 A significant correlation was observed between urinary heparanase activity and the 
excretion of albumin in type 1 and type 2 diabetic patients (r = 0.20; P< 0.05, Figure 
2A), whereas in patients with MGP, such a correlation was not found (r = 0.11; 
P= 0.43, Figure 2B). The increased heparanase activity in the urine correlated with the 
age of the patients with type 1 diabetes and MGP (r = 0.55; P< 0.0001 and r = 0.33; 
P< 0.05, respectively). Gender did not influence heparanase activity.
Figure 2. Associations between urinary 
heparanase activity and albuminuria. A) 
Scatter plot showing a positive correlation 
between urinary heparanase activity in 
diabetic patients (type 1 and type 2) and 
albuminuria (r = 0.20; P< 0.05). B) No 
significant associations were observed 
between urinary heparanase activity and 
albuminuria in patients with MGP (r = 0.11; 
P= 0.43).
 Despite the association between albuminuria and heparanase activity in type 1 
diabetic patients, some patients with macroalbuminuria did not show any urinary 
heparanase activity. Previously, we reported that glomerular heparanase expression 
was increased in rats with adriamycin nephropathy, which could be reversed after 
treatment of these rats with an angiotensin II type 1 receptor blocker (AT1) [8] or 
with an angiotensin II converting enzyme inhibitor (ACEi) (Van den Hoven et al. 
conditionally accepted). Therefore, we evaluated whether heparanase activity could 
be influenced by treatment of diabetic patients with an ACEi or with an AT1 receptor 
blocker. Diabetic patients treated with inhibitors of the RAAS tended to have a 
decreased heparanase activity in the urine compared with diabetic patients treated with 
Urinary heparanase activity in diabetes
70 71
other anti-hypertensive drugs, such as beta-blockers, calcium antagonists or diuretics, 
although this difference was not statistically significant (Figure 3A). Diabetic patients 
not treated with anti-hypertensives showed a lower urinary heparanase activity than 
patients treated with RAAS-inhibitors or with other anti-hypertensives. This was 
associated with a significantly lower albuminuria in these groups (0.7 (0.3-1.1) mg/
mmol versus 20.8 (2.1-51.6) mg/mmol, P< 0.001 and versus 4.3 (1.2-61) mg/mmol, 
P< 0.05, respectively). We also checked whether endogenous heparanase inhibitors, 
i.e. HS, were present in the urine and whether these inhibitors could affect heparanase 
activity. However, Figure 3B shows that HS excretion in the urine was not related to 
urinary heparanase activity as analysed for all patients.
Figure 3. Effect of anti-hypertensive 
treatment or urinary HS excretion on 
heparanase activity. A) A lower urinary 
heparanase activity was observed in diabetic 
patients that were treated with RAAS-
inhibitors compared to diabetic patients that 
were treated with other anti-hypertensive 
drugs (P= 0.1). Additionally, a significantly 
reduced urinary heparanase activity could 
be detected in diabetic patients that were 
not treated with any anti-hypertensive drugs 
compared to patients treated with RAAS-
inhibitors or other anti-hypertensives. B) 
Urinary HS excretion was not correlated with 
heparanase activity in the urine of patients 
with type 1 diabetes, type 2 diabetes or MGP. 
*= P< 0.05, ** = P< 0.01
Heparanase may originate from tubuli in patients with MGP
 In order to determine whether urinary heparanase activity originated from damaged 
tubuli or was caused by disturbed tubular protein reabsorption, we studied the relation 
of urinary heparanase activity with the excretion of β2-microglubulin (a marker for 
tubular damage) only in patients with MGP. In these patients, a positive correlation 
was found (r= 0.34; P<0.05) between heparanase activity and β2-microglubulin 
excretion, suggesting that the heparanase activity in the urine of patients with MGP 
originates from damaged tubuli. Unfortunately, β2-microglobulin excretion was not 
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measured in the urine from diabetic patients, because the necessary alkalinization of 
the urine was not incorporated in the protocol for urine collection in diabetic patients. 
Heparanase mRNA expression in leukocytes from diabetic patients
 To evaluate whether heparanase activity in the urine could originate from the 
circulation, we determined heparanase mRNA expression in leukocytes in a subgroup 
of patients with type 1 diabetes with normo-, micro-, or macroalbuminuria. Heparanase 
mRNA expression in leukocytes was not different between the albuminuric groups 
(Figure 4). 
Figure 4. Heparanase mRNA 
expression in leukocytes from 
patients with type 1 diabetes.
No difference was observed 
in relative heparanase mRNA 
expression (fold) in leukocytes 
of normo-, micro-, and 
macroalbuminuric patients with 
type 1 diabetes as determined by 
quantitative RT real-time PCR.
Discussion
 In this study, we demonstrated the presence of an increased urinary heparanase 
activity in patients with type 1 and type 2 diabetes, which was associated with the 
degree of albuminuria. These results are in accordance with previous studies, which 
demonstrated that heparanase activity was present in the urine of both normo-, and 
microalbuminuric patients with type 1 diabetes [18, 20]. Additionally, we detected 
increased levels of urinary heparanase activity in patients with MGP, showing that 
this phenomenon is not restricted to diabetes, but also present in other non-diabetic 
proteinuric diseases. Previously, increased urinary heparanase activity was found in 
patients with minimal change disease [19, 25]. 
 Although the level of heparanase in the urine was associated with albuminuria, in 
some patients with albuminuria no heparanase activity could be detected. Since the 
use of ACEi or AT1 blockers reduced glomerular heparanase expression in adriamycin 
nephropathy [8], we examined whether treatment with RAAS-inhibitors could affect 
urinary heparanase activity. Indeed, diabetic patients treated with RAAS-inhibitors 
had a lower urinary heparanase activity compared to patients treated with other anti-
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hypertensive drugs, although this difference was not statistically significant. This 
supports that the RAAS-system could be involved in the regulation of heparanase and 
may explain why certain albuminuric diabetic patients have no detectable levels of 
heparanase activity in their urine. We also investigated whether the presence of urinary 
heparanase inhibitors may have influenced urinary heparanase activity. However, no 
association was found between HS excretion in the urine and the level of urinary 
heparanase activity, which suggests that the presence of HS in the urine does not affect 
the heparanase activity assay we have applied.
 Additionally, we observed that both urinary heparanase excretion and albuminuria 
were associated with age but not with gender. This association in diabetic patients was 
not observed in patients with other proteinuric diseases. In MCNS, but also in healthy 
controls, an inverse relationship was found between plasma heparanase activity and 
age [19].
 Many cell types express heparanase, including platelets, leukocytes, endothelial 
cells and also tumor cells [26]. Until now, it is still uncertain which cells are responsible 
for the increased urinary secretion of active heparanase in patients with renal diseases. 
In this study, we checked in a subgroup of patients whether the increased activity found 
in the urine of patients with type 1 diabetes could originate from circulating cells, i.e. 
leukocytes. However, no differences in heparanase mRNA expression in leukocytes 
were found between normo-, micro-, and macroalbuminuric patients. Therefore, 
leukocytes are unlikely to be a source for heparanase in the urine of diabetic patients. 
We and others have reported that glomerular heparanase expression is upregulated 
predominantly in podocytes and glomerular endothelial cells in several human and 
experimental proteinuric diseases [7-10]. Recently, an increased expression and 
activity of heparanase was found in podocytes that were exposed to high glucose [13]. 
Additionally, we have preliminary data that mediators of the RAAS, but also ROS are 
involved in the regulation of heparanase expression by podocytes (Van den Hoven et 
al., conditionally accepted). Mouse glomerular endothelial cells [27] also expressed 
heparanase, which was elevated after stimulation with pro-inflammatory cytokines 
[28]. Another source for heparanase could be proximal tubular cells, since heparanase 
is expressed in tubuli of healthy persons [7, 9, 13, 20] and even increased in patients 
with overt DNP [7]. The observation that in patients with MGP heparanase activity 
in the urine correlated with β2-microglobulin excretion suggests that the increased 
activity of heparanase in the urine could be of tubular origin. 
 Degradation of HS in the GBM by heparanase has been generally considered of 
primary importance for the charge-selective permeability of the GBM. A decreased 
expression or undersulfation of HS in the GBM has been reported in various human 
and experimental glomerular diseases, including DNP, minimal change disease, 
lupus nephritis and MGP [4, 29, 30]. Since the loss of HS consistently correlated 
inversely with the degree of proteinuria in these diseases, we assumed that HS directly 
contributed to the charge-selectivity of the GBM. However, recent data question the 
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primary role of HS for charge-selectivity. Rats injected with heparinase III did not 
develop proteinuria, despite the loss of HS and negative charge from the GBM [31]. 
Furthermore, genetic manipulation, preventing HS expression in the GBM like in 
podocyte-specific EXT1 knockout mice, lacking the enzyme for HS polymerization 
[32], in podocyte-specific agrin knockout mice [33] and in perlecan knockout mice 
[34] was not associated with proteinuria. Furthermore, we have preliminary data that 
transgenic overexpression of human heparanase in mice only induced slightly elevated 
levels of proteinuria (Van den Hoven et al., in press). In addition, we have preliminary 
data that treatment of rats with adriamycin nephropathy with the aldosterone receptor 
blocker spironolactone restored the loss of HS expression in the GBM and reduced the 
increased heparanase expression in this model, whereas proteinuria was not reduced 
(Van den Hoven et al., conditionally accepted). These results strongly suggest that HS 
has no primary role in charge-selective filtration.
 Do these findings exclude a role for heparanase in the development of proteinuric 
diseases? In fact, upregulation of heparanase expression in DNP, adriamycin 
nephropathy and passive Heymann nephritis was consistently associated with a loss 
of HS in the GBM [7, 8, 11]. Importantly, treatment with heparinoids, heparanase 
inhibitors and even anti-heparanase antibodies resulted in amelioration of proteinuria 
[11, 12, 35]. In the above mentioned models, in which HS expression in the GBM 
was manipulated (agrin, perlecan, or EXT1 knockout mice and injection of bacterial 
heparinase III in rats), no glomerular pathology was co-existent [31-34]. Therefore, it 
cannot be excluded that the consequences of HS decrease are different in the various 
models that were examined. These studies cannot exclude a role for heparanase and 
loss of HS in glomerular diseases. The exact mechanisms through which heparanase 
contributes in the pathogenesis of proteinuria seem to be more secondary. Heparanase 
could be one of the contributors in a multi-hit pathogenesis of proteinuria. Heparanase 
could be involved in the liberation of HS-bound factors, such as FGF, VEGF, CTGF, 
cytokines and chemokines, which may enhance proteinuria. Degradation of HS by 
heparanase could also lead to disturbance of interactions between glomerular cells and 
the GBM, especially podocytes [36]. 
 In conclusion, an increased urinary heparanase activity was found in patients with 
type 1 and type 2 diabetes, which correlated with albuminuria and age. Increased 
urinary heparanase activity was not only restricted to diabetes, since it was also 
elevated in the urine of patients with MGP. Nevertheless, we cannot conclude yet 
whether increased heparanase activity is causing proteinuria or is a consequence of 
proteinuria. 
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Abstract
 Heparan sulfate (HS) in the glomerular basement membrane (GBM) is important 
for regulation of the charge-dependent permeability. Heparanase has been implicated 
in HS degradation in several proteinuric diseases. This study analyzed the role of 
heparanase in HS degradation in Adriamycin nephropathy (AN), a model of chronic 
proteinuria-induced renal damage.
 Expression of heparanase, HS, and the core protein of agrin (to which HS is attached) 
was determined on kidney sections from rats with AN in different experiments. First, 
expression was examined in a model of unilateral AN in a time-course study at 6-wk 
intervals until week 30. Second, rats were treated with the hydroxyl radical scavenger 
dimethylthiourea (DMTU) during bilateral AN induction. Finally, 6 wk after AN 
induction, rats were treated with angiotensin II receptor type 1 antagonist (AT1A) or 
vehicle for 2 wk. 
 Heparanase expression was increased in glomeruli of rats with AN, which correlated 
with HS reduction at all time points and in all experiments. Treatment with DMTU 
prevented the increased heparanase expression, the loss of GBM HS, and reduced 
albuminuria. Finally, treatment of established proteinuria with AT1A significantly 
reduced heparanase expression and restored glomerular HS. In conclusion, an 
association between heparanase expression and reduction of glomerular HS in AN was 
observed. The effects of DMTU suggest a role for reactive oxygen species (ROS) in 
upregulation of heparanase. Antiproteinuric treatment by AT1A decreased heparanase 
expression and restored HS expression.
 These results suggest involvement of radicals and angiotensin II in the modulation 
of GBM permeability through HS and heparanase expression.
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Introduction
 The GBM consists of many extracellular matrix proteins, including HS 
proteoglycans, mainly agrin. Loss of negatively charged HS molecules results in an 
altered charge-dependent permeability of the GBM [1]. The importance of HS in the 
charge-dependent permeability of the GBM has been demonstrated in several studies. 
First, digestion of HS by heparitinase resulted in increased permeability of the GBM 
for ferritin and albumin [2, 3]. Second, injection of a specific mAb against HS caused 
massive albuminuria in rats [4]. Third, loss of anionic HS has been reported in several 
human and experimental glomerulopathies, which was inversely correlated with the 
degree of proteinuria [5, 6]. It is suggested that proteinuria-induced renal damage is 
associated with loss of glomerular HS in diabetic and nondiabetic renal disease [7-9].
 HS loss in proteinuric renal disease can be attributed to several mechanisms 
(reviewed in reference [1]), such as depolymerization of HS by ROS, masking of HS 
by nucleosome/Ig complexes, reduction of both HS production and sulfation as a result 
of hyperglycemia, complement-mediated cleavage of HS, and proteolytic cleavage of 
the HS attachment site on the core protein by enzymes.
 Heparanase is an endo-β(1,4)-D-glucuronidase that is involved in the cleavage 
of HS and hence is associated with extracellular matrix degradation and tissue 
remodeling [10-13]. A recent study in patients with diabetic nephropathy suggested 
that loss of HS in the GBM is attributable to accelerated HS degradation by increased 
heparanase expression [14]. Studies in experimental renal diseases (passive Heymann 
nephritis, puromycin aminonucleoside nephrosis, and anti-GBM nephritis) suggest 
that heparanase also may be involved in nondiabetic proteinuric disease [15-18].
In chronic proteinuric renal diseases, blockade of the renin-angiotensin system (RAS) 
reduces proteinuria and thereby reduces progressive renal function loss. In AN, a 
model of chronic proteinuric renal damage [19], we previously reported a decrease of 
HS expression, which was caused partially by hydroxyl radicals [7]. Furthermore, we 
found that RAS blockade protects against loss of HS in established AN [9]. However, 
whether changes in heparanase may be involved in the decrease of HS expression 
in AN and/or the effects of RAS blockade is unknown. Therefore, in this study we 
first determined the time course of heparanase and HS expression in relation to the 
development of proteinuria and renal structural damage in AN. For this purpose, we 
used the unilateral variant of the AN model to allow good resolution over time. Next, 
the effect of scavenging of ROS during the period of induction of AN on heparanase 
and HS expression and on proteinuria was studied. Finally, we evaluated the potential 
of antiproteinuric treatment with an AT1A to restore the disbalance between heparanase 
and HS in established AN with persistent proteinuria.
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Materials and methods
Animals and experimental design
 Male Wistar rats were housed in a temperature-controlled room with a 12-h light-
dark cycle and with free access to food and water. Twentyfour-hour urine samples 
were collected every 2 wk in metabolic cages, with measurement of water and food 
intake. Surgical procedures took place under isoflurane anesthesia in N2O/O2 (1:2). 
Systolic BP was measured weekly by the tail-cuff method in conscious rats [20]. At the 
end of the study, the abdominal aorta was cannulated, a 2-ml blood sample was taken, 
and kidneys were perfused in situ with saline and removed. Proteinuria was measured 
on a BNII third-generation nephelometer (Dade Behring, Mannheim, Germany) by 
using a 20% trichloroacetic acid solution. The Committees for Animal Experiments of 
the University of Groningen and the Radboud University Nijmegen, The Netherlands, 
approved all studies.
 Experiment 1. Unilateral AN was induced by temporarily clipping the left renal 
artery and vein through a midline abdominal incision [20], followed by Adriamycin 
(1.5 mg/kg body wt) injection via the tail vein. After 12 min, when Adriamycin 
had been cleared from the circulation [19], the clamp was removed. For studying 
expression of heparanase, HS and renal damage over time, eight rats (at each time 
point) were killed at weeks 6, 12, 18, 24, and 30. In this experiment, the right kidney, 
exposed to Adriamycin, was compared with the control (nonexposed, left) kidney. 
Previously, we showed that the clipped left kidney did not differ from healthy control 
kidneys, not even after 30 wk [21].
 Experiment 2. Bilateral AN was induced by intravenous injection of 5 mg/kg 
body wt Adriamycin via the tail vein. One group of rats (n=8) received an initial 
intraperitoneal injection of the hydroxyl scavenger dimethylthiourea (DMTU; 500 
mg/kg body wt; Sigma, St. Louis, MO) 6 h before Adriamycin injection, followed by 
treatment with DMTU (1.25 mg/kg body wt) twice a day for 7 d. The control group 
(n=7) received saline instead of DMTU. Rats were killed 4 wk after the injection 
of Adriamycin. Urine was collected at weeks 0 and 4 for determination of urinary 
albumin excretion.
 Experiment 3. Bilateral AN was induced by intravenous injection of Adriamycin 
(2 mg/kg body wt) via the tail vein. At week 6, a renal biopsy was performed via a 
dorsolateral incision. After removal of a part of the lower pole from the left kidney, 
gel foam (Spongostan; Ferrosan, Copenhagen, Denmark) was applied for hemostasis. 
After recovery, rats were treated with the angiotensin II type 1 receptor antagonist 
(AT1A) L158,809 (150 mg/L drinking water; n=20) or vehicle (n=10). In previous 
experiments, the biopsy did not affect the course of renal damage [9, 22]. Treatment 
was continued until the rats were killed at week 8. Eight healthy rats that were killed 
at week 6 were used as time controls.
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Immunofluorescence staining
 To determine heparanase, HS, and agrin core protein expression, we performed 
indirect immunofluorescence staining on 2 µm cryostat kidney sections. Tissue 
sections were fixed in 100% acetone for 10 min at 4°C, followed by 1 h of incubation 
of primary antibodies diluted in PBS that contained 1% BSA and 0.01% sodium azide 
at room temperature. After washing in PBS, the appropriate secondary antibodies 
were diluted in PBS and incubated for 1 h at room temperature, with 5% normal rat 
serum and 10% normal goat serum. Specific primary and secondary antibodies that 
were used are summarized in Table 1. Subsequently, the sections were washed in 
PBS and embedded in Vectashield mounting medium H-1000 (Vector Laboratories, 
Burlingame, CA).
 For investigation of which glomerular cell type was responsible for the expression 
of heparanase in AN, sections were double-stained with anti-heparanase and (1) anti-
agrin, to distinguish between the outside of the GBM covered by podocytes and the 
inside with endothelial cells lining the GBM; (2) anti-synaptopodin, which stains the 
cytoskeleton of podocytes; and (3) anti-Thy1.1, which is a mesangial cell marker. For 
investigation of in which tubular cell type heparanase was expressed, double stainings 
were performed with anti-heparanase and (1) anti-aquaporin 2, a marker for collecting 
ducts; (2) anti-calbindin D-28k, a marker for distal convoluted tubuli; and (3) anti-
P-glycoprotein, a marker for proximal tubuli (summarized in Table 1). Confocal 
laser scanning microscopy (Leica, Heidelberg, Germany) was used to evaluate the 
stainings.
Quantification of immunofluorescence staining and histochemistry
 The kidney sections were randomly coded and evaluated by two independent 
observers on a Zeiss Axioskop microscope (equipped with an epi-illuminator). For 
agrin and HS expression, linearity of the GBM was scored at an arbitrary scale of 0 
to 10 (0= no staining, 1= 10% linear GBM staining, etc., with a maximum score of 10 
for 100% staining). Heparanase expression was scored from 0 to 5 arbitrary units for 
staining intensity. Expression was analyzed in 25 glomeruli per animal.  
 Focal glomerulosclerosis (FGS) was scored semiquantitatively on periodic acid-
Schiff-stained paraffin sections (4 µm), as described previously [23]. FGS lesions 
were defined as glomerular areas with mesangial expansion and adhesion formation 
simultaneously present in one segment. Scoring was performed on a scale of 0 to 4 in 
50 glomeruli per kidney moving from outer to inner cortex. The FGS scores presented 
in Tables 2 and 3 are the median FGS scores per 50 glomeruli per experimental animal 
group multiplied by 100 (score in arbitrary units from 0 to 400).
Statistical analyses
 Data are expressed as median and 95% confidence intervals. Differences between 
groups were determined by Kruskal-Wallis and Mann-Whitney U tests. Linear 
Glomerular heparanase expression in adriamycin nephropathy
82 83
regression was performed to detect whether proteinuria and heparanase and HS 
expression were associated. Analyses were performed using SPSS version 12.0 (SPSS, 
Inc., Chicago, IL) and GraphPad Prism, version 4.0 software (GraphPad Software, 
Inc., San Diego, CA). Statistical significance was regarded at P<  0.05.
Results
Clinical and morphologic data
 Data on proteinuria and BP for the time-course study (experiment 1) and the 
intervention study (experiment 3) are shown in Tables 2 and 3, respectively. In 
unilateral AN, proteinuria was increased at all time points and BP was normal. The 
score for FGS was increased in the Adriamycin-exposed kidney compared with the 
nonexposed control kidney and progressed over time. When rats were treated with 
DMTU before induction of bilateral AN, albuminuria at week 4 was lower compared 
with that in saline-treated rats with AN (255 (185 to 276) versus 353 (274 to 436) 
Antibody Specificity and epitope Dilution Source Secondary antibodya 
HPA1 Rabbit anti-heparanase: 
50-kDa/8-kDa 
heterodimer
1:100 ProsPec-Tany 
Technogene, Rehovot, 
Israel
Goat anti-rabbit IgG 
Alexa 594 or 488
JM403 Mouse anti-rat HS: 
N-unsub- stituted 
glucosamine unit
1:300 [4, 41] Goat anti-mouse IgM 
Alexa 488
MI91 Hamster anti-agrin core 
protein: N-terminus
1:800 [42] Goat anti-hamster 
IgG Cy3
OX7 Mouse anti-Thy 1.1: 
Mesangium cells 
1:300 PharMingen, San 
Diego, CA, USA
Goat anti-mouse IgG 
Alexa 488
G1D4 Mouse anti-
synaptopodin: Podocyte 
cytoskeleton
1:1 Progen Biotechnik, 
Heidelberg, Germany
Goat anti-mouse IgG 
Alexa 488
300 Mouse anti-calbindin 
D-28k: Distal 
convoluted tubuli
1:300 Swant, Bellinzona, 
Switzerland
Goat anti-mouse IgG 
Alexa 488
AQP2 Guinea pig anti-
aquaporin 2: 
Collecting duct
1:300 Kindly provided by Dr. 
P. Deen [43]
Goat anti-guinea pig 
IgG Alexa 488
C219 Mouse anti-P-
glycoprotein: Proximal 
tubuli
1:20 Abcam, Cambridge, 
UK
Goat anti-mouse IgG 
Alexa 488
Table 1. Antibodies used for immunofluorescence.
aSecondary Alexa antibodies were purchased from Invitrogen (Molecular Probes, Breda, The 
Netherlands) and were used in a dilution of 1:200; Cy 3-labeled antibody was obtained from Jackson 
ImmunoResearch Laboratories (Cambridgeshire, UK) and used in a dilution of 1:800.
Chapter 5
82 83
Week 6 Week 12 Week 18 Week 24 Week 30
Uprot 
(mg/24h) 122 (72-367) 191 (142-414) 237 (183-395) 221 (70-351) 265 (159-459)
SBP (mmHg) 140 (112-146) 140 (122-166) 140 (122-156) 163 (120-183) 152 (138-190)
FGS control 0 (0-16) 2 (0-12) 8 (2-24) 19 (2-54) 24 (2-50)
FGS ADR 3 (0-16)b 20 (0-48)b 43 (10-78)b 45 (6-96)b 67 (38-148)b
Table 2. Characteristics of the time-course study in unilateral AN (experiment 1)a.
aADR, adriamycin-exposed kidney; AN, Adriamycin nephropathy; FGS, focal segmental 
glomerulosclerosis; SBP, systolic BP; Uprot, proteinuria. bP< 0.05 versus control (nonexposed kidneys).
Vehicle AT1 antagonist Controls
Week 6 Week 8 Week 6 Week 8 Week 6
Uprot 
(mg/24h) 777 (254-883)* 697 (257-834)* 680 (250-904)* 245 (33-638)
#& 13(11-17)
SBP 
(mmHg) 149 (140-171) 144 (97-156) 143 (124-164) 113 (60-148)
#& 140 (131-161)
FGS 
score 20 (0-30)* 30 (2-52) 12 (0-97)* 16 (2-87) 0 (0-2)
Table 3. Characteristics of the intervention study in bilateral AN (experiment 3)a.
aAT1, angiotensin II receptor type 1; bP< 0.05 versus controls; cP< 0.05 versus week 6; dP< 0.05 versus 
vehicle.
mg/24h; P< 0.05). In the intervention study at week 6 (before treatment with AT1A 
started), proteinuria was markedly increased compared with healthy controls. 
Treatment during 2 wk with AT1A reduced proteinuria and BP. The score for FGS did 
not change during the 2 wk of treatment. In the vehicle-treated group, proteinuria and 
BP and FGS score remained stable.
Heparanase overexpression is associated with reduced HS expression in AN: time 
course
 Glomerular HS and heparanase expression in the exposed and nonexposed kidney, 
assessed by indirect immunofluorescence staining on cryostat sections, is shown in 
Figure 1. HS showed a nice linear staining along the GBM in control kidneys (Figure 
1A). However, in Adriamycin-exposed kidneys, the intensity of HS expression in 
the GBM was reduced, whereas agrin expression remained unaltered (Figure 1B). 
Semiquantitative analysis revealed that HS was significantly reduced in Adriamycin-
exposed kidneys at all time points without changes over time, whereas agrin core 
protein expression did not differ between control and Adriamycin-exposed kidneys 
(Figure 2, A and B). Heparanase expression was markedly increased in all Adriamycin-
exposed kidneys (Figure 1D) as compared with the control kidneys (Figure 1C), which 
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Figure 1. Heparan sulfate (HS; proteoglycans) and heparanase expression in Adriamycin 
nephropathy (AN) and control kidneys (indirect immunofluorescence staining). (A) 
JM403 staining for HS and MI91 staining for agrin core protein in a control kidney; a nice 
linear staining of the glomerular basement membrane (GBM) is observed for both HS and 
agrin. (B) HS and agrin staining in an Adriamycin-exposed kidney: Glomerular HS staining is 
decreased, whereas agrin staining remains linear. (C) HS and heparanase staining in a control 
kidney: Heparanase is present in the tubuli but absent in the glomerulus. (D) HS and heparanase 
expression in an Adriamycin-exposed kidney: A glomerulus with reduced HS expression and 
increased heparanase expression. Magnification, x40. For full-colour representation see; 
Colour Figures.
was confirmed by semiquantitative analysis. Heparanase expression was increased 
significantly at all time points (Figure 2C) without changes over time. The reduction 
in glomerular HS expression significantly correlated with an increase in heparanase 
expression (R2 = 0.34, P< 0.001; Figure 2D). Taken together, these results indicate that 
increased heparanase expression and loss of glomerular HS are early events in the time 
course of the Adriamycin-induced nephrotic syndrome.
Chapter 5
84 85
Figure 2. Semiquantitative analysis of glomerular HS, agrin, and heparanase expression 
in arbitrary units (A.U.) at different time points in unilateral AN (experiment 1).  (A) 
HS expression in the GBM was significantly decreased in AN at all time points. (B) Agrin 
core protein expression did not differ between Adriamycin-exposed and control kidneys. (C) 
Glomerular heparanase expression was upregulated in AN at all time points. (D) Correlation 
between HS staining and heparanase expression in unilateral AN. Open symbols indicate score 
of nonexposed kidneys; filled symbols indicate score of Adriamycin-exposed kidneys. 
*P< 0.05.
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DMTU reduces the early effect of Adriamycin on HS and heparanase expression
 Because HS reduction in AN has been attributed to a depolymerization of HS by 
ROS [7], we studied whether the increased heparanase expression could be attributed 
to ROS by treating rats with the hydroxyl radical scavenger DMTU during disease 
induction by Adriamycin and the first week afterward. When the rats were killed, 3 wk 
later, a loss of HS was observed in the saline-treated rats that was partly prevented by 
the treatment with DMTU (Figure 3A), whereas expression of agrin was comparable 
in both groups (data not shown), which is in line with previous experiments [7]. It 
is interesting that the glomerular heparanase expression in AN rats that were treated 
with the ROS scavenger DMTU was significantly lower compared with that in saline-
treated AN rat (Figure 3B).
Figure 3. Effect of treatment with 
the hydroxyl radical scavenger 
dimethylthiourea (DMTU) before 
disease induction by Adriamycin and 
the first week afterward (experiment 
2). (A) Decrease of HS expression in AN 
could be partly prevented by treatment 
with DMTU. (B) Heparanase expression 
was significantly lower after treatment with 
DMTU. *P< 0.05.
Reduction of heparanase and increase in HS expression after treatment with 
AT1A
 Next, we investigated whether, in established proteinuria, antiproteinuric treatment 
by AT1A can reduce glomerular heparanase expression along with restoration of 
HS expression in the GBM. HS (proteoglycans) and heparanase expression was 
determined in bilateral AN, before (week 6) and after 2 wk of treatment with AT1A 
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or vehicle (week 8). Glomerular HS expression was decreased in all Adriamycin-
exposed animals at week 6, and heparanase expression was markedly increased, which 
was comparable with the results observed in the unilateral model of AN (Figure 4). 
Treatment with AT1A significantly increased glomerular HS expression compared 
with the vehicle-treated animals (Figure 4A), which was, interestingly, accompanied 
by a significant reduction in heparanase (Figure 4B). However, AT1 receptor blockade 
did not completely restore HS expression to normal levels as observed in the healthy 
controls. For the individual Adriamycin animals (vehicle and AT1A at weeks 6 and 8), 
the reduction in glomerular HS expression was significantly correlated with increased 
heparanase expression (R2 = 0.63, P<  0.001; Figure 4C).
Figure 4. Effects of treatment with 
angiotensin type I receptor antagonist 
(AT1A) or vehicle (VEH) on heparanase 
and HS expression in bilateral AN 
(Experiment 3) compared with 
healthy control rats at week 6. Indirect 
immunofluorescence double staining was 
performed on kidney biopsies before 
(week 6) and after treatment (week 8). (A) 
Glomerular HS expression was reduced 
before treatment but restored after 2 wk of 
treatment with AT1A. Treatment with VEH 
did not restore HS expression. (B) After 2 
wk of treatment with AT1A, heparanase 
expression decreased, and it did not change 
with VEH treatment. (C) Correlation 
between HS staining and heparanase 
expression in bilateral AN. *P< 0.05.
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Heparanase expression in glomeruli and tubuli
 Heparanase expression in AN is located at the outer side of the GBM and is 
minimally expressed within the capillary loops (Figure 5, A through C). Co-localization 
with synaptopodin confirms that heparanase is expressed by the podocytes and not by 
mesangium cells, because no co-localization with anti-Thy1.1 could be observed. 
 Heparanase is expressed in tubuli of both normal and diseased animals. Tubular 
HS and heparanase expression was not altered by either Adriamycin injection or AT1A 
treatment compared with controls. Using specific tubular markers, we observed that 
heparanase is expressed mainly in proximal tubuli. No expression was found in the 
distal convoluted tubuli or collecting ducts (Figure 5, D through F).
Figure 5. Immunofluorescence double staining with anti-heparanase (green) and anti-
agrin (red) (A), and with anti-heparanase (red) and anti-synaptopodin (B), or anti-
Thy1.1 (C) (both in green). Glomerular heparanase is expressed mainly at the outside of 
the GBM, confirmed by co-localization with the podocyte marker synaptopodin. Minimal 
staining was observed in the capillary loops (according to the agrin/heparanase staining). No 
co-localization with mesangium cells was shown. For tubular heparanase expression, we used 
immunofluorescence double staining with anti-heparanase (red) and anti-calbindin D-28k (D), 
anti-aquaporin 2 (E), and anti-Pglycoprotein (F; all green). Tubular heparanase is expressed 
mainly in the proximal tubuli, because it co-localized with P-glycoprotein. No co-localization 
with the distal convoluting tubuli and collecting ducts was shown. Magnification, x63. For full-
colour representation see; Colour Figures.
Discussion
 Our data demonstrate that glomerular heparanase expression is increased in 
Adriamycin-induced nephropathy and associated with a decreased HS expression in 
the GBM. These changes occur early after disease induction and remain stable during 
follow-up, whereas renal structural damage progresses. We previously found ROS to 
induce loss of glomerular HS [7]; our data show that treatment with the ROS scavenger 
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DMTU reduces heparanase expression compared with saline-treated Adriamycin rats, 
with subsequently a better preservation of glomerular HS expression and amelioration 
of albuminuria. Finally, glomerular heparanase expression in established AN was 
reversible by antiproteinuric treatment with RAS blockade, along with an increased 
glomerular HS expression.
 In a previous study, we reported that by treatment with a ROS scavenger, HS 
expression was not completely restored and albuminuria was not completely prevented 
in AN [7], suggesting that additional mechanisms are involved in the reduction of 
HS in this model. Our study demonstrates that heparanase expression is increased 
in AN and correlated with the loss of HS in the GBM, suggesting that heparanase 
may play an important role in HS reduction. The increased expression of heparanase 
in AN is in line with the findings in puromycin aminonucleoside nephrosis, passive 
Heymann nephritis, and anti-GBM nephritis [15-18]. The loss of glomerular HS also 
is in accordance with previous studies in proteinuric renal disease [7-9]. Our data on 
a consistent association between HS and heparanase suggest that heparanase is an 
important factor involved in the breakdown of HS and thereby in the development of 
proteinuria. The pathogenic potential for heparanase in proteinuria is supported by a 
recent study showing that inhibition of heparanase prevented both proteinuria and loss 
of HS in passive Heymann nephritis [16]. Moreover, heparin and heparin derivatives 
that inhibit heparanase have been shown to exert antiproteinuric effects in diabetic 
nephropathy, further supporting the impact of heparanase [24].
 As mentioned before, ROS have already been demonstrated to be involved in the 
loss of HS in AN, which we explained by ROS-mediated depolymerization of HS 
[7]. In this study, treatment of AN with DMTU prevented the increase in heparanase 
expression and the loss of HS in the GBM. Whether ROS production in this model is 
persistent seems unlikely, because treatment with DMTU (6 h before and for only 1 
wk after Adriamycin administration) partially prevents proteinuria, loss of HS, and 
heparanase overexpression at later stages.
 Treatment with an angiotensin-converting enzyme (ACE) inhibitor or AT1A 
ameliorates proteinuria in both human and experimental renal diseases, including AN, 
and provides renoprotection [21, 25-30]. Antiproteinuric treatment with AT1A in this 
study led to a partially restored glomerular HS expression. This effect of AT1A on 
HS expression in AN is comparable with the effect of ACE inhibition that preserved 
glomerular HS expression in rats with AN [9]. Along with the restored HS expression 
after treatment with AT1A, we observed a markedly reduced glomerular heparanase 
expression. In vitro experiments show that angiotensin II reduces HS expression in the 
extracellular matrix of human podocytes, raising the possibility of a direct effect [31]. 
No data on intrarenal angiotensin II are available in AN; however, we have reported 
elevated intrarenal activity of ACE in AN, consistent with a local activation of RAS 
[32].
 We used three different approaches to study the expression of glomerular 
heparanase and HS in AN. The first was a unilateral model with a relatively low 
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(1.5 mg/kg body wt) Adriamycin dosage to allow good resolution over time. In the 
second study, the acute bilateral AN model (5 mg/kg body wt) with DMTU treatment 
was used with short-term follow-up. Finally, in the chronic bilateral AN model with 
AT1 intervention, we used 2 mg/kg body wt. Despite variations in the induction and 
severity of the model, the observed correlation between HS and heparanase was 
present consistently.
 The changes in glomerular heparanase expression in the Adriamycin model and its 
reversibility by ROS scavenging or RAS blockade observed here theoretically could 
be due to different factors, namely (1) ROS, (2) angiotensin II, and/or (3) proteinuria. A 
single intrarenal administration of Adriamycin leads to a chain of reactions. Generation 
of ROS leads to injury of the podocytes, resulting in persistent proteinuria and 
increased production of (local) angiotensin II. All three elements (ROS, angiotensin II, 
and proteinuria), in our opinion, could be sequentially responsible for the persistence 
of heparanase overexpression. Although the generation of ROS can be induced by 
angiotensin II [33-35], ROS also are thought to be induced by Adriamycin per se. 
The beneficial effects of DMTU treatment during the induction phase of AN support a 
role for ROS in the induction of changed charge-selective properties of the GBM, as a 
result of both a direct effect of ROS on HS and ROS-induced heparanase expression. 
The effects of RAS blockade, showing reversibility of heparanase upregulation in 
established nephropathy, support a role for angiotensin II in heparanase expression. 
As to proteinuria, the time course study with early changes in heparanase and HS 
expression, which were stable during long-term follow-up despite prolonged exposure 
to proteinuria, suggests that increased heparanase and decreased HS expression are 
causal to proteinuria rather than a consequence. Furthermore, in a model of protein-
overload nephropathy [36], we could not demonstrate a reduction in HS or an increase 
in heparanase expression (data not shown).
 Our results suggest that both ROS and RAS are involved in upregulation of 
heparanase expression. Several studies have demonstrated that there is a link between 
ROS and RAS signaling. Angiotensin II has been shown to induce ROS production, 
whereas ROS mediates several effects of angiotensin II, such as on protein synthesis, 
cell hypertrophy, and vascular endothelial growth factor production. Scavengers of 
ROS ameliorate angiotensin II-induced or angiotensin II-mediated effects, whereas 
ACE inhibition or angiotensin II receptor blockade were able to reverse oxidative 
stress [37-40]. Further studies would be needed to address the possible interactions 
between ROS and RAS in regulation of heparanase expression in AN.
 Heparanase plays an important role in the loss of HS in AN. Heparanase expression 
is increased early in the time course of AN and shows a clear association with the 
loss of HS in the GBM and proteinuria, suggesting that heparanase is an important 
mediator of loss of glomerular HS and development of proteinuria in AN. Scavenging 
of ROS prevented upregulation of heparanase and loss of HS. In addition to direct 
ROS-mediated depolymerization of HS, which we have shown previously in vitro, 
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ROS indirectly may contribute to the HS loss in AN by upregulation of heparanase 
expression. It is feasible that in AN, both direct and indirect ROS-mediated mechanisms 
are operative. Reduction of heparanase and the subsequent restoration of glomerular 
HS contribute to the beneficial effects of RAS blockade. Our results suggest that both 
ROS and RAS play a role in heparanase induction and in the breakdown of HS in AN. 
However, the interplay between ROS and RAS in the induction of heparanase requires 
further investigation.
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Abstract
 Inhibition of the renin-angiotensin-aldosterone system (RAAS) provides 
renoprotection in adriamycin nephropathy (AN), along with a decrease in 
overexpression of glomerular heparanase. Angiotensin II (AngII) and reactive oxygen 
species (ROS) are known to regulate heparanase expression in vivo. However, it is 
unknown whether this is also the case for aldosterone. Therefore, we further assessed 
the role of aldosterone, AngII and ROS in the regulation of glomerular heparanase 
expression.
 Six weeks after the induction of AN, rats were treated with vehicle (n=8), lisinopril 
(75 mg/L, n=10), spironolactone (3.3 mg/d, n=12) or the combination of lisinopril 
and spironolactone (n=14) for 12 weeks. Age-matched healthy rats served as controls 
(n=6). After 18 weeks, renal heparanase and HS expression were examined by 
immunofluorescence staining. In addition, the effect of aldosterone, AngII and ROS 
on heparanase mRNA expression in cultured podocytes was determined.
 Treatment with lisinopril, spironolactone, or their combination significantly 
blunted the increased glomerular heparanase expression and restored the decreased 
HS expression in the GBM. Addition of aldosterone to cultured podocytes resulted 
in a 2.3-fold increased heparanase mRNA expression, which could be inhibited by 
spironolactone. Heparanase expression in podocytes was also significantly increased 
after stimulation with AngII (2-fold) or ROS (2.5-fold). 
 In conclusion, our in vivo and in vitro results show that not only AngII and ROS, but 
also aldosterone is involved in the regulation of glomerular heparanase expression.
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Introduction
 The RAAS is a potent mediator in the initiation and progression of chronic kidney 
disease. Functional blockade of RAAS with angiotensin-converting enzyme inhibition 
(ACEi) and/or AngII type 1 receptor blockade (ARB) is currently common practice 
for both the prevention and treatment of chronic kidney disease. Many reports 
have shown that AngII, the primary mediator of the RAAS, mediates progressive 
renal damage. However, recent studies suggest that the mineralocorticoid hormone 
aldosterone, involved in sodium and potassium homeostasis, is an additional factor in 
the development and progression of renal disease itself [1, 2]. In line with this notion, 
administration of an aldosterone receptor blocker (aldoRB) on top of ACEi exerts an 
added renoprotective effect compared to ACEi alone [3-5]. 
 The mechanisms of the adverse effects of aldosterone on the kidney are incompletely 
known. In experimental and human glomerular diseases a decreased expression of 
HS in the GBM is commonly present [6]. This loss of HS could be attributed to an 
increased expression of heparanase, which is an endo-β(1-4)-D-glucuronidase that 
cleaves HS side chains. In several experimental and human glomerular diseases, such 
as passive Heymann nephritis, puromycin-induced nephrosis, anti-GBM nephritis, 
diabetic nephropathy, adriamycin-induced nephrosis (AN) and minimal change disease 
an increased expression of glomerular heparanase was observed, which correlated with 
a decreased expression of HS in the GBM [7].  
 Recently, we demonstrated that in AN, a model for chronic proteinuria-induced 
renal damage, ARB and scavengers of hydroxyl radicals, reduced or prevented 
glomerular heparanase expression and restored loss of HS in the GBM [8]. This 
suggests that AngII and ROS are involved in the regulation of heparanase expression 
in vivo in AN. Furthermore, it is known that both aldosterone and AngII may induce 
ROS as mediators of renal injury [9, 10]. It is unknown whether aldosterone is able to 
induce glomerular heparanase expression. Therefore, in the present study, we evaluated 
the effects of aldoRB by spironolactone, ACEi by lisinopril, or a combination of 
spironolactone and lisinopril on the gomerular expression of heparanase and HS in rats 
with AN. In addition, we evaluated whether aldosterone, AngII and ROS were able to 
directly regulate heparanase expression in vitro in cultured mouse podocytes.
Material and methods
Animals and experimental design
 Fifty male Wistar rats (HsdCpb: Wu; Harlan Inc, Zeist, The Netherlands) weighing 
250 to 275 grams were used in this study. The animals were housed in a temperature-
controlled room with a 12 hour light-dark cycle. Animals had free access to food and 
water. All surgical procedures took place under isoflurane anaesthesia in N
2
O/oxygen. 
 Adriamycin nephrosis (AN) was induced by injection of 1.75 mg/kg adriamycin 
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(Doxorubicin®) into the tail vein (n=44). After 6 weeks, when proteinuria had 
stabilized, rats were stratified according to proteinuria and received treatment for 12 
weeks. Vehicle-treated rats received normal drinking water (VEH, n=8). Lisinopril 
was administered in the drinking water (75 mg/L; LIS, n=10). The spironolactone 
group (SPIR, n=12) received subcutaneous 60-day slow release pellets (3.3 mg/day; 
Innovative Research of America, Sarasota, FL, USA). After 8 weeks (at week 14) a 
second pellet was placed for the remaining 4 weeks. The fourth group was treated 
with a combination of lisinopril and spironolactone (LIS+SPIR, n=14). Untreated 
rats served as time controls (CON, n=6). At the end of the study (week 18) rats were 
anaesthetized, blood was collected by cannulation of the abdominal aorta, kidneys 
were perfused in situ with saline and removed. All experimental procedures were 
approved by the local Animal Ethics Committees.
Clinical parameters
 During the study, body weight and systolic blood pressure were measured weekly, 
as described previously [11]. Urine was collected 2-weekly in metabolic cages 
with measurement of water intake. Urinary protein excretion was measured by the 
pyrogallol red molybdate method. We measured urinary malondialdehyde (MDA) as a 
marker for oxidative stress by thiobarbituric acid reactivity [12]. Serum concentration 
of creatinine was determined with the Jaffé method, analyzed on a multi-test analyzer 
system (Merck Mega, Darmstadt, Germany). 
Histological assessment of renal damage
 Pieces of kidneys were fixed in 4% paraformaldehyde and embedded in paraffin. 
Sections (4 μm) were stained with periodic acid-Schiff and examined by light 
microscopy in a blinded fashion to evaluate focal glomerulosclerosis (FGS). We semi-
quantitatively scored 50 glomeruli on a scale of 0 to 4. FGS was scored positive when 
collapsed capillary lumens, mesangial matrix expansion, hyalinosis, and adhesion 
formation were present in the same quadrant. If 25% of the glomerulus was affected, a 
score of 1 was given, 50% was scored as 2, 75% as 3 and 100% as 4. The FGS scores 
presented in Table 2 are the median FGS scores per 50 glomeruli per experimental 
group, multiplied by 100 (score in arbitrary units from 0-400).
 
Immunofluorescence staining
 Expression of heparanase, HS and agrin was determined by indirect 
immunofluorescence staining on 2 μm cryostat kidney sections as described previously 
[8, 13]. Sections were double stained with a rabbit anti-heparanase antibody, diluted 
1:100, (Prospectany, Rehovot, Israel) and a mouse monoclonal anti-HS antibody, 
JM403, which recognizes HS in the GBM, diluted 1:300, or double stained with a 
monoclonal hamster anti-agrin antibody, MI91, diluted 1:800 and JM403. Blinded 
sections were examined with a Zeiss Axioskop microscope by two independent 
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observers. Agrin and HS expression were scored in 25 glomeruli per rat on a scale of 0-
10 (in arbitrary units (AU) for linearity of the GBM. Heparanase expression was scored 
on a scale from 0-5 for staining intensity [8]. Scoring between both observers was 
consistent, since analysis by the Bland and Altman method showed little interobserver 
variability with mean differences and 95% limits of agreement of 0.036 (-0.03/0.11) 
for agrin, -0.13 (-0.29/0.03) for HS and -0.24 (-0.30/-0.18) for heparanase.
Cell culture
 Mouse podocytes, (MPC-5) derived from the conditionally immortalized mouse 
(H-2Kb) with a temperature-sensitive variant of the SV40 large T antigen were cultured 
as reported [14]. To evaluate the effects of aldosterone, AngII and ROS on heparanase 
expression, podocytes were seeded on flasks pre-coated with 10% collagen A 
(Biochrom AG, Berlin, Germany) and cultured for 14 days at 37ºC in an atmosphere 
of 5% CO
2
. Hereafter, culture medium was replaced by RPMI 1640 containing 0.5% 
FCS for 24 hours. Subsequently, podocytes were stimulated for 18 hours with 100 
nM aldosterone (Sigma), 1 µM AngII (Sigma), 50 µM xantine with 50 mU xantine 
oxidase (Sigma, Zwijndrecht, The Netherlands), to generate extracellular ROS, or 5 
mM NADH (Roche Diagnostics, Penzberg, Germany), to generate intracellular ROS. 
Specific antagonists were added in fresh medium with 0.5% FCS for 1 hour at 37˚C 
prior to the addition of AngII, aldosterone and generators of ROS. The aldosterone 
receptor was blocked with different concentrations of spironolactone (1, 10 and 100 
nM; Sigma); AngII receptor type 1 or 2 were inhibited by 5 μM L158,890 (MSD) 
or 5 μM P123,319 (Sigma), respectively. All experiments were performed at least in 
triplicate.
RNA isolation and real-time RT-PCR
 Total RNA was extracted from podocytes using the RNeasy Mini Kit (Qiagen 
Benelux, Venlo, The Netherlands). RNA (1 μg) was reverse-transcribed into cDNA 
using first strand cDNA synthesis kit with oligo dT primers and Superscript reverse 
transcriptase (Invitrogen). The mRNA levels of the mineralocorticoid receptor (MR), 
heparanase and serum glucocorticoid-regulated kinase 1 (SGK-1; positive control) 
were quantified by real-time PCR with the MyiQTM Single-Color Real-Time PCR 
Detection System (Bio-Rad, Veenendaal, The Netherlands). Each PCR reaction was 
performed with the use of Fast-start sybr green mix (Roche Diagnostics) and gene-
specific primers, as listed in Table 1 (Biolegio BV, Malden, The Netherlands). PCR 
conditions were: 10 min at 95°C, followed by 40 cycles at 95°C for 30 seconds, 56°C 
for 30 seconds, and 72°C for 30 seconds. Expression of the housekeeping genes β-actin 
and/or RNA polymerase II was used to quantify heparanase expression by the delta-
delta cycle time (Ct) method. 
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Gene Sequence Product
β-actin Forward 5’-GTGGGCCGCTCTAGGCACCAA-3’ 539 bp
Reverse 5’-CTCTTTGATGTCACGCACGATTTC-3’
RPII Forward 5’-GAGCCACCACGTCCAATGATATTGTGG-3’ 265 bp
Reverse 5’-GATCGTGCTGCTGCTTCCATAAGG-3’
HPSE-1 Forward 5’-GAGCGGAGCAAACTCCGAGTGTATC-3’ 217 bp
Reverse 5’-GATCCAGAATTTGACCGTTCAGTTGG-3’
SGK-1 Forward 5’-CTGTTCTACCATCTCCAGAG-3’ 328bp
Reverse 5’-CCGTAGAGCATCTCATACAG-3’
MR Forward 5’-GTGGACAGTCCTTTCACTACCG-3’ 285bp
Reverse 5’-TGACACCCAGAAGCCTCATCTC-3’
Table 1. Mouse primers used in this study.
Statistical analysis
 Data were tested for normality and when non-normal distribution was present 
differences between groups were detected by Kruskal-Wallis and Mann-Whitney U 
tests, otherwise ANOVA with Bonferroni post-hoc tests were used. Spearman’s Rho 
correlation coefficients were calculated. Linear regression was performed to calculate 
the association between proteinuria, HS and heparanase. Statistical analyses were 
performed using SPSS version 14.0 (SPSS Inc., Chicago, IL, USA) and GraphPad 
Prism version 4.0 (GraphPad Software Inc., San Diego, CA, USA). Statistical 
significance was assumed at the 5% level.
Results
Clinical characteristics and renal structural damage 
 Clinical characteristics of the animals are described in detail elsewhere [15] and 
are summarized in Table 2. Briefly, six weeks after induction of nephrosis and before 
the start of treatment mean proteinuria was 214±125 mg/24h. In vehicle-treated rats 
proteinuria progressed to 641±287 mg/24h at week 18. Treatment with spironolactone 
monotherapy did not significantly reduce proteinuria, whereas treatment with 
lisinopril and the combined treatment of lisinopril and spironolactone significantly 
reduced proteinuria compared to vehicle-treated animals and animals treated with 
only spironolactone. However, there was no significant difference between lisinopril 
monotherapy and the combined treatment with lisinopril/spironolactone with regard to 
proteinuria and blood pressure. Lisinopril and the combination therapy significantly 
reduced blood pressure compared to vehicle-treated animals and non-treated controls. 
Body weight and serum creatinine were not different between the groups. 
RPII, RNA polymerase II ; HPSE-1, heparanase; SGK-1, serum glucocorticoid-regulated kinase 1; MR, 
mineralocorticoid receptor.
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 To evaluate the effects of the different treatment modalities on the level of oxidative 
stress, we measured urinary malondialdehyde (MDA). Urinary MDA was significantly 
elevated in vehicle-treated animals compared to control. Lisinopril, spironolactone and 
the combined treatment all tended to reduce urinary MDA levels compared to vehicle, 
without differences between the groups (Table 2). 
 There was a significant increase in FGS in all adriamycin animals compared 
with control animals, with the highest values in vehicle, followed by spironolactone, 
lisinopril and with the lowest FGS score in the lisinopril + spironolactone group 
(P< 0.05 for trend). The FGS score was significantly reduced in the lisinopril + 
spironolactone group compared to the vehicle and spironolactone groups (Table 2).
CON
(n= 6)
VEH
(n= 8)
LIS
(n= 12)
SPIR
(n= 10)
LIS + SPIR
(n= 14)
Body weight (gram) 504 ± 52 †# 474 ± 28 451 ± 28 455 ± 28 464 ± 30
Proteinuria (mg/24h) 28 ± 9 *† 641 ± 287 289 ± 218 * 569 ± 284 187 ± 190 *†
Urinary MDA (nmol/24h) 40 ± 8 64 ± 30 & 55 ± 8 50 ± 9 51 ± 8
Blood pressure (mmHg) 137 ± 8 *† 169 ± 33 118 ± 25 *† 150 ± 14 101 ± 25 *†
S creatinine (μmol/L) 55 ± 2 69 ± 14 65 ± 11 67 ± 15 69 ± 13
FGS (0-400) 2 ± 3 57 ± 84 & 18 ± 31 † 40 ± 38 & 12 ± 12 &†*
Table 2. Clinical features at week 18.
Parameters at the end of the study are shown. All values are expressed as mean ± SD. Abbreviations are: 
CON, healthy control; VEH, vehicle; LIS, lisinopril; SPIR, spironolactone; LIS + SPIR, combination of 
lisinopril and spironolactone; MDA, malondialdehyde; FGS, focal glomerulosclerosis. *P< 0.05 versus 
VEH, †P< 0.05 versus SPIR, #P< 0.05 versus LIS, ‡P< 0.05 versus all groups, &P< 0.05 versus CON.
Treatment with ACEi and/or aldoRB restores HS expression in the GBM and 
reduces glomerular heparanase expression
 To evaluate the effects of treatment with ACEi (lisinopril), aldoRB (spironolactone) 
or a combination of ACEi and aldoRB (lisinopril + spironolactone) on HS and 
heparanase expression in AN, we performed immunofluorescence stainings on rat 
kidney cryosections (Figure 1). Figure 1A shows a linear HS staining of the GBM and 
no glomerular heparanase expression in control rats, whereas in diseased adriamycin 
nephrotic animals  HS expression was decreased and associated with an increased 
glomerular heparanase expression. Monotherapy with lisinopril or spironolactone and 
combination therapy with lisinopril + spironolactone partially restored HS expression, 
whereas the combination of lisinopril + spironolactone therapy seems to be the most 
effective therapy for restoration of HS in the GBM (Figure 1A and B). Additionally, 
glomerular heparanase expression was significantly reduced after treatment with 
lisinopril, spironolactone or lisinopril + spironolactone (Figure 1C). The combined 
treatment with ACEi and aldoRB also appeared to be superior in the suppression of 
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glomerular heparanase expression. These data strongly suggest that both aldosterone 
and AngII are involved in the increased glomerular heparanase expression in AN. 
Figure 2 shows that there was a clear correlation between the decreased expression 
of HS in the GBM and the glomerular heparanase expression taken all groups into 
account (R2 = 0.59, P< 0.01; Figure 2A). Furthermore, a significant association was 
found between urinary protein excretion and expression of HS in the GBM (R2 = 0.37, 
P< 0.01, Figure 2B).
Figure 1. Effect of ACEi and/or aldoRB on HS and heparanase expression in adriamycin 
nephropathy. (A) Immunofluorescence staining of rat kidney sections revealed a linear 
expression of HS in the GBM of control rats, whereas HS expression was decreased in animals 
with AN treated with vehicle (VEH). Treatment with either ACEi (LIS), aldoRB (SPIR) or a 
combination (LIS + SPIR) resulted in restoration of HS expression. In addition, the decrease 
of HS in rats with AN was associated with an increased glomerular heparanase expression, 
which could be downregulated after treatment with LIS, SPIR and the combination therapy. 
B) Quantification of the scores revealed a significant decrease of GBM HS in VEH compared 
to CON, which was partially, but significantly restored after treatment with LIS, SPIR or 
the combination. C) Quantification of the scores revealed a significant increased glomerular 
expression of heparanase in VEH compared to CON. After treatment with LIS, SPIR or the 
combination, glomerular heparanase expression was significantly reduced. * P< 0.05 versus 
CON, # P< 0.05 versus VEH, @ P< 0.01 for trend. For full-colour representation see Chapter 
10; Colour Figures.
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Figure 2. Correlations between proteinuria, expression of HS in the GBM and glomerular 
heparanase expression. (A) The reduction of HS expression in the GBM strongly correlated 
with the increased glomerular heparanase expression taking into account the different groups 
(▪VEH, ▲LIS, ▼SPIR, ♦LIS+SPIR), (R2 = 0.59, P< 0.01). (B) Furthermore, the degree of 
proteinuria correlated with the decreased expression of HS in the GBM (R2 = 0.37, P< 0.01).
Aldosterone-induced heparanase mRNA expression by podocytes is attenuated 
by spironolactone
 To extend the findings of aldoRB on glomerular heparanase expression in AN from 
our in vivo study, we evaluated the effect of aldosterone on heparanase expression by 
cultured podocytes. We first determined whether the podocytes were able to respond 
to aldosterone by measuring the expression of the mineralocorticoid receptor (MR). 
Indeed, there was a considerable expression of MR (Ct= 27.0), whereas no differences 
could be observed in expression of MR after aldosterone stimulation or aldosterone 
stimulation combined with aldoRB (Figure 3). Exposure of podocytes to 100 nM 
aldosterone increased heparanase mRNA expression about 2.3-fold. Treatment of the 
cells with spironolactone prior to stimulation with aldosterone, prevented heparanase 
expression completely at the lowest dose tested, i.e. 1 nM SPIR. In addition, we 
determined the mRNA expression of serum glucocorticoid-regulated kinase 1 (SGK-
1) as a positive control, since aldosterone is a known inducer of SGK-1 [16]. Indeed, 
SGK-1 expression was upregulated about 5-fold in podocytes after stimulation with 
aldosterone, which could be inhibited by spironolactone. These data reveal that the 
MR is constitutively expressed in mouse podocytes and that aldosterone is able to 
induce SGK-1 and heparanase expression in these cells. 
Angiotensin II-induced heparanase mRNA expression is mediated via the 
angiotensin II type 1 receptor 
 Previously, it has been demonstrated that this podocyte cell line expresses both type 
1 and 2 receptors for AngII [14]. Exposure of podocytes to AngII resulted in a 2-fold 
increased heparanase mRNA expression (P< 0.05), which could be inhibited by AngII 
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type 1 receptor blockade (Figure 4). Blockade of AngII type 2 receptor had no effect on 
AngII-induced heparanase mRNA expression levels, implicating that AngII-induced 
heparanase expression in podocytes is mediated via the AngII type 1 receptor.
Role for reactive oxygen species in regulation of heparanase expression
 The actions of AngII and aldosterone may involve ROS [9, 10], whereas we have 
demonstrated in AN that ROS are able to induce glomerular heparanase expression 
[8]. Therefore, we tested the effects of intracellularly or extracellularly generated 
ROS on heparanase expression by cultured podocytes. Exposure of podocytes to 
xanthine/xanthine oxidase, which produces extracellularly generated superoxide and 
hydrogen peroxide, induced a 3-fold increased heparanase mRNA expression (Figure 
5). Moreover, intracellularly generated radicals, which are produced after incubation 
of the cells with NADH, increased heparanase expression about 2.5-fold. These 
data reveal the involvement of ROS in the regulation of heparanase expression by 
podocytes. 
Discussion
 Our in vivo and in vitro data show that aldosterone induces glomerular heparanase 
expression, which can be blocked by spironolactone. Moreover, we demonstrated 
Figure 3. Effect of aldosterone 
and aldoRB on heparanase 
mRNA expression in mouse 
podocytes. Stimulation of mouse 
podocytes with aldosterone 
for 18 hours resulted in a 2.3-
fold increase of heparanase 
mRNA expression. Blockade 
of the aldosteron receptor with 
spironolactone (SPIR) prevented 
the aldosterone-induced 
upregulation of heparanase. 
High mRNA expression of the 
positive control for aldosterone 
induction, SGK-1, could be 
detected after exposure to 
aldosterone, which was also 
inhibited after preincubation with 
SPIR. The mineralocorticoid 
receptor was present in these 
podocytes (Ct = 27.0), which 
was unaffected by aldosterone 
or aldosterone + SPIR.
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Figure 4. Effect of angiotensin II 
and AngII receptor blockade on 
heparanase mRNA expression in 
mouse podocytes.
Heparanase mRNA expression 
increased 2-fold after stimulation of 
mouse podocytes with AngII for 18 
hours. This effect could be abrogated 
by treatment with an AngII type 1 
receptor antagonist (L158,890) prior 
to exposure to AngII. Blockade of 
the AngII type 2 receptor (P123,319), 
however, did not prevent AngII-induced 
heparanase mRNA expression.
Figure 5. Effect of ROS on 
heparanase mRNA expression in 
mouse podocytes.
Exposure of mouse podocytes 
to xanthine/xanthine oxidase, 
which generates extracellular 
radicals such as superoxide and 
hydrogen peroxide, revealed a 3-
fold increased heparanase mRNA 
expression. Also, exposure to 
NADH, inducing intracellular 
generation of reactive oxygen 
species, resulted in a 2.5-fold 
increased heparanase mRNA 
expression. 
that AngII and ROS directly induce glomerular heparanase expression in vitro in 
podocytes. 
 Consistent with our previous study [8], a decreased HS expression in the GBM was 
associated with an increased glomerular heparanase expression in AN. These effects are 
attenuated by treatment with the aldoRB spironolactone, suggesting that aldosterone, 
at least in part, mediates these effects. This is supported by the in vitro data, showing 
that aldosterone directly induces heparanase expression in podocytes, which could be 
blocked by spironolactone. ACEi also reduced heparanase expression and restored HS 
expression in vivo, suggesting involvement of AngII in the regulation of heparanase 
expression as well. Combining both treatments was superior in normalizing HS and 
heparanase expression in AN, as compared to monotherapy with either ACEi or 
aldoRB. 
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 Glomerular heparanase expression in proteinuric models is mainly localized 
in podocytes, suggesting that podocytes are responsible for the regulation of 
heparanase expression. Aldosterone binds to the mineralocorticoid receptor (MR) 
in the cytoplasm, which after its translocation to the nucleus, results in transcription 
of target genes involved in controlling blood pressure and volume status, like serum 
and glucocorticoid-regulated kinase 1 (SGK-1) [16]. We demonstrated that the MR is 
expressed by differentiated mouse podocytes and that aldosterone highly upregulated 
SGK-1 expression by these cells, which could be inhibited by spironolactone. Most 
importantly, aldosterone induced heparanase mRNA expression in podocytes, which 
could be attenuated by pre-treatment of the cells with spironolactone. These data 
strongly indicate that aldosterone is directly involved in the induction of heparanase 
mRNA expression by podocytes.  
 Previously, we showed in vivo in AN, that reduction of HS in the GBM and the 
increased glomerular heparanase expression could be reversed by AngII type 1 
receptor blockade, suggesting the involvement of AngII in the regulation of heparanase 
expression [8]. We now investigated whether AngII can directly induce heparanase 
mRNA expression in vitro. Stimulation of podocytes with AngII resulted in the 
induction of heparanase, which could be inhibited by AngII type 1 receptor blockade, 
but not by AngII type 2 receptor blockade. This demonstrates that AngII-induced 
heparanase expression by podocytes is mediated via the AngII type 1 receptor. 
 HS expression in rats with AN after treatment with aldoRB and/or ACEi was 
not completely restored to the level of healthy control rats. This phenomenon could 
possibly be attributed to the presence of ROS. We previously reported that scavenging 
of hydroxyl radicals in this model, partially prevented loss of HS and suppressed 
heparanase expression, suggesting a role for ROS in the regulation of heparanase 
expression [8, 17]. Now we show that urinary MDA, as a marker for oxidative stress, 
was elevated in AN, and lower after treatment with aldoRB and/or ACEi. When we 
stimulated podocytes with xanthine/xanthine oxidase, which generates superoxide and 
hydrogen peroxide extracellularly, or with NADH (intracellularly generated ROS), an 
increased heparanase mRNA expression was observed. Notably, AngII and aldosterone 
also may induce ROS leading to renal injury [9, 10], which implies that regulation of 
heparanase expression in podocytes by RAAS may occur at several interacting levels. 
Very recently, it was shown that uni-nephrectomized rats continuously infused with 
aldosterone and fed a high-salt diet, developed a progressive proteinuria, which 
could be prevented by treatment with eplerenone, an aldosterone receptor blocker, 
or the ROS scavenger tempol [16]. In the same study it was shown that addition of 
aldosterone to cultured rat podocytes induced SGK-1, which could be prevented by the 
addition of tempol.
 Spironolactone monotherapy did not reduce proteinuria significantly in the 
nephrotic rats, despite a significantly reduced glomerular heparanase expression and 
a partially restored HS expression in the GBM. This observation is in line with recent 
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data that question the primary role of HS in charge-selective glomerular permeability. 
The loss of HS in the GBM, in rats after infusion of the bacterial HS-degrading 
enzyme heparinase, in podocyte-specific agrin or EXT/1 knock-out mice, or in a 
mouse model with transgenic overexpression of heparanase did not lead to severe 
proteinuria [7, 13, 18]. However, it should be noted that these studies do not exclude a 
role for heparanase and/or heparanase-mediated HS loss in the complex pathogenesis 
of proteinuria. Chronic loss of bioactive HS fragments, HS-bound factors, such as 
growth factors, cytokines and chemokines, the chronic disturbance of HS-dependent 
glomerular cell-GBM interactions, and cellular responses induced by direct binding 
of the heparanase protein to glomerular cells, still may be critically involved in the 
development of proteinuria and its downstream effects on renal damage [7].
 The absence of an anti-proteinuric effect in the spironolactone-treated rats supports 
the pharmacological specificity of the reduction of heparanase and improvement of HS 
expression by spironolactone, as it excludes the possibility that these effects are the 
non-specific consequences of proteinuria (reduction), i.e., heparanase expression is not 
induced by proteinuria, which is an important conclusion that could not be drawn from 
previous studies. In line with the current data in the lisinopril group, we previously 
showed that proteinuria in AN was reduced during antihypertensive intervention by 
RAAS-blockade [8, 19]. Our current data in the spironolactone group show that in 
this model, apparently, partial restoration of HS expression in the GBM and reduction 
of glomerular heparanase expression are not sufficient to ameliorate proteinuria. This 
finding may be explained by the fact that in addition to a restored HS expression in the 
GBM, a reduction of blood pressure is required to achieve a reduction on proteinuria. 
 In conclusion, our in vivo and in vitro results show that aldosterone, AngII and 
ROS are critically involved in the regulation of glomerular heparanase expression. 
Furthermore, in AN, the most effective reduction in glomerular heparanase expression 
and restoration of HS in the GBM, was achieved by the combination of ACE inhibition 
and aldosterone receptor blockade. 
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Abstract
 Heparan sulfate (HS) in the glomerular basement membrane (GBM) has been 
considered crucial for the charge-selective filtration. In many proteinuric diseases, 
increased glomerular expression of heparanase is associated with decreased HS. 
 Here, we used mice overexpressing heparanase and evaluated the expression of 
different HS domains in kidney and other tissues measured with anti-HS antibodies. 
Glycosaminoglycan-associated anionic sites were visualized by the cationic dye 
cupromeronic blue. 
 HPSE-tg mice showed a differential loss of HS domains in several tissues. An 
unmodified and a sulfated HS domain resisted heparanase action in vivo and in vitro. 
Glycosaminoglycan-associated anionic sites were reduced about fivefold in the GBM 
of HPSE-tg mice, whereas glomerular ultrastructure and renal function remained 
normal. 
 Heparanase-resistant HS domains may represent remnant chains or chains not 
susceptible to cleavage. Importantly, the strong reduction of glycosaminoglycan-
associated anionic sites in the GBM without development of a clear renal phenotype, 
questions the primary role of HS in charge-selective filtration. We cannot, however, 
exclude that overexpression of heparanase and HS loss in the GBM in glomerular 
diseases contributes to proteinuria.
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Introduction
 HS proteoglycans (HSPGs) are expressed at the surface of virtually all cells and 
in the extracellular matrix. HSPGs consist of a core protein with linear covalently 
attached HS sugar side chains that belong to the family of strong negatively charged 
glycosaminoglycans that also includes heparin and non-sulfated hyaluronan. The 
HS chain comprises up to 150 α(1-4)-glucuronate-β(1-4)-N-acetyl-glucosamine 
disaccharide units that can be modified extensively. Modifications of HS include N-
deacetylation/N-sulfation of N-acetyl-glucosamine, C-5 epimerization of glucuronic 
acid to iduronic acid, and 2-O-, 3-O- and 6-O-sulfation. The structure of the HS 
chains may be edited by HS-modifying enzymes that include heparanase, a β(1-4)-
endoglucuronidase that cleaves HS at specific sites, and HS 6-O-endosulfatases that 
specifically remove 6-O-sulfate. The combination of possible modifications gives rise 
to an enormous structural diversity of the HS chain, which dictates the binding and 
modulation of a myriad of factors that include growth factors, chemokines, cytokines, 
enzymes, and structural proteins. These HS-bound factors are key mediators in many 
biological and pathological processes [1, 2].
 For several decades, it has been hypothesized that the negatively charged HS 
in the GBM is crucial for the charge-selective permeability of the glomerular 
capillary filter. Seminal studies by Farquhar, Kanwar and coworkers demonstrated 
the presence of glycosaminoglycans, including HS, in the GBM, whereas removal 
of glycosaminoglycans in the GBM by perfusion of bacterial glycosaminoglycan-
degrading enzymes led to the passage of ferritin and labeled bovine serum albumin 
through the GBM [3-6]. Furthermore, the injection of anti-HS(PG) antibodies led 
to albuminuria in rats [7, 8]. Finally, in many experimental and human glomerular 
diseases, such as diabetic nephropathy, minimal change disease and membranous 
glomerulopathy, a decreased expression of HS in the GBM was observed when probed 
with our monoclonal anti-HS antibody JM403 [9-13], which in general correlated 
with the level of urinary protein excretion. In contrast to HS, the expression of agrin, 
the HSPG core protein most abundantly present in the GBM [14], was not altered. 
In recent years it became evident that the decreased expression of HS in the GBM 
in several human and experimental proteinuric diseases could be attributed to an 
increased glomerular expression of heparanase [15-21]. However, we showed that 
intravenous injection of the bacterial HS-degrading enzyme heparinase III in rats 
resulted in a near complete loss of anionic sites in the GBM without the development 
of proteinuria within 48 hours [22]. This finding challenged the primary role of HS in 
the GBM in charge-selective filtration.
 Mammalian heparanase is synthesized as a 68 kDa pre-proheparanase protein. After 
cleavage of an N-terminal signal peptide the latent proheparanase protein of 65 kDa is 
formed, which has no enzymatic activity. The proheparanase protein is proteolytically 
processed by cathepsin L in endosomes/lysosomes, which yields an active heterodimer 
consisting of a 8 kDa N-terminal subunit and a 50 kDa C-terminal subunit [23, 24]. 
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Cleavage of HS chains by heparanase occurs at a few selective sites within a HS chain. 
Heparanase cleaves the β(1-4) bond within HS, which requires N- and 6-O-sulfated 
moieties in a specific context as exemplified in the trisaccharide sequence GlcNS6OS-
α(1-4)-GlcA-β(1-4)-GlcNS6OS [25, 26]. The role of heparanase in metastasis, 
angiogenesis and inflammation has been well-established [23]. Recently, we generated 
transgenic mice overexpressing human heparanase (HPSE-tg) [27]. A first inventory 
of HPSE-tg mice showed a very mild proteinuria compared to controls. In the current 
study we analyzed the expression of different HS domains, in particular in the kidney, 
in both HPSE-tg and control mice of up to 8 months old by probing with specific 
anti-HS antibodies. Furthermore, we determined the presence of glycosaminoglycan-
associated anionic sites in the GBM by probing with the cationic dye cupromeronic 
blue. Finally, we evaluated glomerular ultrastructure and renal function. 
Material and methods 
Transgenic heparanase overexpressing mice
 HPSE-tg and control mice with a mixed background (C57BL/6 (90-95%) and 
BALB/c (5-10%)) were generated and genotyped as described [27]. Kidney tissue, 
urine and serum were obtained from 3 to 12 months-old mice. The housing and 
handling of the animals was approved by the local animal ethics committees. 
Analysis of creatinine, albumin and heparan sulfate in urine and blood samples
 Urinary and serum creatinine were measured enzymatically (Roche Diagnostics, 
Penzberg, Germany). Serum creatinine was used as a measure for renal function. 
Urinary albumin was measured by radial immunodiffusion [12, 28], using goat 
antiserum against mouse albumin [29] and purified mouse albumin (Sigma, 
Zwijndrecht, The Netherlands) as a standard. Urinary albumin excretion was expressed 
as the ratio mg albumin/mg creatinine. The presence of glycosaminoglycans in the 
urine was determined after separating urinary glycosaminoglycans by agarose gel 
electrophoresis followed by a combined azure A-silver staining [30]. 
RNA isolation, reversed transcription and PCR
 Total RNA was extracted from renal cortex using the RNeasy mini-kit (Qiagen 
Benelux, Venlo, The Netherlands). cDNA was prepared by reverse transcription of 1 μg 
RNA using oligo(dT) primers (Invitrogen, Breda, The Netherlands). Heparanase cDNA 
was amplified with primers specific for the human heparanase gene. Forward primer 
(F): 5’-caagaaggaatcaacctttgaag-3’, Reversed primer (R): 5’-gtagtccaggagcaactgag-3’ 
using platinum PCR Supermix (Invitrogen) . The expression of mouse β-actin was 
included as a control. F: 5’-gtgggccgctctaggcaccaa-3’, R: 5’-ctctttgatgtcacgcacgatttc-
3’. PCR conditions were: denaturation at 95°C for 3 minutes, followed by 40 cycles 
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of 95°C for 15 seconds, 57°C for 30 seconds, and 72°C for 30 seconds and finally 
elongation at 72°C for 10 minutes. PCR products were separated on a 2% agarose gel 
and visualized with ethidium bromide.
Western blot analysis
 Renal cortex was dissolved in lysis buffer containing 50 mM Tris-HCl (pH 8.0), 150 
mM NaCl, 0.5% Triton X-100 (Sigma) and EDTA-free protease inhibitors (Roche). 
Heparanase was concentrated by incubating equal amounts of total protein overnight at 
4°C with heparin-agarose beads (Sigma) [24]. Beads were washed twice in phosphate-
buffered saline (PBS), boiled in Laemmli sample buffer and resolved by SDS-PAGE. 
Proteins were transferred to a polyvinylidene difluoride membrane (Bio-Rad). Blots 
were blocked with 1% Boehringer blocking reagent (Roche) in PBS. Heparanase was 
detected by incubation with rabbit polyclonal antibody HPA1 (1:700, ProsPecTany 
Technogene, Rehovot, Israel) followed by a goat anti-rabbit peroxidase-conjugated 
antibody (1:8000; Santa Cruz). Heparanase protein was visualized using enhanced 
chemiluminescence reagent (Perbio Science, Etten-Leur, The Netherlands) and 
ECL hyperfilm (Amersham Biosciences, Buckinghamshire, UK). 
Antibodies, immunofluorescence staining and treatment with active heparanase
 The expression of different HS domains, chondroitin sulfate, dermatan sulfate, agrin 
core protein and heparanase was detected by specific antibodies as listed in Table 1. 
The phage display-derived single chain antibodies (scFv) were prepared as described 
[31-33]. Mouse kidney sections were fixed in acetone for 10 minutes at 4°C and then 
incubated for 1 hour at room temperature with primary antibodies. For monoclonal 
mouse antibodies, sections were first blocked using the mouse-on-mouse kit (Vector 
Laboratories, Burlingame, CA). Sections were washed with PBS and incubated with 
secondary antibodies for 1 hour at room temperature. The scFv antibodies were 
detected by the rabbit anti-VSV antibody (1:500; MBL, Nagoya, Japan). The mouse 
IgM antibodies, hamster IgG antibody and rabbit IgG antibodies were, respectively, 
detected by goat anti-mouse IgM Alexa 488 (1:200; Invitrogen), goat anti-hamster 
FITC (1:400; MP Biomedicals, Eschwege, Germany) and goat anti-rabbit IgG Alexa 
488 (1:200; Invitrogen). All antibodies were diluted in PBS supplemented with 2% 
(w/v) bovine serum albumin (BSA) and 0.05% (v/v) Tween-20 (Sigma). Normal goat 
serum (4%) was added to all secondary antibodies. Finally, sections were washed in 
PBS, embedded in Vectashield mounting medium H-1000 (Vector Laboratories Inc., 
Burlingame, CA, USA) and examined with a Zeiss Axioskop microscope (Carl Zeiss 
B.V., Sliedrecht, The Netherlands).
 To mimic the effect of in vivo heparanase overexpression in vitro, renal cryosections 
of normal mice were incubated with active recombinant human heparanase (0.22 µg/
ml) in 50 mM sodium acetate buffer (pH 5.0) for 2 hours at 37ºC. Then, sections were 
washed in PBS, fixed and stained as described above.
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Antibody Antibody isotype Preferred epitopes Source or reference
JM403 Monoclonal mouse IgM anti-HS: GlcN [8, 34]
NAH46 Monoclonal mouse IgM anti-HS: GlcNAc-GlcA
Seikagaku, Tokyo, 
Japan
AO4B08 scFv anti-HS: GlcNS6S-IdoA2S [32, 35] 
EV3B2 scFv anti-HS: GlcNS±6S-GlcA/IdoA [31]
HS3A8 scFv anti-HS: GlcNS6S-IdoA2S [31]
HS4C3 scFv anti-HS: GlcNS3S6S-GlcA/IdoA2S [33]
HS4E4 scFv anti-HS: GlcNAc/GlcNS-IdoA [31, 35] 
LKIV69 scFv anti-HS: GlcNS-IdoA2S [36]
IO3H10 scFv anti-CS A, C and E: [37]
HPA1 Rabbit IgG anti-human heparanase
ProsPecTany, 
Rehovot, Israel
MI91
Monoclonal Hamster 
IgG
anti-agrin, N-terminus [14]
Table 1. Antibodies used in this study.
ScFv, single chain variable fragment antibody; HS, heparan sulfate; GlcN, N-unsubstituted glucosamine; 
GlcNS, N-sulfated glucosamine; 6S, 6-O-sulfated; IdoA, L-iduronic acid; 2S, 2-O-sulfated; GlcA, D-
glucuronic acid; 3S, 3-O-sulfated; CS A, C, and E, Chondroitin sulfate A, C, and E. 
Digestion of heparan sulfate by recombinant heparanase in ELISA
 Flat bottom 96-well plates (Nunc A/S, Roskilde, Denmark) were coated with 5 
μg/well HS from bovine kidney (Seikagaku, Tokyo, Japan) in PBS overnight at 4°C. 
Wells were left untreated or incubated with 0.3 μg/ml or 2.5 μg/ml active recombinant 
human heparanase in 50 mM sodium acetate buffer (pH 5.0) for 3 hours at 37ºC. Plates 
were washed with PBS with 0.5% Tween and blocked with PBS with 1% gelatin for 1 
hour. Plates were washed with PBS/Tween and incubated with anti-HS antibodies for 1 
hour in PBS/gelatin. Dilutions of anti-HS antibodies were chosen from serial dilutions 
on coated HS that allowed detection of a decrease in HS. Anti-HS antibody binding 
was detected by incubating with the appropriate horseradish peroxidase-conjugated 
antibodies in PBS/gelatin for 1 hour. Finally, the plates were washed with PBS/Tween 
and incubated with tetramethylbenzidine solution (SFRI Laboratories, Berganton, 
France). After 15 minutes, the reaction was stopped with 2 M H
2
SO
4
 and absorption 
was measured at 450 nm.
Visualization of glycosaminoglycan-associated anionic sites by cupromeronic 
blue staining
 Glycosaminoglycan-associated anionic sites were visualized by the critical 
electrolyte concentration method as described [38]. We have shown previously 
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that this staining method is rather specific for HS because heparinase III treatment 
abolished cupromeronic blue staining in the GBM, while the staining was not influenced 
by chondroitinase ABC treatment [22, 39]. Pieces of cortex were fixed for 24 hours in 
25 mM sodium acetate (pH 5.6) containing 2.5% (v/v) glutaraldehyde, 0.2 M MgCl
2
 
and 0.2% (w/v) cupromeronic blue (Seikagaku, Tokyo, Japan). Subsequently, tissue 
was washed three times with fixing solution and three times with water containing 1% 
(w/v) Na-tungstate. Tissue was dehydrated by sequentially incubating in solutions with 
increasing concentrations of ethanol containing 1% Na-tungstate. After incubation in 
100% ethanol, tissue was incubated in propyleneoxide, followed by incubation with 
50% (v/v) propyleneoxide and epon for 16 hours, and with 100% (v/v) epon for a 
subsequent 16 hours. Finally, tissue was embedded by sequentially increasing the 
temperature (37ºC, 45ºC, and 60ºC for 24 hours each). Ultrathin sections were prepared 
and then examined with a Jeol TEM 1010 microscope (JEOL, Tokyo, Japan). 
Determination of glomerular ultrastructure by Transmission Electron 
Microscopy
 Pieces of cortex were fixed in 2.5% glutaraldehyde dissolved in 0.1 M sodium 
cacodylate buffer, pH 7.4, for 7 days at 4°C. After washing in cacodylate buffer, tissue 
was postfixed in palade-buffered 2% OsO
4
 for 1 hour, dehydrated, and embedded in 
Epon 812, Luft’s procedure (Merck, Darmstadt, Germany). Ultrathin sections (90 
nm) were stained with 4% uranyl acetate for 45 minutes followed by lead citrate for 
5 minutes at room temperature. Sections were examined with a Jeol 1200 EX2 electron 
microscope (JEOL). 
Statistical analysis
Significance was evaluated by the non-parametric Mann-Whitney U test using 
GraphPad Prism 4.0 (GraphPad Software, Inc., San Diego, CA, USA). P-values ≤ 0.05 
were considered statistically significant. 
Results
Renal overexpression of human heparanase in HPSE-tg mice 
 The expression of mammalian heparanase in kidneys from HPSE-tg and control 
mice was evaluated (Figure 1), which exclusively revealed mRNA (Figure 1A) and 
protein (Figure 1B) expression of human heparanase in HPSE-tg mice. Both the latent 
65 kDa proheparanase protein and the 50 kDa subunit of active heparanase could be 
detected, whereas the 50 kDa protein was more abundantly expressed (Figure 1B). 
Immunofluorescence staining of renal sections revealed the expression of the human 
heparanase protein in both tubuli and glomeruli of HPSE-tg mice (Figure 1C). 
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Differential loss of distinct HS domains in HPSE-tg and control mice
 The expression of different HS domains in renal sections of HPSE-tg and control 
mice was evaluated by probing with specific anti-HS antibodies. We applied the 
monoclonal antibody NAH46 recognizing N-acetylated unmodified HS domains, 
which resembles the structure of the bacterial polysaccharide K5 [40], the monoclonal 
antibody JM403 recognizing HS domains containing N-unsubstituted glucosamine 
residues [34], and phage display-derived single chain antibodies recognizing sulfated 
HS domains (Table 1, Figure 2). HS domains containing N-unsubstituted glucosamine 
residues probed with JM403, were completely absent in kidneys of HPSE-tg mice 
(Figure 2B) compared to controls (Figure 2A). Note the loss of staining by JM403 
along the capillary wall in the GBM of HPSE-tg mice. In contrast, the expression of N-
acetylated unmodified HS domains probed with NAH46, in different renal structures 
including the GBM, was not different between control (Figure 2C) and HPSE-tg mice 
(Figure 2D). There was a moderate to strong expression of sulfated HS domains in the 
GBM of controls probed with HS4C3, EV3B2, HS3A8 and AO4B08 (Figure 2E, 2G, 
2I and 2K). The expression of these sulfated HS domains in the GBM of HPSE-tg mice 
was either strongly decreased (HS4C3, Figure 2F) or lost (EV3B2 and HS3A8, Figure 
2H and 2J), whereas the expression of the sulfated HS domain defined by AO4B08 
persisted (Figure 2L). The sulfated HS domains defined by HS4E4 and LKIV69 that 
are not located in the GBM of controls (Figure 2M and 2O), were also lost in HPSE-tg 
mice (Figure 2N and 2P). An increased glomerular dermatan sulfate (DS) or chondroitin 
sulfate (CS) expression could serve as potential compensatory mechanisms for the loss 
of HS in the GBM of HPSE-tg mice. Analysis with specific antibodies revealed no 
Figure 1. Renal overexpression 
of human heparanase in HPSE-
tg mice. (A)  Heparanase mRNA 
expression analysis revealed a 
high human heparanase mRNA 
expression in the kidney of HPSE-
tg mice, whereas no expression was 
observed in controls. (B) Western 
blot analysis of kidney tissue lysates 
showed that both the latent 65 kDa 
heparanase and the processed 50 
kDa heparanase are expressed in 
HPSE-tg mice but not in controls. 
(C) Immunofluorescence staining 
demonstrated that heparanase is 
overexpressed in both glomeruli and 
tubuli of HPSE-tg mice compared to 
controls. Magnification, 40x.
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glomerular expression of DS in either HPSE-tg or control mice (data not shown), while 
probing for CS with the anti-CS antibody IO3H10 only revealed a hardly detectable 
glomerular staining, which was similar for HPSE-tg mice and controls (Figure 2Q and 
2R), and in line with previous findings [37]. Table 2 summarizes the morphological 
expression of the different HS/CS domains in renal sections of HPSE-tg mice and 
controls. 
Figure 2. Transgenic overexpression of heparanase in HPSE-tg mice leads to differential 
loss of HS domains. Expression of HS domains with N-unsubstituted glucosamine residues 
is especially found in the GBM of controls, as probed with antibody JM403 (A), whereas no 
expression could be detected in the glomeruli of HPSE-tg mice (B). However, expression of 
unmodified N-acetylated HS domains in the GBM, recognized by antibody NAH46, was similar 
in controls and HPSE-tg mice (C,D). There was a moderate to strong expression of sulfated HS 
domains in the GBM of control kidneys, as probed with HS4C3, EV3B2, HS3A8 and AO4B08 
(E,G,I,K). Expression of the sulfated HS domains in the GBM of HPSE-tg mice was either 
strongly reduced (HS4C3) (F) or abolished (EV3B2 and HS3A8) (H,J), while expression of the 
sulfated HS domains recognized by AO4B08 in the GBM of HPSE-tg mice was normal (L). 
Expression of sulfated HS domains that are not located in the GBM of controls, but mainly in 
the Bowman’s capsule and tubular basement membrane (HS4E4 and LKIV69) (M and O) was 
also absent in HPSE-tg mice (N and P). Glomerular expression of chondroitin sulfate (CS), 
which could serve as a compensatory mechanism for the glomerular loss of HS in HPSE-tg 
mice, was hardly detectable in controls (Q) and not increased in HPSE-tg mice (R). See also 
Table 2 for a summary of the expression of HS/CS domains in the kidney. Magnification, 40x. 
Heparanase overexpression and heparan sulfate loss
120 121
JM
40
3
N
A
H
46
H
S4
C
3
E
V
3B
2
H
S3
A
8
A
O
4B
08
H
S4
E
4
L
K
IV
69
IO
3H
10
C
on
tr
H
tg
C
on
tr
H
tg
C
on
tr
H
tg
C
on
tr
H
tg
C
on
tr
H
tg
C
on
tr
H
tg
C
on
tr
H
tg
C
on
tr
H
tg
C
on
tr
H
tg
G
B
M
+
 +
–
+
+
+
+
+
 +
±
+
–
±
–
±
±
–
–
–
–
±
±
M
es
an
gi
um
–
–
+
+
+
 +
±
+
±
±
–
±
±
–
–
–
–
–
–
B
ow
m
an
’s
 
ca
ps
ul
e
±
–
+
+
+
–
+
+
–
+
–
+
+
+
+
+
–
+
 +
±
+
 +
+
 +
T
B
M
±
–
+
+
+
 +
±
+
+
–
+
 +
–
+
+
+
+
+
–
+
–
+
 +
+
 +
P
T
C
–
–
+
+
+
 +
±
+
+
–
+
 +
–
+
+
–
–
–
–
+
 +
+
 +
B
lo
od
 
ve
ss
el
s
–
–
+
+
+
–
+
–
+
 +
–
–
–
+
–
+
 +
–
+
+
T
ab
le
 2
. R
en
al
 e
xp
re
ss
io
n 
of
 d
is
ti
nc
t 
H
S 
do
m
ai
ns
 in
 H
P
SE
-t
g 
an
d 
co
nt
ro
ls
 a
s 
pr
ob
ed
 w
it
h 
an
ti
-H
S 
an
ti
bo
di
es
. 
C
on
tr
, 
co
nt
ro
l 
m
ic
e;
 H
tg
, 
H
P
SE
-t
g 
m
ic
e;
 G
B
M
, 
gl
om
er
ul
ar
 b
as
em
en
t 
m
em
br
an
e;
 T
B
M
, 
tu
bu
la
r 
ba
se
m
en
t 
m
em
br
an
e;
 P
T
C
, 
pe
r 
tu
bu
la
r 
ca
pi
ll
ar
ie
s;
 +
 +
, s
tr
on
g 
st
ai
ni
ng
; 
+
, g
oo
d 
st
ai
ni
ng
; 
±,
 m
od
er
at
e 
st
ai
ni
ng
; 
an
d 
–,
 a
bs
en
t. 
Chapter 7
120 121
 The differential loss of HS domains in renal sections of HPSE-tg mice could 
be explained by locally different concentrations of active mammalian heparanase. 
Therefore, we treated renal sections of normal mice with active recombinant human 
heparanase. Probing of heparanase-treated renal sections with anti-HS antibodies 
revealed essentially the same differential loss of HS domains as observed in HPSE-tg 
mice (Figure 3). The HS domain containing N-unsubstituted glucosamine residues 
Figure 3. Treatment of normal 
mouse kidney sections or coated 
HS with recombinant active 
heparanase leads to differential 
loss of HS domains.
Expression of N-unsubstituted HS 
domains, probed with JM403 (A) 
and the highly sulfated HS domains, 
probed with HS4C3, EV3B2, 
HS3A8, HS4E4 and LKIV69 (B-F), 
was either strongly decreased or 
lost after heparanase treatment. 
Expression of the sulfated HS 
domain defined by AO4B08 (G) 
and the unmodified N-acetylated 
HS domain defined by NAH46 
(H) persisted after exposure to 
heparanase. Note that the differential 
loss of HS domains was comparable 
to the patterns of HS expression in 
HPSE-tg mice (compare with Figure 
2 A-P). (I) HS of bovine kidney 
coated in microtiter plates exposed to 
recombinant active heparanase at 0.3 
or 2.5 µg/ml for 3 hours also revealed 
a differential loss of HS domains . At 
2.5 µg/ml a 93% decrease of the HS 
domain containing N-unsubstituted 
glucosamine residues defined by 
JM403 and a 70-86% decrease for 
the sulfated HS domains defined 
by EV3B2, HS3A8, HS4E4 and 
LKIV69 can be calculated. The 
sulfated HS domain defined by 
HS4C3 was reduced 45%, whereas 
the sulfated HS domain defined by 
AO4B08 was reduced 31%, and the 
N-acetylated unmodified HS domain 
defined by NAH46 was reduced 9%. 
Magnification, 40x. 
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defined by JM403, and the sulfated HS domains defined by HS4C3, EV3B2, HS3A8, 
HS4E4 and LKIV69, were either strongly decreased or completely lost (Figure 3A-
F). In contrast, the sulfated HS domain defined by AO4B08 and the N-acetylated 
unmodified HS domain defined by NAH46, resisted heparanase treatment (Figure 3G 
and 3H). Finally, we treated HS from bovine kidney, coated in microtiter plates, with 
active mammalian heparanase at two concentrations followed by probing with anti-
HS antibodies. This experiment confirmed the results obtained in vivo in the HPSE-tg 
mice and in vitro on renal sections of normal mice treated with active mammalian 
heparanase (Figure 3I). The HS domains in ELISA after treatment with heparanase, as 
defined by the anti-HS antibodies, persisted in the following order NAH46> AO4B08> 
HS4C3> HS4E4> LKIV69> HS3A8> EV3B2> JM403. Note that although in ELISA 
binding of AO4B08 decreased more (31%) than that of NAH46 (9%), the binding 
of AO4B08 to tubular basement membranes after HPSE digestion was still stronger 
compared with NAH46. This can be explained by the fact that the staining of AO4B08 
to tubular basement membranes of control sections was already much stronger than 
for NAH46. Treatment of renal sections of HPSE-tg and control mice, and treatment 
of coated HS, with the bacterial HS-degrading enzyme heparinase III, resulted in the 
loss of all HS domains (data not shown). In addition to renal sections, we evaluated the 
expression of HS domains in sections of spleen and liver of HPSE-tg and control mice. 
This revealed similar data as obtained for the kidney (data not shown). 
 In summary, overexpression of mammalian heparanase leads to a differential loss 
of HS domains in the GBM, which is similar for different tissues.
Loss of glycosaminoglycan-associated anionic sites in the GBM does not lead to a 
clear renal phenotype
 In addition to the analysis with anti-HS antibodies, we visualized the number of 
glycosaminoglycan-associated anionic sites in the GBM of HPSE-tg and control mice 
by probing with the cationic dye cupromeronic blue [38] (Figure 4). As expected, 
cupromeronic blue stained the GBM of controls, which was most intense at the 
podocyte side as revealed by black dots (Figure 4A and 4B), whereas occasionally 
some residual cupromeronic blue staining was found in the GBM of HPSE-tg mice, 
mainly at the endothelial side (Figure 4C and 4D). Visual scoring of the number 
of black dots in the GBM on several sections revealed a ~5-fold reduction of the 
number of glycosaminoglycan-associated anionic sites in HPSE-tg mice compared 
with controls. To evaluate whether there was a difference in overall turnover of HS in 
HPSE-tg compared to control mice, we analyzed the presence of glycosaminoglycans 
in the urine. Glycosaminoglycans were present in the urine of 8/11 HPSE-tg mice and 
4/8 control mice (data not shown). Since we did not observe intracellular accumulation 
of HS, this suggests that chronic overexpression of heparanase does not lead to an 
increased biosynthesis and urinary secretion of HS. 
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 It has been assumed that the charge-selective properties of the capillary filter are 
dictated by the negatively charged HS in the GBM. Therefore, we measured urinary 
albumin and creatinine in HPSE-tg and control mice. It appeared, that on average 
the HPSE-tg mice (n=11) showed a low, but statistical significant higher level of 
albuminuria compared to controls (n=9), although the majority of HPSE-tg mice 
had urinary albumin/creatinine ratios within the normal range (Figure 5). Renal 
function, as measured by the concentration of serum creatinine, did not significantly 
differ between HPSE-tg mice (22.5 µM ± 1.8) and controls (21.5 µM ± 1.5) as found 
previously [27]. Finally, we examined the glomerular ultrastructure of HPSE-tg 
Figure 4. Analysis of the number of glycosamino-glycan-associated anionic sites in the 
GBM of HPSE-tg and control mice. (A,B) Glycosaminoglycans, visualized by the cationic 
dye cupromeronic blue, were observed as a dotted-like pattern in the GBM of control mice, 
which was most intense at the side of the podocytes. (C,D) In the GBM of HPSE-tg mice, 
cupromeronic blue staining was strongly decreased, although occasionally some staining 
remained, mainly at the endothelial site of the GBM. Semi-quantitative analysis (by counting 
the black dots per GBM surface area from 10 random sections of three individual mice of each 
mice strain) revealed a ~5-fold decreased binding of cupromeronic blue in the GBM of HPSE-
tg mice compared with control mice. Magnification, 10,000x (A and C), magnification, 20,000x 
(B and D).
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(n=6) mice and controls (n=4) (Figure 6). No differences could be observed between 
controls (Figure 6A and 6B) and HPSE-tg mice (Figure 6C and 6D). The appearance 
of GBM thickness, podocyte foot processes architecture, glomerular endothelium and 
mesangium was similar for HPSE-tg and control mice. 
 In summary, despite the chronic overexpression of heparanase, leading to a ~5-
fold decrease of glycosaminoglycan-associated anionic sites in the GBM, HPSE-tg 
mice show a normal renal function and architecture without development of severe 
albuminuria.
Figure 5. Urinary albumin/
creatinine ratios in HPSE-tg and 
control mice. In HPSE-tg mice, 
only a mild, but significant increase 
in urinary albumin excretion 
could be detected using radial 
immunodiffusion. However, the 
majority of HPSE-tg mice showed 
a normal albumin/creatinine ratio. 
*P< 0.05 
Discussion
 In recent years it has been shown that in several (experimental) proteinuric diseases 
heparanase is upregulated, which was associated with a decreased expression of HS in 
the GBM [15-21]. It has been postulated that this heparanase-mediated loss of HS in 
the GBM leads to proteinuria. 
 In this study we show that chronic and systemic overexpression of heparanase 
leads to the differential loss of specific HS domains from the GBM. An unmodified 
N-acetylated HS precursor domain (NAH46) and one sulfated HS domain (AO4B08) 
persisted, whereas another sulfated domain persisted partially (HS4C3). Moreover, this 
differential loss of HS domains was similar in several tissues, i.e. kidney, spleen and 
liver. Heparanase only cleaves at specific positions within one HS chain, which results 
in small HS fragments of different sizes [25, 41, 42]. Three different explanations 
can be postulated for the differential loss of HS domains after heparanase cleavage. 
First, the HS domains that (partially) persist may be present in the remnants of HS 
Chapter 7
124 125
chains that remain bound to the core protein after cleavage by heparanase, and which 
do not contain sites susceptible to cleavage by heparanase. Second, the unmodified 
N-acetylated HS domain reflects the first structure after initial HS biosynthesis [1], 
whereas the domain defined by antibody AO4B08 may be the first sulfated HS domain 
arising. Indeed, biochemical analysis of HS of the whole liver and kidney of HPSE-tg 
mice revealed 2-3-fold shortened HS chains, which were relative highly 2-O-sulfated 
compared to controls [27, 43] (and JP Li et al. unpublished observations). So, the 
continuous action of heparanase may lead to trimmed HS chains consisting of HS 
domains that do not contain sites susceptible to cleavage by heparanase. However, we 
showed no significant higher urinary secretion of HS in HPSE-tg mice or glomerular 
intracellular accumulation of sulfated HS, making this option less likely. Third, but 
less likely, the existence of a subgroup of native HS chains solely consisting of N-
acetylated domains defined by NAH46 and sulfated domains defined by AO4B08 
and/or HS4C3 (Figure 7). 
 We showed the loss of HS domains with N-unsubstituted glucosamine residues in 
the GBM of patients with overt diabetic nephropathy, which was associated with an 
increased glomerular expression of heparanase [20]. In agreement with our current 
findings, we also could show that the expression of unmodified N-acetylated HS 
Figure 6. Glomerular ultrastructure of HPSE-tg and control mice.
A normal architecture of the glomerular filtration barrier was observed in all kidney tissue 
sections of control mice (A and B) and HPSE-tg mice (C and D); magnification, 5,000x (A and 
C), magnification 15,000x (B and D). 
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domains in the GBM of diabetic patients was similar to healthy controls (Wijnhoven et 
al., in press). The ratio of expression of HS domains with N-unsubstituted glucosamine 
residues (JM403) versus unmodified N-acetylated HS domains (NAH46) in the GBM, 
may be a measure for the glomerular activity of heparanase, which most likely is 
distinct from other mechanisms leading to loss of HS in the GBM during proteinuric 
diseases [44].
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Figure 7. Possible explanations for the differential loss of HS domains observed after 
cleavage by heparanase. A differential loss of HS domains was observed after in vivo and in 
vitro cleavage of HS by heparanase, which may be explained by three different possibilities. (A) 
Unmodified N-acetylated domains (NAH46) and the sulfated domains recognized by AO4B08 
may be remnants of HS after cleavage by heparanase and are close to the core protein. The 
epitope defined by HS4C3 is not fully resistant to heparanase cleavage and is therefore strongly 
decreased but not absent, whereas the N-unsubstituted domains, recognized by JM403 and the 
sulfated domains defined by EV3B2, HS3A8, HS4E4, LKIV69 are lost after degradation of HS 
by heparanase. (B) HS biosynthesis is not sufficient due to constant trimming of the HS chains 
by the continuous action of heparanase in HPSE-tg mice, yielding the unmodified N-acetylated 
HS domains (NAH46) and the sulfated HS domains (AO4B08) that are not susceptible to 
heparanase cleavage. HS chains may be modified due to constant degradation by heparanase. 
Only the unmodified N-acetylated HS domains (NAH46) and the AO4B08 domains can be 
synthesized and are resistant to cleavage by heparanase. (C) Native HS chains exist that solely 
consist of N-acetylated domains and sulfated domains as defined by AO4B08 are resistant to 
cleavage by heparanase since they lack cleavage sites.
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 In a first inventory of HPSE-tg mice, we observed a mild level of proteinuria [27]. 
Since this could be explained by the presence of the sulfated HS domains defined by 
AO4B08 and HS4C3 in the GBM of HPSE-tg mice as we show now, we measured the 
total content of glycosaminoglycan-associated anionic sites in the GBM. Probing with 
the cationic dye cupromeronic blue revealed a 5-fold reduction of glycosaminoglycan-
associated anionic sites in the GBM of HPSE-tg mice. The staining of the GBM by 
AO4B08 is weak in the GBM of both HPSE-tg and control mice, whereas the staining 
of the GBM by HS4C3 is strongly reduced in the GBM of HPSE-tg mice. Nevertheless, 
the sulfated HS domains defined by AO4B08 and HS4C3 may be responsible for the 
remaining glycosaminoglycan-associated anionic sites in the GBM of HPSE-tg mice 
as revealed by cupromeronic blue staining. Assessment of renal function, by measuring 
serum creatinine levels, albuminuria and glomerular ultrastructure of the mice used 
for HS analysis, revealed only a marginal level of albuminuria, although statistical 
significant. Furthermore, renal function of HPSE-tg mice was normal and glomerular 
architecture of HPSE-tg mice and controls was similar. In our first inventory we also 
found a normal renal function in HPSE-tg mice, but then we had the impression that 
there was a diffuse local podocyte foot process effacement in HPSE-tg mice [27], 
but this was not substantiated in the current stock of mice. This may be explained 
by further inbreeding of the HPSE-tg treat in the C57BL/6 background, whereas it 
is important to stress that foot process effacement and proteinuria not always have to 
correlate [45]. Nevertheless, we show that glomerular overexpression of heparanase, 
which is relevant for several (experimental) glomerular diseases [15-21], does not lead 
to significant albuminuria despite the ~5-fold loss of  glycosaminoglycan-associated 
anionic sites in the GBM. These data question the primary role of HS in the GBM 
in determining the charge-selective properties of the capillary filter. Furthermore, 
maturation and morphology of podocytes, glomerular endothelium and mesangium 
appear not to be influenced by the lack of the majority of HS in the GBM and other 
glomerular structures. 
 Recently, other studies also questioned the primary role of HS in the GBM in charge-
selective filtration. Mice with podocytes lacking agrin did not develop proteinuria nor 
revealed an aberrant glomerular architecture [46]. Mice with podocytes lacking the HS 
polymerase EXT1 did develop glomerular ultrastructural abnormalities and podocyte 
loss during the first 8 months, whereas a mild albuminuria became evident at an age 
of 8 months [45]. Rats injected with the bacterial HS-degrading enzyme heparinase 
III leading to the nearly complete loss of glycosaminoglycan-associated anionic sites 
in the GBM, did not develop albuminuria within the observation period of 48 hours 
[22]. Mice deficient in perlecan and/or collagen XVIII, HSPG core proteins, mainly 
expressed in the mesangium and Bowman’s capsule, also did not develop glomerular 
abnormalities and albuminuria under physiological conditions [47, 48]. 
 Although our current study differs in the approach from the studies mentioned above, 
fundamentally, they all exclude a primary role of HS in charge-selective filtration. 
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However, in our opinion, we can still not exclude a role for glomerular expression 
of heparanase and loss of HS in the GBM in the development of proteinuria. We 
propose two possible mechanisms that are compatible with the current data. In the first 
sequential mechanism, the heparanase-mediated release of HS fragments or HS-bound 
factors from the GBM in a situation with glomerular pathology may induce processes 
leading to or enhancing proteinuria. This pathway is not established in the HPSE-tg, 
podocyte-specific agrin- and EXT1-deficient mice, since chronic constitutive absence 
of HS in the GBM under physiological conditions does not allow the binding of such 
growth factors or inflammatory mediators and subsequent release of HS fragments 
or HS-bound factors. The 48 hours period as tested for healthy rats injected with 
heparinase III may have been too short to execute the pathological processes induced by 
the release of HS fragments or HS-bound factors. In the absence of a proinflammatory 
microenvironment, HS loss does not lead to pathological consequences. In other 
words, a single hit is not sufficient for development of proteinuria. Second, assuming 
such a multi-hit mechanism, the heparanase-mediated loss of HS in the GBM in 
combination with additional pathological events/signals, like for example local 
production of angiotensin II, ROS or cytokines, may lead to activation of glomerular 
cells and development of proteinuria. In all studies mentioned above, only one signal 
was manipulated, i.e. the loss of HS in the GBM. Although our study closely resembles 
the actual situation of various glomerular diseases by forcing heparanase-mediated HS 
loss in the GBM, this occurs under non-pathogenic conditions. See reference [21] for 
additional discussion on this issue.
 That heparanase activity has relevance for development of proteinuria can be 
derived from earlier studies, which revealed that specific inhibition of heparanase 
in a proinflammatory situation, like passive Heymann nephritis and experimental 
anti-GBM nephritis, significantly reduced the development of proteinuria [17, 49]. 
More definitive studies are required to elucidate the role of heparanase and HS in 
the development of proteinuria. Proof for this assumption of a multi-hit genesis of 
proteinuria has to come from experimentally-induced glomerular diseases in different 
models, in which heparanase or HS expression is manipulated. In this respect, 
induction of proteinuria, by for example streptozotocin in HPSE-tg mice, in HPSE-
deficient mice, or in mice with HPSE-, agrin- or EXT1-deficient podocytes, definitely 
will give more insight in the importance of heparanase-mediated loss of HS in the 
pathogenesis of proteinuria. 
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Abstract
 Heparanase is an endo-β(1–4)-D-glucuronidase that degrades heparan sulfate (HS) 
polysaccharide side chains. The role of heparanase in metastasis, angiogenesis, and 
inflammation has been established. Recent data suggest a role for heparanase in several 
proteinuric diseases and an increased glomerular heparanase expression is associated 
with loss of HS in the glomerular basement membrane (GBM). Furthermore, an 
increase in heparanase activity was detected in urine from proteinuric patients. Mice 
with transgenic heparanase overexpression developed mild proteinuria. Glomerular 
heparanase activity is proposed to lead to loss of HS in the GBM and proteinuria. 
Because the primary role of GBM HS for charge-selective permeability has been 
questioned recently, heparanase may induce or enhance proteinuria by (i) changes in 
the glomerular cell–GBM interactions, due to loss of HS; (ii) release of HS-bound 
factors and HS fragments in glomeruli; or (iii) intracellular signalling by binding of 
heparanase to glomerular cells. Which of these mechanisms is prevailing requires 
further research. The precise mechanisms leading to increased heparanase expression 
in the different glomerular cell types remain elusive, but may involve hyperglycemia, 
angiotensin II, aldosterone, and reactive oxygen species. This review focuses on the 
role of heparanase in HS degradation in proteinuric diseases and the possibility/
feasibility of heparanase inhibitors, such as heparin(oids), as treatment options.
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Heparan sulfate proteoglycans 
 HS proteoglycans (HSPGs) are widely distributed glycoproteins with many ascribed 
biological and structural functions. HSPGs consist of a core protein, to which linear 
HS polysaccharide chains are covalently linked. HSPGs are present in extracellular 
matrices, especially basement membranes, and on cell surfaces where they are involved 
in cell–cell and cell–matrix adhesion. HSPGs function in storage and release of ligands 
including extracellular matrix molecules, enzymes, enzyme inhibitors, growth factors, 
chemokines, and cytokines, which are involved in physiological and pathological 
processes such as tissue repair, embryogenesis, inflammation, autoimmunity, 
angiogenesis, and tumor metastasis [1]. The role of HS in glomerular inflammation 
was recently reviewed in this journal by Rops et al.[2]. The specific interactions 
between HS and its ligands largely depend on the N- and O-sulfation pattern of HS 
and the presence of specific carboxyl groups. HS chain biosynthesis occurs in the 
Golgi apparatus and involves more than 15 different enzymes. The HS chain consists 
of up to 300 repeating N-acetyl-glucosamine and glucuronic acid residues, which 
can be modified at various positions. The first HS modification is N-deacetylation 
and subsequent N-sulfation of N-acetyl-glucosamine to GlcNS residues, which is 
catalyzed by four N-deacetylase/Nsulfotransferase isoenzymes. A single glucuronosyl 
C5-epimerase catalyzes the epimerization of glucuronic acid to iduronic acid. Finally, a 
large family of 2-O-, 3-O-, and 6-O-sulfotransferase isoenzymes catalyzes the 2-O-, 3-
O-, and 6-O-sulfation. The large number of possible combinations/modifications in the 
HS chain leads to an enormous structural and functional diversity of HS. In glomeruli, 
HS is attached to different core proteins depending on their location. Extracellular 
matrix core proteins include agrin, perlecan, and collagen XVIII, whereas glomerular 
cell-associated core proteins include syndecans and glypicans [1, 2]. Agrin is the most 
abundantly expressed core protein in the GBM [3].
HS alterations in proteinuric diseases
 Until recently, the covalently linked HS chains of agrin were considered to be the 
major determinants for the charge-dependent permeability of the GBM. This was 
supported by a number of observations, including an increased GBM permeability 
for negatively charged molecules (i.e., albumin) after GBM HS removal by bacterial 
heparitinase [4]. Previously, we have developed several antibodies specific for the 
HSPG core protein agrin and its HS side chains [5, 6]. In rats, selective proteinuria 
developed when a monoclonal antibody (i.e., JM403) directed against HS in the GBM 
was injected intravenously [7]. Moreover, we consistently demonstrated a decrease 
of GBM HS in proteinuric diseases, including overt diabetic nephropathy, systemic 
lupus erythematosus, minimal change, and membranous glomerulopathy, whereas 
the amount of the core protein agrin remained unaltered [6]. Diabetic nephropathy 
in humans is characterized by microalbuminuria which is, at later stages, associated 
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with a loss of the negative charge of the GBM [6, 8]. Interestingly, administration of 
heparin(oids) in experimental and human diabetic nephropathy prevented loss of GBM 
anionic sites and was associated with decreased albuminuria [9-11]. The underlying 
protective mechanism(s) of this observation remain elusive and will be further discussed 
below. Whether HS in the GBM is primarily responsible for the charge-dependent 
filtration has recently become questionable. Firstly, recent data in early human and 
experimental diabetic nephropathy revealed an increase in albumin excretion without 
structural changes in glomerular HS expression [12]. No albuminuria developed after 
in vivo degradation of HS in the GBM by heparitinase I in rats [13]. Recent studies 
revealed that podocyte-specific agrin knockout mice (which do not express HS in 
the GBM) also do not develop proteinuria [14] and mice with transgenic heparanase 
overexpression (almost completely lacking HS in the GBM) surprisingly only develop 
mild albuminuria [15]. In addition, proteinuria in podocyte-specific EXT-1 knockout 
mice, lacking the key enzyme glycosyltransferase responsible for HS polymerization, 
was only detected after 8 months [16]. It remains to be determined whether these 
observations can be extrapolated directly to glomerular diseases. In the heparitinase-
induced loss of HS, the observation period was only 24–48 h and a bacterial HS-
degrading enzyme was applied [13]. In the models with a targeted disruption leading 
to HS loss, as described above, compensatory and adaptive mechanisms were not 
formally excluded, although in the agrin knockout mice, the net negative charge of the 
GBM was decreased. Furthermore, a gradual decrease of HS may induce pathogenic 
mechanisms, which are different from those in acutely induced loss of HS or genetic 
manipulation that prevents HS expression in the GBM. Remarkably, a decrease of 
HS in the GBM, which inversely correlated with proteinuria, has been consistently 
documented in the majority of glomerular diseases, [6, 8] which in some cases was 
associated with the upregulation of the HS-degrading enzyme, heparanase.
Heparanase
 The gene encoding heparanase (HPSE-1) is expressed in several cell types and 
tissues, and is abundantly expressed in lymphoma, melanoma, and carcinoma cells 
[17, 18]. Heparanase is an endo-β(1–4)-D-glucuronidase that cleaves the glycosidic 
bond within the HS chain via hydrolysis. The active site of heparanase may involve 
residues Glu225 and Glu343 that participate in the cleavage of HS [19]. HS cleavage by 
heparanase yields HS fragments 5–7 kDa in size (10–20 sugar units) and the proposed 
cleavage site for heparanase requires N- and 6-O-sulfated moieties in a specific 
orientation (Figure 1) [20, 21].
Chapter 8
136 137
Synthesis and cellular trafficking of heparanase
 The heparanase gene encodes for a 543 amino-acid polypeptide, giving rise to 
a 68 kDa, pre-proheparanase containing a signal peptide sequence (residues 1–35). 
The latent pre-proheparanase is processed in the endoplasmatic reticulum where 
it is glycosylated and the signal peptide is cleaved off, yielding the latent 65 kDa 
proheparanase. Thereafter, it is transported to the Golgi apparatus, packaged into 
vesicles and secreted. The secreted enzyme is then re-internalized through binding 
to cell-associated HSPG (in particular syndecan), low-density lipoprotein receptor-
related protein, mannose 6-phosphate receptors, and possibly other receptors [22]. The 
internalized 65 kDa protein is then transferred to late endosomes/lysosomes, where 
it is proteolytically processed by cathepsin L [23] into the active heterodimer, which 
consists of an 8 kDa N-terminal subunit and a 50 kDa C-terminal subunit (Figure 2).
Regulation of heparanase activity
 Heparanase activity must be tightly regulated to ensure structural integrity of 
basement membranes and coordinated growth factor release. Moreover, its regulation 
is cell-type specific. Basal heparanase mRNA expression is positively regulated by 
the transcription factors Ets1, Ets2, Sp1, and GA-binding protein, whereas heparanase 
gene expression is downregulated by heparanase promoter methylation [24]. In 
addition, post-translational regulation may occur at several processing sites including 
the endoplasmatic reticulum, Golgi apparatus, and cell membrane (where secretion, 
internalization, and processing into the active form occurs). The optimal pH for 
heparanase enzyme activity is between pH 5.0 and 6.0. At neutral pH, heparanase is 
able to bind HS, however, no enzymatic activity is detectable [17]. Hence, heparanase 
enzymatic activity is limited to acidic microenvironments, for example at inflammatory 
sites, tumor cores, and at the GBM facing sites of podocytes, whereas at physiological 
pH, heparanase functions as a cell adhesion and signalling molecule [25]. Finally, 
Figure 1. Heparanase cleavage site and HS substrate specificity.
The minimal oligosaccharide sequence in HS that is necessary for substrate recognition by 
heparanase is suggested to be a highly sulfated trisaccharide GlcN-GlcUA-GlcN. Furthermore, 
at least one N-sulfate group on the reducing side of glucosamine and a 6-O-sulfate group on 
the nonreducing side of glucosamine, are considered to be crucial for substrate recognition [20, 
21].
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naturally occurring heparanase inhibitors, such as heparin or HS degradation products, 
appear to affect heparanase activity and/or binding.
Figure 2. Heparanase processing. 
Top: heparanase is synthesized as a latent pre-proheparanase of 68 kDa, which is targeted to 
the endoplasmatic reticulum by a signal peptide (s.p., Met1–Ala35). Middle: after cleavage of 
the s.p., the 65 kDa inactive proheparanase is transported to the Golgi and secreted, processes 
that depend on glycosylation. Six putative glycosylation sites ( ) are indicated. Bottom: 
heparanase is processed into the active enzyme after removal of a linker domain (Ser110–Glu157) 
by cathepsin L, yielding an active heterodimer composed of 8 kDa (Gln34–Glu109) and 50 kDa 
(Lys158–Ile543) subunits. Glu225 and Glu343, located in the active site of the enzyme are critical for 
heparanase enzymatic activity.
Involvement of heparanase in physiological and pathological 
processes
 Heparanase is involved in many biological and pathological processes[24]. 
Activated immune cells, including T cells and macrophages, express active 
heparanase, which upon liberation facilitates diapedesis by cleavage of HS in the 
extracellular matrix and basement membranes. Cell homing to sites of inflammation 
can be arrested by heparanase inhibition. Moreover, degradation of HS by heparanase 
releases HS-bound factors (including fibroblast growth factor, vascular endothelial 
growth factor, connective tissue growth factor, and chemokines), thereby potentially 
enhancing pathological processes such as tumor growth, and enhancing angiogenesis 
and immune reactions. Many investigators have studied the importance of heparanase 
in tumor cell biology. Briefly, tumor cell invasiveness is correlated with heparanase 
expression and activity. Furthermore, heparanase inhibition arrests metastatic disease 
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progression. Enhanced heparanase expression correlates with metastatic potential, 
tumor vascularity, and reduced postoperative survival of cancer patients [24]. Human 
microvascular endothelial cells also express heparanase, which can be upregulated 
upon activation with proinflammatory cytokines or fatty acids, whereas heparanase 
expression can be downregulated after stimulation with vascular endothelial growth 
factor [26]. Similarly, we have recently found that conditionally immortalized 
mouse glomerular endothelial cells express heparanase, which can be upregulated by 
proinflammatory cytokines [27].
Heparanase expression in proteinuric diseases
 Published studies revealed enhanced glomerular heparanase expression in several 
experimental and human glomerular diseases (Table 1). The fact that heparanase is 
able to cleave HS in the GBM, suggests that heparanase expression may be responsible 
for the decrease of HS in the GBM. The first observation that the active form of 
heparanase may play a role in the development of proteinuria was made in rats with 
puromycin aminonucleoside-induced nephrosis at day 14 (this model is analogous to 
minimal change disease in humans) [28]. Interestingly, at day 5 of the disease, an 
increased amount of the inactive form of heparanase was expressed, suggesting that 
increased heparanase activity was probably not involved in the initiation of proteinuria. 
Heparanase expression in puromycin aminonucleoside nephrosis was mainly 
localized in podocytes. In passive Heymann nephritis, a rat model for membranous 
glomerulopathy in which a decrease of HS in the GBM has been observed, [29] 
glomerular heparanase expression was increased threefold in the proteinuric phase 
[30]. Heparanase expression was mainly confined to endothelial cells and podocytes. 
Urine from proteinuric rats had a fourfold higher amount of heparanase activity, 
compared to control nonproteinuric animals. Complement activation was required for 
induction of both proteinuria and heparanase expression in passive Heymann nephritis. 
Treatment with a polyclonal anti-heparanase antibody resulted in a threefold reduction 
of proteinuria, suggesting that heparanase activity contributed to the development of 
proteinuria. Because passive Heymann nephritis and puromycin aminonucleoside 
nephrosis are both characterized by podocyte changes, activation of podocytes could 
be one of the potential mechanisms that leads to glomerular heparanase expression 
and activity. Inhibition of heparanase with PI-88, a highly sulfated oligosaccharide, 
in experimental passive Heymann nephritis reduced proteinuria by two-fold in the 
absence of an immune modulating effect, whereas the amount of HS in the GBM was 
preserved [31]. Unexpectedly, transgenic overexpression of human heparanase in mice 
resulted in slightly elevated levels of proteinuria, whereas expression of HS in the 
GBM, almost completely disappeared [15, 32]. In rats with adriamycin nephropathy, 
a decrease of HS in the GBM was observed, which could be reversed after treatment 
with an ACE inhibitor [33]. Very recently, we showed that the decrease in glomerular 
HS in this model was associated with an increase in glomerular heparanase expression. 
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Treatment with an angiotensin II receptor antagonist reduced the increased heparanase 
expression and proteinuria, and restored the expression of HS in the GBM [34]. 
Furthermore, reactive oxygen species, especially hydroxyl radicals, are known to 
be involved in the development of proteinuria in adriamycin nephropathy by direct 
depolymerization of HS [35]. Scavenging of hydroxyl radicals by dimethylthiourea 
prevented both the decrease in HS and the increase in glomerular heparanase expression 
[34]. In rodent models of streptozotocin-induced diabetic nephropathy, we also found 
an inverse correlation between heparanase mRNA/protein and HS expression [15]. 
Disease Species HS in GBM
Glomerular 
heparanase 
expression
Reference
Streptozotocin-induced DNP Rat Reduced (n.s.) Increased [15]
Mouse Reduced (n.s.) Increased [15]
Adriamycin nephropathy Rat Reduced Increased [34]
PHN Rat Reduced Increased [30, 31]
PAN nephrosis Rat n.a. Increased [28]
Anti-GBM nephritis Mouse n.a. Increased [41]
Lupus Mouse Masked by immune 
complexes
Unaltered [46]
DNP Human Reduced Increased [15, 36, 38]
MCD Human Reduced Increased Rutjes et al.*
MG Human Reduced Increased Rutjes et al.*
IgA nephropathy Human Reduced Increased Rutjes et al.*
SLE Human Masked by immune 
complexes
Unaltered [46]
Table 1. Involvement of HS and heparanase expression in proteinuric diseases.
HS, heparan sulfate; GBM, glomerular basement membrane; DNP, diabetic nephropathy; n.s., not 
significant; PHN, passive Heymann nephritis; PAN nephrosis, puromycin aminonucleoside-induced 
nephrosis; n.a., not analyzed in this study; MCD, minimal change disease; MG, membranous 
glomerulopathy; Rutjes et al.*, Published abstract: The role of heparanase in the pathophysiology 
of idiopathic nephrotic syndrome. Nephrology 2005; 10 (Suppl): A117-A232; SLE, systemic lupus 
erythematosus.
 Recently, Maxhimer et al. [36] showed increased glomerular heparanase expression 
in patients with diabetes and found that in vitro expression of heparanase in cultured 
podocytes was upregulated by hyperglycemia. Furthermore, we recently showed that a 
decreased expression of HS in the GBM was associated with an increased glomerular 
heparanase expression in patients with overt diabetic nephropathy, as shown in Figure 
3 [15]. Heparanase expression was also upregulated in glomeruli of patients with 
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minimal change disease, membranous glomerulopathy, and IgA nephropathy [37]. 
Interestingly, an increased expression of heparanase was also detected in the cytoplasm 
of proximal tubules in diabetic patients, whereas heparanase was also observed 
constitutively in tubuli of controls, suggesting a role for heparanase in normal tubular 
physiology.
Figure 3. Heparanase and HS expression in diabetic nephropathy. 
(A) A normal linear staining of HS and agrin along the capillary wall was detected in controls, 
whereas in patients with overt diabetic nephropathy, a loss of HS in the GBM and normal agrin 
expression were observed. (B) The reduction of HS in the GBM of patients with overt diabetic 
nephropathy was associated with an increase in glomerular heparanase expression. In controls, 
no detectable glomerular heparanase expression was observed [15].
 Urinary heparanase activity has been detected in some patients with type 1 diabetes 
who were either normoalbuminuric or microalbuminuric, whereas it was undetectable 
in control urine samples [38]. A newly developed enzyme-linked immunosorbent 
assay method also detected heparanase in the urine of diabetic and cancer patients 
[39]. Because heparanase expression is also increased in tubuli from patients with 
diabetes, it is conceivable that the observed increase in heparanase activity in the 
urine of these patients originates from tubular cells, rather than from podocytes or 
glomerular endothelial cells. An increased urinary heparanase activity is not restricted 
to diabetic nephropathy, because it was also detected in patients with minimal change 
disease, membranous glomerulopathy, and focal segmental glomerulosclerosis [37, 
40]. 
 Because the primary role of HS in the charge-selective properties of the GBM is 
questioned recently, as discussed above, the increase of heparanase expression and 
the decrease of HS in the GBM in glomerular diseases could be a consequence rather 
than a cause of proteinuria. Indeed, interventions (inhibition of the renin-angiotensin-
aldosterone system, reactive oxygen species scavenging) leading to a reduction of 
proteinuria also induced a regression of heparanase expression [34]. However, there 
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is evidence against proteinuria-induced heparanase expression and loss of HS. In the 
studies of Leviodiotis et al., [30, 31, 41] in which heparanase activity was neutralized 
with either anti-heparanase antibodies or the heparanase inhibitor PI-88, proteinuria 
was reduced. In addition, not in all proteinuric diseases, such as lupus nephritis, [27] an 
increase in glomerular heparanase expression was found. Also in overload nephropathy 
proteinuria was not associated with upregulation of heparanase [34]. Despite the recent 
observations that question the primary role of HS in charge-selective filtration, in our 
opinion, there could still be a role of heparanase and heparanase-mediated loss of 
HS in the development of proteinuria. Firstly, heparanase can disturb cell–GBM 
interactions by the degradation of HS. This could lead to the loss of podocytes in the 
urine, which has been described for various glomerular diseases [42]. Glomerular cells 
with a disturbed cell–GBM interaction due to loss of HS may respond different to 
(pathogenic) signals than in the normal situation. Secondly, heparanase activity may 
lead to the release of HS-bound factors (growth factors, cytokines, chemokines) and 
bioactive HS fragments, thereby modulating cellular processes in glomerular cells 
Figure 4: Postulated mechanisms for development of proteinuria by heparanase-induced 
HS degradation. Mechanisms that could lead to the development of proteinuria are: 
1) HS ( ) in the GBM and/or on the cell surface of podocytes and glomerular endothelial cells, 
can be cleaved off by active ( ) heparanase, which may disturb the glomerular cell-GBM 
interactions; 2) Cleavage of HS may result in release of several HS-bound factors such as 
growth factors, cytokines and chemokines ( ) and bio-active HS fragments, which may enhance 
glomerular damage and thereby proteinuria and; 3) Active and inactive ( ) heparanase may 
bind to cell surface HSPG, other receptors ( ) or may function as adhesion molecule itself, 
which may induce a signaling cascade ( ) that results in a change of cell properties. Potentially, 
all these mechanisms may result in detachment of podocytes or flattening of podocyte foot 
processes and the development of proteinuria. Mechanisms depicted for the apical surface of 
podocytes may also act on the basal sites of podocytes and/or the glomerular endothelial cells. 
N, nucleus.
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involved in the development of proteinuria. Finally, active or inactive heparanase 
is also capable of binding to HSPG and other receptors, thereby inducing signaling 
cascades, which may be involved in the development or enhancement of proteinuria. 
A scheme describing the postulated heparanase-mediated mechanisms that could be 
involved in the development of proteinuria is presented in Figure 4.
Intervention by heparin(oids) in proteinuric diseases
 Because heparanase is involved in tumor metastasis, angiogenesis, and 
inflammation, and may be involved in the development or enhancement of proteinuria 
in various glomerular diseases, heparanase is an attractive target for the development 
of novel inhibitors. Several inhibitory molecules have been developed, such as 
neutralizing antiheparanase antibodies, peptides, modified heparin fragments, and 
several other polyanionic molecules such as PI-88, and laminaran sulphate [43]. PI-88 
is currently undergoing phase II/III clinical trials for several types of cancer. Non-
anticoagulant N-acetylated, glycol-split heparins efficiently and specifically inhibit 
heparanase activity, but have a half-life shorter than unfractionated heparin [44]. The 
most recently isolated or developed heparanase inhibitors were reviewed by Ferro et 
al. [43]. Although heparin and heparin derivatives have many biological activities, 
[45] some of these compounds inhibit heparanase activity effectively.40 In face of the 
renoprotective effects of heparin(oids) in diabetic nephropathy, [9] it is tempting to 
speculate that heparanase inhibition may contribute to this beneficial effect.
Future perspectives
 The detection of increased expression of heparanase in glomerular diseases has 
become evident over the last 5 years. Currently, studies are in progress, aiming to unravel 
how heparanase expression and activity are regulated in podocytes and glomerular 
endothelial cells. Hyperglycemia [36], angiotensin II, reactive oxygen species [34], 
and aldosterone (preliminary data) have been shown to regulate heparanase expression/
activity in podocytes. The importance of heparanase will be further evaluated using 
(podocyte-specific) heparanase knockout mice. Induction of proteinuric diseases in 
this knockout model or in the transgenic heparanase overexpressing mouse model, 
including diabetic nephropathy, may provide further clues as to the exact role of 
heparanase and the loss of HS in the development of proteinuria. Specific inhibitors 
of heparanase activity need to be developed to establish the importance of heparanase 
in the development of proteinuria and glomerular diseases. Heparin derivatives could 
constitute such inhibitors, if the heparanase inhibitory capacity can be separated from 
the anticoagulant activity. To evaluate the relative significance of heparanase, it is 
important to select those fractions that have a maximal heparanase inhibitory effect 
and minimal anticoagulant activity. Other potential target sites may be at the level of 
heparanase transcription, trafficking, and processing.
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Summary 
 Diabetic nephropathy (DNP) is a frequent cause of end stage renal disease in the 
Western world. During the last decades, considerable evidence has been obtained that 
the anionic polysaccharide heparan sulfate (HS) in the glomerular basement membrane 
(GBM) acts as a charge-selective filtration barrier for plasma proteins. The relevance 
of HS for the development of proteinuria was demonstrated in several studies. First, 
an increased permeability of the GBM for ferritin and labeled bovine serum albumin 
occurred after enzymatic removal of HS. Furthermore, acute proteinuria was induced 
after injection of a monoclonal anti-HS antibody, which specifically recognizes HS 
in the GBM. Finally, a loss of HS in the GBM was found in several human and 
experimental glomerular diseases, which in general negatively correlated with the 
degree of proteinuria. 
 In this thesis, we hypothesized that the loss of HS in the GBM of patients with DNP 
could be attributed to an increased expression and/or activity of the HS-degrading 
enzyme heparanase. Heparanase is an enzyme capable of cleaving HS polysaccharides 
via hydrolysis, which requires specific modifications within the HS chain. During 
the course of our research, an increased expression of heparanase has already been 
demonstrated by others in several experimental glomerular diseases, including passive 
Heymann nephritis and puromycin-induced aminonucleoside nephrosis.
 
 In the first part of this thesis we evaluated whether heparanase could be involved 
in the pathogenesis of DNP by cleaving HS side chains, thereby altering the charge-
selective properties of the GBM.
 In chapter 2, we demonstrated that the increased glomerular expression of 
heparanase in biopsies from patients with overt DNP was associated with a decreased 
expression of HS in the GBM. Glomerular heparanase expression was mainly confined 
to podocytes and endothelial cells, as assessed by double stainings, with specific 
markers for glomerular cells. Increased heparanase expression was also found in 
tubuli of diabetic patients, predominantly in proximal tubuli. However, heparanase 
was also expressed in proximal tubuli of healthy controls, suggesting involvement of 
heparanase in normal tubular physiology. Heparanase mRNA and protein expression 
were also increased in the glomeruli of rats and mice with streptozotocin-induced 
DNP. These results strongly suggest that heparanase is involved in the degradation of 
HS in the GBM in patients with overt DNP. 
 In chapter 3, we examined whether the increased glomerular expression of 
heparanase in advanced stages of DNP revealed a differential expression of HS 
domains in the GBM. N-unsubstituted domains of HS, as well as sulfated HS domains 
appeared to be decreased or absent in the GBM of patients with overt DNP. In contrast, 
expression of the unmodified N-acetylated HS domains, which resemble the structure 
of the E. coli polysaccharide K5, and expression of a sulfated HS domain, which 
was recognized by the single-chain antibody AO4B08, were normally expressed in 
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the GBM of kidneys from patients with DNP. The in vivo expression of HS domains 
in patients with DNP was similar to the expression of HS domains after in vitro 
degradation of HS by treatment of normal human kidney cryosections with active 
recombinant heparanase. This indicates that the differential expression of HS domains 
in the GBM of patients with DNP most likely is the result of cleavage by heparanase. 
In fact, the ratio between the expression of the unmodified HS domain and the domain 
containing N-unsubstituted residues could be a measure for the glomerular activity of 
heparanase. This new finding distinguishes heparanase-mediated loss of glomerular 
HS from the reduction of HS by other mechanisms.
 Previously, increased levels of active heparanase have been found in the urine of 
patients with diabetes and with minimal change nephrotic syndrome. In chapter 4 
we investigated urinary heparanase activity in patients with type 1 or type 2 diabetes 
with either normo-, micro-, or macroalbuminuria and healthy controls. As non-
diabetic proteinuric disease control, urinary heparanase of patients with membranous 
glomerulopathy (MGP) was also evaluated. Urinary heparanase activity was increased 
in patients with type 1 and type 2 diabetes, with the highest activity in macroalbuminuric 
patients. Also patients with MGP showed elevated levels of active heparanase in the 
urine, which demonstrates that the presence of heparanase in the urine is not restricted 
to diabetes. A positive correlation was found between urinary heparanase activity 
and the degree of albuminuria in diabetic patients. However, not all patients with 
macroalbuminuria had increased urinary heparanase activity. We evaluated whether 
urinary heparanase activity could be influenced by the presence of the heparanase 
inhibitors in the urine, such as HS, or treatment of patients with inhibitors of the renin-
angiotensin-aldosterone system (RAAS) or other anti-hypertensive drugs. It appeared 
that inhibition of the RAAS system tended to a lower urinary heparanase activity than 
treatment with other anti-hypertensive drugs. However, urinary HS secretion and 
heparanase activity were not correlated. 
 
 In the second part of this thesis, we focused on the mechanisms that could be 
involved in the regulation of glomerular heparanase expression. Reactive oxygen 
species (ROS) have been demonstrated to be responsible for the reduction of HS in 
adriamycin nephropathy (AN), a model for chronic proteinuria-induced renal damage. 
Treatment of rats with AN with the hydroxyl scavenger dimethylthiourea (DMTU) 
only partially prevented the loss of HS in the GBM and albuminuria, suggesting the 
role of another mechanism. Additional HS removal could be due to the action of 
heparanase. In chapter 5, we demonstrated that glomerular heparanase expression 
indeed was increased in this model, which was associated with loss of HS in the GBM. 
Both the decreased HS and the increased heparanase expression could be partially 
prevented by treatment of rats with DMTU prior to disease induction. This suggests 
that ROS are involved in the induction of heparanase expression. In this study, we 
also investigated the effect of anti-proteinuric treatment of rats with AN with an 
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angiotensin II receptor blocker 1 (AT1A) on HS and heparanase expression. The 
increased heparanase expression in AN could be inhibited and HS expression could 
be partially restored after treatment with AT1A, implicating that also angiotensin II 
contributes to the induction of heparanase expression. 
 Blockade of the renin-angiotensin-aldosterone system with ACEi or AT1A is 
beneficial in reducing blood pressure and proteinuria in many patients with proteinuric 
diseases. However, long-term treatment with ACEi can result in aldosterone escape, 
which can also be a mediator of renal damage per se. A combination of treatment 
with ACEi and an aldosterone receptor blocker (aldoRB) has been demonstrated to 
be effective in amelioration of proteinuria. In chapter 6, we investigated the effect 
of ACEi, an aldoRB or a combination of both treatments on HS and heparanase 
expression in AN. Treatment with ACEi, aldoRB or with the combination of both all 
resulted in reduction of heparanase expression and in restoration of HS expression in 
the GBM. Treatment with a combination of ACEi and aldoRB was the most effective, 
suggesting that both angiotensin II and aldosterone are responsible for heparanase 
induction and HS loss. Treatment with the aldoRB alone was not sufficient to 
reduce proteinuria, while improvement of HS expression and decrease of heparanase 
expression was observed. This suggests that increased heparanase expression as such 
is not a consequence of proteinuria and that in AN, a reduction of heparanase and 
improvement of HS alone is not sufficient to reduce proteinuria. Furthermore, in this 
study, the in vitro effects of aldosterone, angiotensin II and ROS were investigated 
on heparanase expression in cultured mouse podocytes. Aldosterone, angiotensin 
II as well as ROS were able to induce heparanase mRNA expression in podocytes. 
Increased expression of heparanase by angiotensin II could be inhibited by angiotensin 
II type 1 receptor blockade, but not by angiotensin II type 2 receptor blockade. These 
in vivo and in vitro results demonstrate that aldosterone, angiotensin II and ROS are 
critically involved in the regulation of glomerular heparanase expression. 
 Mice with transgenic overexpression of mammalian heparanase (HPSE-tg) have 
been generated previously. We used this model to study the expression of different HS 
domains in the kidney of these mice (chapter 7). Expression of N-unsubstituted HS 
domains recognized by JM403 and highly sulfated HS domains detected with different 
anti-HS single chain antibodies in the GBM was strongly decreased or completely 
absent in the GBM of HPSE-tg mice. However, glomerular expression of the 
unmodified N-acetylated HS domain, recognized by anti-K5 (E. coli polysaccharide 
K5; NAH46) and expression of a highly sulfated HS domain, as detected with the 
single chain antibody AO4B08 were not different between HPSE-tg mice and controls. 
These results were also obtained after in vitro degradation of HS in normal mouse 
kidney sections or of coated HS in microtiter plates by active recombinant heparanase. 
This differential expression of HS after the action of heparanase both in vivo and in 
vitro may be explained by three different possibilities: 1) Unmodified N-acetylated 
HS domains (NAH46) and the sulfated domains recognized by AO4B08 may be 
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remnants of HS after cleavage by heparanase and are located close to the core protein; 
2) HS biosynthesis is not sufficient due to constant trimming of the HS chains by the 
continuous action of heparanase in HPSE-tg mice, yielding unmodified N-acetylated 
HS domains (NAH46) and sulfated HS domains (AO4B08) that are resistant to 
heparanase cleavage; or 3) There exists a subgroup of HS chains that solely consist of 
unmodified N-acetylated HS domains and sulfated HS domains defined by AO4B08, 
since these domains lack heparanase cleavage sites. Despite the dramatic loss of 
glycosaminoglycan-associated anionic sites in the GBM, HPSE-tg mice only developed 
mild albuminuria, whereas glomerular ultrastructure and renal function were normal. 
These observations question the primary role of HS in the charge-selective filtration, 
but do not exclude a role for heparanase in the complex pathogenesis of proteinuria.
 For several decades, HS has been regarded important for the charge-selective 
properties of the GBM. However, very recently, the primary role of HS in the charge-
dependent permeability of the GBM and the development of proteinuria has been 
questioned. We found that expression of different HS domains and glycosaminoglycan-
associated anionic sites in the GBM of mice with transgenic overexpression of 
heparanase was almost completely lost, whereas only minimal albuminuria was 
detected and a normal glomerular ultrastructure was present. In another study, we 
found that degradation of glomerular HS by intravenous injection in rats with the 
bacterial HS-degrading enzyme heparinase III did not result in proteinuria, despite 
the loss of the vast majority of HS and anionic charge. Additionally, podocyte-specific 
agrin knock-out mice and podocyte-specific EXT1 knock-out mice, which lack the 
enzyme for HS polymerization, have a strongly reduced HS expression in the GBM, 
but kidney function is normal without the development of proteinuria. Although all 
these studies exclude a primary role of GBM-HS in charge-selective filtration, we 
still cannot exclude a role for glomerular heparanase expression and loss of GBM-HS 
in the pathogenesis of proteinuria. In chapter 8, we discuss the role of heparanase 
in glomerular diseases. We propose several mechanisms that may be involved in the 
pathogenesis of proteinuria due to the action of heparanase. First, degradation of 
HS by heparanase may lead to loss of HS fragments or HS-bound factors, including 
growth factors, chemokines, cytokines e.g. that may lead to pathogenic events. 
Furthermore, binding of heparanase to specific cell surface receptors may result in 
signaling thereby inducing specific cellular responses. Moreover, loss of HS in the 
GBM may affect GBM-glomerular cell interactions, thereby influencing the response 
of glomerular cells to pathogenic factors. Finally, degradation of HS by heparanase 
may disturb HS-dependent glomerular cell-GBM interactions. These events, either 
alone or in combination may be critically involved in the development or enhancement 
of proteinuria and its downstream effects on renal damage. 
Future perspectives
 Recent findings question the primary role of HS in the charge-selective filtration. 
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However, as discussed above, these studies do not exclude a role for heparanase and 
heparanase-mediated HS loss in the pathogenesis of proteinuria. In our opinion, the 
development of proteinuria is not a single-hit mechanism. The knock-out mouse 
models used to study the role of HS in the development of proteinuria only manipulated 
one signal, i.e. the loss of HS in the GBM. The chronic constitutive absence of HS in 
the GBM from birth in these models does not allow the binding of growth factors 
and subsequent release of these factors and HS-fragments. Furthermore, a period 
of 48 hours after the injection of bacterial heparinase III in rats to digest HS in the 
GBM may be too short for the induction of several pathological events leading to 
proteinuria. In addition, HS fragments released after cleavage by bacterial heparinase 
III are different from HS fragments released after cleavage by mammalian heparanase, 
and therefore may have different bio-activities. It is important to stress that inhibition 
of heparanase activity with specific anti-heparanase antibodies or chemical inhibitors 
resulted in amelioration of proteinuria. If the development of proteinuria is a multi-
hit mechanism, not only the heparanase-mediated loss of HS in the GBM, but also 
additional pathological events, such as for example release of angiotensin II, ROS or 
cytokines in a pro-inflammatory environment, should be involved and manipulated 
experimentally. Therefore, to address the role of heparanase and heparanase-mediated 
HS loss in the development of proteinuria additional studies are required.
 Proteinuria should be induced in podocyte-specific heparanase knock-out mice, 
heparanase overexpression mice and in mice with a deficiency in podocyte-specific 
agrin or EXT1 with for example, streptozotocin or adriamycin. When proteinuria in 
these models will develop similar to that in controls, than there is strong evidence 
that heparanase and/or HS loss are not important for the development of proteinuria. 
However, to investigate whether proteinuria is a multi-hit mechanism, we should 
evaluate and manipulate more than one signal, i.e. loss of HS or the expression of 
heparanase. Induction of proteinuria by streptozotocin or adriamycin may induce 
these additional signals/hits. Therefore, the kinetics of the (renal) production of 
cytokines/growth factors/components of the RAAS system/ROS should be evaluated 
in the experimental models described above and compared to controls. Additionally, 
it would be interesting to investigate the effect of treatment with combinations of 
different drugs such as heparin, ACEi, AT1A, aldoRB and scavengers of ROS, all 
having an effect on heparanase expression/activity, in models with experimentally-
induced glomerular diseases (AN). This may give us further insight in the mechanisms 
involved in the regulation of heparanase and the development of proteinuria. Also, 
inhibition of the effects of these different stimuli on heparanase expression should be 
evaluated. Finally, the effects of these heparanase-inducing factors, i.e. angiotensin 
II, aldosterone and ROS, should be evaluated in cell co-cultures of podocytes and 
glomerular endothelial cells, since heparanase is predominantly expressed by these 
cells. This setting will enable the study of the interaction of these two cell types in the 
regulation of heparanase expression. 
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Samenvatting 
 Diabetische nefropathie (DNP) is een frequente oorzaak van nierfalen in de Westerse 
wereld. Gedurende de afgelopen decennia is er duidelijk geworden dat het negatief 
geladen polysacharide heparansulfaat (HS) in de glomerulaire basaalmembraan (GBM) 
van belang is voor de ladingsafhankelijke filtratie van plasma-eiwitten. De relevantie 
van HS voor de ontwikkeling van proteïnurie is aangetoond in een aantal studies. Ten 
eerste, na enzymatische verwijdering van HS is een toename in de permeabiliteit van 
de GBM voor ferritine en gelabeld serumalbumine aangetoond. Verder ontwikkelt 
zich een acute proteïnurie na injectie van een monoclonaal anti-HS antilichaam, 
dat specifieke HS-domeinen in de GBM herkent. Tenslotte is er een verlies van HS-
expressie in de GBM gevonden in een aantal humane en experimentele glomerulaire 
ziekten. De afname van HS is negatief gecorreleerd met de mate van  proteïnurie.
 In dit proefschrift wordt de hypothese getoetst, dat het verlies van HS in de GBM 
van patiënten met DNP wordt veroorzaakt door een toename in de expressie en/of 
activiteit van het HS-afbrekende enzym heparanase. Heparanase is een enzym dat 
in staat is om HS polysachariden af te breken door middel van hydrolyse, waarvoor 
specifieke modificaties in de HS-keten noodzakelijk zijn. Gedurende de uitvoering van 
ons onderzoek werd een toename in de expressie van heparanase ook aangetoond door 
andere onderzoeksgroepen in een aantal experimentele glomerulaire ziekten, zoals 
passieve Heymann nefritis en puromycine-geïnduceerde nefrose. 
 In het eerste gedeelte van dit proefschrift evalueren we de betrokkenheid van 
heparanase bij de pathogenese van DNP door HS zijketens af te breken en daarbij de 
ladingsafhankelijke eigenschappen van de GBM te veranderen. 
 In hoofdstuk 2 laten we zien dat een toename van glomerulaire heparanase 
expressie in biopten van patiënten met een vergevorderd stadium van DNP is 
geassocieerd met een afname van HS-expressie in de GBM. Door middel van 
dubbelkleuringen met specifieke markers voor glomerulaire cellen, laten we met name 
expressie van heparanase zien in podocyten en glomerulaire endotheelcellen. Een 
toename in heparanase expressie zagen we ook in de tubuli van patiënten met diabetes, 
voornamelijk in de proximale tubuli. Echter, de proximale tubuli van gezonde controles 
vertonen ook heparanase expressie, wat betekent dat heparanase mogelijk een rol speelt 
in de normale tubulaire fysiologie. Heparanase mRNA- en eiwitexpressie zijn ook 
toegenomen in de glomeruli van ratten en muizen met streptozotocine-geïnduceerde 
DNP. Deze resultaten suggereren dat heparanase een rol speelt in de degradatie van HS 
in de GBM van patiënten en proefdieren met een vergevorderd stadium van DNP.
 In hoofdstuk 3 laten we zien dat de toegenomen glomerulaire expressie van 
heparanase in latere stadia van DNP leidt tot een differentiele expressie van HS 
domeinen in de GBM. Zowel de expressie van HS domeinen met vrije NH
3
+-groepen 
als N-gesulfateerde HS domeinen is afgenomen of zelfs verdwenen in de GBM van 
patiënten met een vergevorderd stadium van DNP. Daarnaast vertonen deze patiënten 
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een normale expressie van niet-gemodificeerde N-geacetyleerde HS domeinen, 
die vergelijkbaar is met de structuur van het E. coli polysacharide K5, en van een 
N-gesulfateerd HS domein, die wordt herkend door het single chain antilichaam 
AO4B08.  De in vivo expressie van HS domeinen in patiënten met DNP is gelijk aan 
de expressie van HS domeinen na in vitro degradatie van HS door de behandeling 
van normale humane niercoupes met actief recombinant heparanase. Dit suggereert 
dat de differentiële expressie van HS domeinen in de GBM van patiënten met DNP 
hoogstwaarschijnlijk het resultaat is van de enzymatische werking van heparanase. De 
ratio tussen de expressie van ongemodificeerde HS domeinen en domeinen die bestaan 
uit vrije NH
3
+-groepen, zou een maat kunnen zijn voor de glomerulaire activiteit van 
heparanase. Deze nieuwe bevinding onderscheidt heparanase-gemedieerd verlies 
van glomerulair HS van de afname van HS door middel van andere reeds bekende 
mechanismen.
 In eerder onderzoek werden toegenomen spiegels van actief heparanase gevonden 
in de urine van patiënten met diabetes en van patiënten met een nefrotisch syndroom 
ten gevolge van minimale laesies glomerulopathie. In hoofdstuk 4 is de urine van 
patiënten met type 1 en type 2 diabetes met normo-, micro-, of macroalbuminurie 
en gezonde controles getest op heparanase activiteit. Als controle groep voor 
niet-diabetische patiënten met albuminurie dienen patiënten met membraneuze 
glomerulopathie (MGP) geanalyseerd op heparanase-activiteit. Heparanase-activiteit 
is toegenomen in de urine van patiënten met type 1 en type 2 diabetes, waarbij de 
hoogste heparanase-activiteit wordt gevonden bij patiënten met macroalbuminurie. 
Ook patiënten met MGP vertonen een verhoogde heparanase-activiteit in de urine, 
hetgeen suggereert dat een toegenomen activiteit van heparanase in de urine niet 
beperkt blijft tot diabetes. Er is een positieve correlatie tussen heparanase-activiteit 
in de urine en de mate van albuminurie bij patiënten met diabetes. Echter, niet alle 
patiënten met een macroalbuminurie hebben een toegenomen heparanase-activiteit 
in de urine. We hebben bepaald of heparanase activiteit in de urine beïnvloed wordt 
door de aanwezigheid van heparanase remmers in de urine, zoals HS, of door de 
behandeling van patiënten met remmers van het renine-angiotensine-aldosteron 
systeem (RAAS) of andere anti-hypertensiva. Behandeling met remmers van RAAS 
blijkt geassocieerd met een lagere heparanase-activiteit in de urine vergeleken met 
behandeling met andere anti-hypertensiva. Echter, er is geen correlatie tussen HS-
excretie en heparanase-activiteit in de urine.
 
 In het tweede gedeelte van dit proefschrift hebben we ons gericht op de 
mechanismen die betrokken kunnen zijn bij de regulatie van glomerulaire heparanase 
expressie. In eerder onderzoek werd door ons aangetoond dat zuurstofradicalen (ROS) 
verantwoordelijk zijn voor de afname van HS in adriamycine nefropathie (AN), een 
model voor chronisch proteïnurie-geïnduceerde nierschade. Behandeling van ratten 
met AN met de hydroxylscavenger dimethylthiourea (DMTU) voorkwam de afname 
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van HS in de GBM maar gedeeltelijk, hetgeen suggereert dat een ander mechanisme 
ook een rol zou kunnen spelen. In hoofdstuk 5 beschrijven we dat de glomerulaire 
expressie van heparanase is toegenomen in AN, hetgeen is geassocieerd met een 
afname van HS in de GBM. Zowel de afgenomen expressie van HS als de toegenomen 
expressie van heparanase kunnen gedeeltelijk worden voorkomen door behandeling 
met DMTU vóór inductie van de ziekte. Dit suggereert dat ROS betrokken zijn bij de 
inductie van heparanase-expressie. In deze studie hebben we ook onderzocht wat het 
effect is van anti-proteïnurische behandeling van ratten met AN met een angiotensine 
II type 1 receptorblokker (AT1A) op HS en heparanase-expressie. De toegenomen 
expressie van heparanase in AN wordt geremd en de afgenomen HS expressie 
wordt gedeeltelijk hersteld na behandeling met AT1A, hetgeen impliceert dat ook 
angiotensine II bijdraagt aan de inductie van heparanase-expressie.
 Remming van RAAS met angiotensine-converting enzyme inhibitors (ACEi) of 
AT1A is nuttig voor verlaging van bloeddruk en proteïnurie bij veel patiënten met 
proteïnurische ziekten. Een combinatie van behandeling met ACEi en een aldosteron-
receptorblokker (aldoRB) blijkt effectiever in het verminderen van de proteïnurie. In 
hoofdstuk 6 hebben we het effect van ACEi, van aldoRB of van een combinatie van 
beide behandelingen op HS en heparanase expressie in AN onderzocht. Behandeling 
met ACEi, met aldoRB of met de combinatie van beide resulteert in een afname van 
heparanase-expressie en in herstel van HS-expressie in de GBM. Behandeling met 
de combinatie van ACEi en aldoRB is het meest effectief, wat suggereert dat zowel 
angiotensine II als aldosteron verantwoordelijk zijn voor inductie van heparanase-
expressie en verlies van HS. Behandeling met aldoRB alleen is niet voldoende om 
de proteïnurie te reduceren, terwijl er wel verbetering van HS-expressie en afname 
van heparanase-expressie is. Dit impliceert dat de toegenomen heparanase-expressie 
op zich geen gevolg is van de proteïnurie en dat in AN een reductie in heparanase-
expressie en een vermindering van de afname van HS alleen niet genoeg zijn om 
proteïnurie te verlagen. Verder hebben we in deze studie in vitro de effecten van 
aldosteron, angiotensine II en ROS op heparanase-expressie bestudeerd in gekweekte 
muispodocyten. Zowel aldosteron, angiotensine II als ROS zijn in staat om heparanase 
mRNA expressie te induceren in deze podocyten. Verhoogde expressie van heparanase 
door angiotensine II worden geremd door angiotensine II type 1 receptorblokkade, 
maar niet door angiotensine II type 2 receptorblokkade. Deze in vivo en in vitro 
resultaten laten zien dat aldosteron, angiotensine II en ROS allen betrokken zijn bij de 
regulatie van glomerulaire heparanase expressie.
 We hebben muizen met een transgene overexpressie van humaan heparanase 
(HPSE-tg) gebruikt om de expressie van verschillende HS domeinen in de nier van 
deze muizen te bestuderen (hoofdstuk 7). De expressie van HS domeinen met vrije 
NH
3
+-groepen, welke worden herkend door anti-HS JM403, en hoog gesulfateerde 
HS domeinen, welke worden gedetecteerd met verschillende anti-HS single-chain 
antilichamen, is sterk afgenomen of compleet afwezig in de GBM van HPSE-tg muizen. 
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Echter, in vergelijking met de controles wordt in HPSE-tg muizen geen verschil 
gevonden in de glomerulaire expressie van het ongemodificeerde N-geacetyleerde HS 
domein, herkent door een anti-K5 antilichaam (E. coli polysaccharide K5; NAH46) en 
de expressie van een hoog gesulfateerd HS domein, gedetecteerd met het single-chain 
antilichaam AO4B08. Vergelijkbare resultaten worden gevonden na in vitro degradatie 
van HS in normale muizen-niercoupes of HS in microtiterplaten met actief recombinant 
heparanase. Deze differentiële expressie van HS domeinen na de enzymatische actie 
van heparanase, zowel in vivo als in vitro, zou op drie mogelijke manieren verklaard 
kunnen worden: 1) Ongemodificeerde N-geacetyleerde HS domeinen (NAH46) en 
de gesulfateerde HS domeinen herkend door AO4B08 zijn overblijfselen van HS na 
degradatie door heparanase; deze HS domeinen zitten dicht bij het core-eiwit; 2) HS-
biosynthese is niet voldoende ten gevolge van de constante afbraak van de HS ketens 
door de continue actie van heparanase in HPSE-tg muizen. Dit levert ongemodificeerde 
N-geacetyleerde HS domeinen (NAH46) en gesulfateerde HS domeinen (AO4B08) 
op die resistent zijn voor heparanase afbraak; 3) Er bestaat een subgroep van HS 
dat alleen bestaat uit ongemodificeerde N-geacetyleerde HS domeinen (NAH46) en 
gesulfateerde HS domeinen (AO4B08), omdat deze HS domeinen geen knipplaatsen 
hebben voor heparanase. Ondanks een sterke afname van de glycosaminoglycaan-
geassocieerde anionische lading in de GBM, ontwikkelen deze HPSE-tg muizen maar 
een milde albuminurie en hebben ze een normale glomerulaire ultrastructuur en een 
normale nierfunctie. Deze observaties zetten vraagtekens bij de primaire rol van HS in 
de ladingsafhankelijke filtratie, maar sluiten een rol voor heparanase in de complexe 
pathogenese van proteïnurie echter niet uit.
 Sinds enkele decennia wordt HS beschouwd als de belangrijkste determinant in 
de ladingsselectieve filtratie van de GBM. Echter, zeer recent zijn er vraagtekens 
geplaatst bij deze primaire rol van HS in de ladingsafhankelijke filtratie van de 
GBM en de ontwikkeling van proteïnurie. Wij hebben gevonden dat de expressie 
van verschillende HS domeinen en glycosaminoglycaan-geassocieerde anionische 
lading in de GBM van muizen met transgene overexpressie van heparanase voor 
het grootste gedeelte is verdwenen, terwijl deze muizen maar een milde albuminurie 
ontwikkelen en een normale glomerulaire ultrastructuur vertonen. In een andere 
studie hebben we aangetoond dat degradatie van glomerulair HS door intraveneuze 
injectie van ratten met het bacteriële HS-afbrekende enzym heparinase III niet leidt 
tot proteïnurie, ondanks het verlies van het grootste gedeelte van HS en anionische 
lading. Verder hebben podocyt-specifieke agrine knock-out muizen en podocyt-
specifieke EXT1 knock-out muizen, die het enzym voor HS polymerisatie missen, 
een sterk afgenomen HS-expressie in de GBM, maar een normale nierfunctie zonder 
ontwikkeling van proteïnurie. Hoewel deze studies een primaire rol voor GBM-HS 
in de ladingsafhankelijke filtratie onwaarschijnlijk maken, kunnen we een rol voor 
glomerulaire heparanase-expressie en verlies van GBM-HS in de pathogenese van 
proteïnurie niet uitsluiten. In hoofdstuk 8 bediscussiëren we de rol van heparanase in 
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glomerulaire ziekten. We stellen een aantal aan heparanase gerelateerde mechanismen 
voor, die betrokken kunnen zijn bij de pathogenese van proteïnurie. Ten eerste, 
degradatie van HS door heparanase kan leiden tot verlies van HS fragmenten of HS-
gebonden factoren, zoals groeifactoren, chemokines en cytokines, die glomerulaire 
afwijkingen kunnen veroorzaken. Ten tweede, binding van heparanase aan specifieke 
receptoren op het celoppervlak kan resulteren in inductie van specifieke cellulaire 
reacties. Bovendien kan verlies van HS in de GBM glomerulaire celinteracties met 
de GBM aantasten, hetgeen de reactie van glomerulaire cellen op pathogene factoren 
zou kunnen beïnvloeden. Tenslotte, degradatie van HS door heparanase kan de 
HS-afhankelijke glomerulaire cel-GBM interactie verstoren. Deze mechanismen, 
individueel of in combinatie, kunnen van groot belang zijn voor het ontstaan of voor 
de verdere ontwikkeling van proteïnurie en uiteindelijk nierschade.
Toekomstperspectieven
 Recente bevindingen hebben de primaire rol van HS in de ladingsafhankelijke 
filtratie sterk in twijfel getrokken. Echter, zoals hierboven al is beschreven, kunnen 
deze studies een rol voor heparanase en heparanase-gemedieerd verlies van HS 
in de pathogenese van proteïnurie niet geheel uitsluiten. Naar onze mening is de 
ontwikkeling van proteïnurie geen ‘single-hit’ mechanisme. Bij de knock-out 
muizenmodellen die gebruikt zijn om de rol van HS in de ontwikkeling van proteïnurie 
te bestuderen was maar één factor gemanipuleerd, namelijk de expressie van HS in 
de GBM. De constitutieve afwezigheid van HS in de GBM vanaf de geboorte in 
deze knock-out modellen, maakt de binding van groeifactoren en het vrijkomen van 
deze factoren en HS-fragmenten onmogelijk. Verder kan een periode van 48 uur na 
de injectie van het bacterieel heparinase III in ratten voor degradatie van HS te kort 
zijn voor de inductie van verscheidene pathologische gebeurtenissen die leiden tot 
proteïnurie. Bovendien zijn de HS-fragmenten die vrijkomen na de degradatie door 
het bacteriële heparinase III verschillend van de HS-fragmenten na degradatie door 
mammalian heparanase, waardoor ze een verschillende bioactiviteit kunnen hebben. 
Het is belangrijk om te benadrukken dat remming van heparanase activiteit met 
specifieke anti-heparanase antilichamen of chemische heparanaseremmers resulteert in 
een verlaging van de proteïnurie. Ervan uitgaande dat de ontwikkeling van proteïnurie 
een ‘multi-hit’ mechanisme is, dan zijn niet alleen het heparanase-gemedieerd verlies 
van HS in de GBM van belang, maar ook additionele pathologische gebeurtenissen 
zoals de werking van angiotensine II, ROS of cytokines in een pro-inflammatoir 
milieu. Deze additionele pathologische gebeurtenissen zouden dan ook experimenteel 
gemanipuleerd moeten worden. Daarom zijn er aanvullende studies noodzakelijk om 
de rol van heparanase en heparanase-gemedieerd verlies van HS in de ontwikkeling 
van proteïnurie te evalueren.
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 Proteïnurie zal moeten worden geïnduceerd met bijvoorbeeld streptozotocine 
of adriamycine in (podocyt-specifieke) heparanase knock-out muizen, heparanase 
overexpressie muizen, en in podocyte-specifieke agrine of EXT1 knock-out muizen. 
Wanneer proteïnurie zich in deze modellen op dezelfde manier ontwikkelt als in de 
normale controles, dan is er een sterk bewijs dat heparanase en/of HS niet van belang 
zijn voor het ontstaan van proteïnurie. Echter, om te onderzoeken of proteïnurie het 
gevolg is van een ‘multi-hit’ mechanisme, zullen we meer dan een enkel signaal, 
verlies van HS of expressie van heparanase, moeten manipuleren. Streptozotocine of 
adriamycine zouden deze additionele signalen/hits voor proteïnurie kunnen induceren. 
Daarom moet de kinetiek van de productie van cytokines/groeifactoren/componenten 
van RAAS/ROS (in de nier) geëvalueerd worden in de experimentele modellen die 
hierboven zijn beschreven en worden vergeleken met controles. Bovendien zou het 
interessant zijn om het effect te bestuderen van behandeling met combinaties van 
verschillende geneesmiddelen, zoals heparine, ACEi, AT1A, aldoRB of scavengers 
van ROS, welke allemaal een effect hebben op heparanase-expressie/activiteit 
in modellen met experimenteel-geïnduceerde glomerulaire ziekten (bijvoorbeeld 
adriamycine nefropathie). Dit zou ons meer inzicht kunnen geven in de mechanismen 
die betrokken zijn bij de regulatie van heparanase en de ontwikkeling van proteïnurie. 
Ook zal remming van de effecten van deze verschillende stimuli op heparanase-
expressie geëvalueerd moeten worden. Tenslotte moeten de effecten van de factoren 
betrokken bij de inductie van heparanase, zoals angiotensine II, aldosteron and ROS 
bestudeerd worden in co-culturen van podocyten en glomerulaire endotheelcellen, 
omdat heparanase voornamelijk tot expressie komt in deze beide celtypen. Deze opzet 
zal het mogelijk maken om de interactie van deze twee celtypen te bestuderen in de 
regulatie van heparanase-expressie.
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Figure 1. Expression of HS, HPSE, and agrin in human DNP. Immunofluorescence double 
stainings of (A and C) agrin (red) with HS (green) and (B and D) HS (green) with HPSE (red) 
in kidney sections from (C and D) patient with overt DNP and (A and B) a control. (A) Co-
staining of agrin with HS revealed a linear colocalization (yellow) along the GBM in controls, 
(C) whereas reduction of glomerular HS was observed in patients with DNP. Decrease of 
glomerular HS expression in diabetic patients was associated with an upregulation of HPSE in 
the glomeruli of (D) diabetic patients compared to (B) controls. Original magnification x63.
Chapter 2; Figure 1
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Figure 3. Localization of HPSE in human DNP. Immunofluorescence double staining of 
HPSE with glomerular markers for the GBM (agrin), podocytes (synaptopodin), or mesangial 
cells (perlecan) in a patient with overt DNP. HPSE expression co-localizes with both (A) 
agrin and (B) synaptopodin, representing the extracellular and intracellular HPSE expression, 
respectively. (C) However, HPSE is not expressed by mesangial cells. (D) Tubular HPSE is 
mainly expressed in proximal tubuli, determined by co-staining with anti-P-glycoprotein. 
Original magnification x63.
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Figure 1. Expression of HS 
domains with N-unsubstituted 
glucosamine residues (JM403) 
and of the agrin core protein 
in the GBM of patients with 
overt DNP and controls. A) 
Immunofluorescence double 
staining of renal cryosections from a 
control and a patient with DNP with 
anti-HS antibody JM403 (green) 
and anti-agrin antibody JM72 
(red). In control kidneys, a normal 
linear expression of HS domains 
recognized by JM403 was detected 
in the GBM. HS expression in the 
GBM nicely co-localized with agrin 
core protein expression in controls 
(merge). However, in patients with 
DNP a decreased expression of HS 
domains recognized by JM403 was 
observed in the GBM, whereas 
agrin expression was unaltered. 
B) Quantification of the stainings 
revealed that the expression of 
HS domains with N-unsubstituted 
glucosamine residues, detected 
with JM403, was significantly 
reduced in the GBM of patients 
with DNP compared to controls. C) 
No differences in agrin  expression 
were observed between controls 
and diabetic patients. D) An inverse 
correlation between the expression 
of HS domains recognized by 
JM403 and the level of proteinuria 
was observed. Due to the lack 
of glomeruli in one biopsy, only 
13 biopsies were evaluated. AU, 
arbitrary units. **P<0.01.
Chapter 3; Figure 1
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Figure 5. Renal localization of HPSE in patients with overt DNP. A) Immunohistochemical 
staining of paraffin-embedded renal sections from a patient with DNP with a rabbit anti-HPSE 
antiserum (anti-HPR1) revealed strong HPSE signals in the podocytes (grey arrows) and in the 
proximal tubular cells (black arrows). B) Enlargement from part A.  A normal kidney specimen 
was included and showed no HPSE signal in the glomerulus and weak signals in the tubule (C). 
A normal rabbit serum for a biopsy specimen was included as a negative control (D).    
Chapter 3; Figure 5
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Figure 1. Heparan sulfate (HS; proteoglycans) and heparanase expression in Adriamycin 
nephropathy (AN) and control kidneys (indirect immunofluorescence staining). (A) 
JM403 staining for HS and MI91 staining for agrin core protein in a control kidney; a nice 
linear staining of the glomerular basement membrane (GBM) is observed for both HS and 
agrin. (B) HS and agrin staining in an Adriamycin-exposed kidney: Glomerular HS staining is 
decreased, whereas agrin staining remains linear. (C) HS and heparanase staining in a control 
kidney: Heparanase is present in the tubuli but absent in the glomerulus. (D) HS and heparanase 
expression in an Adriamycin-exposed kidney: A glomerulus with reduced HS expression and 
increased heparanase expression. Magnification, x40.
Chapter 5; Figure 1
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Figure 5. Immunofluorescence double staining with anti-heparanase (green) and anti-
agrin (red) (A), and with anti-heparanase (red) and anti-synaptopodin (B), or anti-
Thy1.1 (C) (both in green). Glomerular heparanase is expressed mainly at the outside of 
the GBM, confirmed by co-localization with the podocyte marker synaptopodin. Minimal 
staining was observed in the capillary loops (according to the agrin/heparanase staining). No 
co-localization with mesangium cells was shown. For tubular heparanase expression, we used 
immunofluorescence double staining with anti-heparanase (red) and anti-calbindin D-28k (D), 
anti-aquaporin 2 (E), and anti-Pglycoprotein (F; all green). Tubular heparanase is expressed 
mainly in the proximal tubuli, because it co-localized with P-glycoprotein. No co-localization 
with the distal convoluting tubuli and collecting ducts was shown. Magnification, x63.
Chapter 5; Figure 5
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Dit is het dan, het resultaat van ruim 4 jaar experimenteren op het lab Nierziekten. Van 
het eerste jaar is helaas niet zo veel terug te vinden in dit proefschrift, wat natuurlijk 
typisch is voor onderzoek. Gelukkig is het toch helemaal goed gekomen, mede dankzij 
de bijdrage van velen, hetzij met een extra paar handen, met extra kennis of met 
wat afleiding. Ik wil dan ook iedereen die mij gedurende mijn promotietijd hebben 
bijgestaan heel erg bedanken. Allereerst wil ik beginnen met mijn begeleiders, mijn 
co-promotor dr. Johan van der Vlag en promotor Prof. dr. Jo Berden.
Beste Johan, ik heb de afgelopen jaren ontzettend veel van je geleerd. Niet alleen jouw 
intensieve en enthousiaste begeleiding, maar ook je expertise, inspiratie en optimisme 
hebben me altijd gemotiveerd en gestimuleerd om door te gaan. Altijd kon ik bij je 
terecht, zowel voor vragen over het onderzoek als voor een leuke discussie. Bedankt 
voor het vertrouwen in mij!
 
Beste Jo, jouw expertise en interesse op het gebied van heparansulfaat hebben me veel 
inzicht gegeven in mijn promotieonderzoek Door alle leerzame werkbesprekingen en 
discussies kwamen we steeds weer op nieuwe ideeën. Ik wil je bedanken voor de kans 
die je me hebt gegeven om op jouw afdeling onderzoek te kunnen doen. 
Ook wil ik mijn tweede co-promotor dr. Toin van Kuppevelt bedanken voor de 
interessante discussies tijdens de NWO-besprekingen en voor de samenwerking en 
steun in het onderzoek
En dan natuurlijk mijn fantastische (ex)collega’s van het lab Nierziekten, Marinka, 
Cor, Wim, Angelique, Casandra, Justin, Nils, Jurgen, Luuk en Peter. Zonder jullie 
had ik nooit met zoveel plezier aan het onderzoek gewerkt. Bedankt voor alle hulp, 
steun, leerzame discussies en gezelligheid. Marinka, jij bent iemand die altijd bereid 
is om te helpen. Ik heb heel veel van je geleerd en het was altijd ontzettend gezellig. 
Ik bewonder je en ik vind het leuk dat je naast me wilt staan als paranimf. Angelique, 
mijn U-genootje, ons onderzoek vertoonde veel overlap waardoor wij elkaar veel 
hebben kunnen helpen. Ik ben je echt ontzettend dankbaar voor alle experimenten die 
je momenteel nog voor ons artikel aan het uitvoeren bent.
Naast het harde werken, werden er natuurlijk ook de nodige labuit-jes georganiseerd, 
die je zo af en toe ook echt nodig hebt, bijvoorbeeld onze jaarlijkse dobbelavond. Cor, 
bedankt voor de perfect georganiseerde avonden bij jouw thuis. Jij was altijd bereid om 
overal en nergens foto’s van te maken. Ik denk dat er dan ook genoeg foto’s in omloop 
zijn voor mijn promotiefeestje. Trouwens, voor mijn mede-junior onderzoekers, 
Casandra en Justin, zullen we ook wel voldoende hebben... Heel veel succes nog met 
het afronden van jullie promotie, het komt allemaal goed! Wim, bedankt voor je hulp 
bij het opzetten van de heparanase assay. Op elk moment van de dag kon ik bij je 
terecht en ook al was je nog zo druk bezig in “je schuur”, je was altijd bereid om me 
172 173
te helpen. Verder bedank ik alle studenten die ik heb mogen begeleiden, Simon, Anne, 
Tim en Simone voor de hulp en de gezelligheid. 
Ik wil de collega’s binnen het NWO-project, Tessa Wijnhoven, Joost Lensen en dr. Bert 
van den Heuvel bedanken voor het delen van kennis tijdens de NWO besprekingen. 
Ik heb veel geleerd van deze besprekingen. Tessa, bedankt voor de single-chain 
antilichamen en de samenwerking. 
Het is erg moeilijk om aan nierbiopten van patiënten met diabetische nefropathie te 
komen, omdat de diagnose “diabetes” bij deze patiënten vaak al is gesteld. Gelukkig 
hebben we met de hulp van de afdeling pathologie van het AMC Amsterdam voldoende 
biopten kunnen verkrijgen om met hoofdstuk 2 te kunnen beginnen. Dr. Jan Aten en 
prof. dr. Jan Weening, ik wil jullie hartelijk bedanken voor de mogelijkheden die 
jullie me hebben gegeven om bij jullie op afdeling coupes te kleuren en te evalueren. 
Ook bedankt voor alle leerzame discussies en jullie inbreng. Niels en Nike, bedankt 
voor jullie hulp bij de kleuringen en het opzetten van de heparanase assay. Ik vond 
het erg prettig om met jullie samen te werken. Wie wat bewaard, heeft wat! Daarom 
wil ik graag dr. Jaap van den Born bedanken voor de niertjes van het streptozotocine 
rattenmodel en Ilse Raats voor de niertjes van het adriamycine rattenmodel. Dr. Roel 
Goldschmeding, Peggy Roestenberg en Frans van Nieuwenhoven van het UMC 
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